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Peptidases play fundamental roles in all living organisms and their dysfunction is 
associated with a variety of diseases. Although sequences of peptidases encoded in 
genomes throughout life have become readily available via high throughput sequencing 
technologies, research on their structural and functional characterizations lags behind due 
to challenges related to their crystallization and time-intensive biochemical/biophysical 
studies. 
Signal Peptide Peptidase (SPP) is an intramembrane aspartyl peptidase that 
cleaves signal peptides within the hydrophobic region of cellular membrane. SPP plays 
important roles in cellular functions such as immune system regulation. Structural 
characterization of membrane proteins including SPP is challenging due to their 
hydrophobic content which is undesirable in crystallization. Structures of membrane 
proteins are severely underrepresented: number of unique membrane protein structures is 
still less than 1% in Protein Data Bank. Here, a new generalizable method was introduced 
to overcome crystallization challenge of membrane proteins. A toolbox of single chain 
antibody fragments (scFvs) specific to the EYMPME peptide (EE) epitope was 
developed for use as co-crystallization chaperones. Structures of designed scFvs were 
solved and their crystallization propensities were systematically explored to improve their 
chaperone abilities. Tight complexation of anti-EE scFvs with an EE-tagged archeal SPP 
and another test membrane protein was demonstrated. Important lessons learned during 
crystallization and co-crystallization trials of scFvs and SPP are discussed in this 
dissertation. 
 xxvii 
To understand peptidases at a mechanistic level requires both high resolution 
structures and extensive structure-function studies in which residues are systematically 
altered and differences in functionality of the peptidase are measured. Although a low 
resolution structure of inactive SPP became available during my PhD studies, details on 
how SPP recognizes and catalyzes its substrate are still not known. Here, preliminary 
data for a structure-function study to understand substrate gating mechanism of SPP are 
presented.  
Finally, structure-function studies of 5-nitroanthralinic acid aminohydrolase 
(5NAA-A), a metallo-peptidase family member that catalyzes a deamination reaction on 
a natural, toxic nitroaromatic compound, are presented. 5NAA-A has evolved a function 
other than peptide hydrolysis but is structurally and evolutionary related to peptidases and 
is thus classified as a non-peptidase homolog. We characterized 5NAA-A biochemically 
and biophysically, and obtained snapshots of its mechanism by solving its crystal 
structures in various states. The 5NAA-A structure and its nucleophilic aromatic 
substitution mechanism expand our understanding of the great diversity of enzymes 






CHAPTER 1: Introduction to Peptidases 
1.1. Roles and function 
1.1.1. Hydrolysis of peptide bonds 
Peptidases (proteases, proteinases, proteolytic enzymes) perform peptide bond 
hydrolysis (Figure 1.1). Peptidases are one of the most abundant families of enzymes, 
accounting for 1-2% of all protein coding genes in a genome (1), and are present in all 
cellular organisms. Peptidases and their homologs fall into different families 
corresponding to distinct catalytic mechanisms and substrate specificities (Section 1.2).  
 
 
Figure 1.1. Peptide bond hydrolysis. Scissile peptide bond is colored in red. 
 
The majority of peptidases catalyze the hydrolysis of -peptide bond(s) between 
natural amino acids (Figure 1.1) but some peptidases perform reactions that are slightly 
different or have additional features. For example, ubiquitin carboxyl-terminal hydrolase 
1 can catalyze an isopeptide bond in an ubiquitin conjugate (2), glutamate 
carboxypeptidase II can hydrolyze a γ-glutamyl bond (3), and  γ-glutamyl transpeptidase 
1 can both transfer and hydrolyze peptide bonds (4). 
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1.1.2. Functions of peptidases in biological processes 
Peptidases are involved in a wide variety of biological processes, including cell 
cycle/proliferation/survival/death, signaling pathways, protein trafficking and immune 
response. Peptidases thus also play important roles in many human diseases such as 
cancer, inflammatory, infectious, cardiovascular and degenerative diseases (5, 6) and are 
attractive targets for the pharmaceutical industry due to their potential as 
diagnostic/prognostic biomarkers and drug targets (7). Currently, approved protease 
inhibitor drugs on the market treat hypertension, coagulation disorders, HIV, diabetes and 
cancer (5, 8). In addition to biological/therapeutic impacts, there are broader applications 
of commercial peptidases such as food processing, detergent and leather industry (9). In 
this chapter, peptidases will be reviewed from a biological and biochemical/biophysical 
standpoint. 
Early studies of peptidases focused on their function in protein catabolism, 
namely, degrading/recycling intracellular and extracellular proteins as a source of amino 
acids for the cell. However, peptidases play many other key roles in which highly specific 
reactions are required to control a biological process (10). Peptidases mediate post-
translational modifications such as signal peptide removal and protein activation by pro-
peptide removal. In this capacity, peptidases can regulate the localization and activity of 
other cellular proteins as well as control protein-protein interactions. Localization of 
peptidases and their substrates control their response to different stimuli (11). Peptidases 
can also deactivate certain proteins, including peptide hormones. Finally, an active area 
of research is the roles of peptidases playing in signaling pathways (12, 13).  
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1.2. Classification, mechanism, structure and regulation 
1.2.1. Classification based on catalytic mechanism 
Traditionally, peptidases were classified into two main groups: (i) endopeptidases, 
which catalyze internal peptide bonds, and (ii) exopeptidases, which target amino or 
carboxy terminus of a protein. However, accumulation of structural and biochemical 
information has led new classifications. The standard classes of peptidases are based on 
their catalytic mechanisms, of which there are six identified by their catalytic nucleophile 
(1, 13, 14). Serine, cysteine, threonine classes use their namesake residue as the 
nucleophile, which forms the acyl-enzyme intermediate (Figure 1.2A-C). For example, 
serine peptidases use a catalytic triad composed of Ser-His-Asp (Figure 1.2A) (15) 
where the nucleophilicity of Ser is enhanced by His and Asp to form a tetrahedral 
intermediate stabilized by the so-called oxyanion hole formed by additional residues in 
the binding pocket (Gly and another Ser). Aspartate, glutamate and metallo- peptidases 
use an activated water as a nucleophile for acid-base catalysis (Figure 1.2D-F). The 
water is activated through a carboxylic acid group of the catalytic residue or a metal ion. 
In metallo-peptidases, a divalent cation, often zinc, is used to reduce the pKa of the water 
molecule for further activation. The divalent metal is coordinated by at least three active 
site residues (usually His, Glu and Asp) and the water molecule. Some metallo-
peptidases, such as carboxypeptidase G2, are di-nuclear with two metal ions in the active 
site (16). A seventh class, asparagine peptide lyases, which self-cleave at asparagine 
residues (17), does not involve conventional hydrolysis; thus, its inclusion in the 





Figure 1.2. Proposed catalytic mechanisms of six peptidase classes. (A-C) Mechanisms of serine, cysteine and threonine peptidases 
respectively. An acyl-enzyme intermediate forms between the carbonyl carbon of the peptide substrate and the corresponding catalytic 
residue. Threonine peptidase uses an N-terminal Thr for nucleophilic attack because N-term acts as a general base. (D-F) Mechanisms 
of aspartate, glutamate and metallo- peptidases respectively. A water molecule is activated for a nucleophilic attack on the carbonyl 




1.2.2. Structural features 
Although they perform parallel mechanisms (Figure 1.2), structures vary widely 
among different classes of peptidases. Among the six peptidase classes, the most diverse 
is the metallo-peptidases (18). Some peptidases are as small as 15 kDa, with only a small 
catalytic domain like the bacterial zinc peptidase ScNP (19) and some are as large as 1-6 
MDa with many domains like the multimeric meprin metalloproteases (20) or the 
proteasome (21).  Many peptidases link their catalytic domain to specialized domains to 
tailor their cellular localization, substrate specificity, kinetic properties and/or inhibitor 
sensitivity. The level of complexity in peptidase structure could be the driving force for 
the evolution of primitive catabolic enzymes to highly specialized enzymes that function 
in cellular processes.  
1.2.3. Specificity and promiscuity  
Peptidases bind to their substrates through a combination of hydrogen bonding, 
electrostatic, and hydrophobic interactions with substrate peptide backbones and/or side 
chains. While some peptidases show high level of specificity targeting unique peptide 
bond such as angiotensin-converting enzyme (22), many are relatively non-specific and 
promiscuous, such as proteinase K (23). The identification of peptidase substrates and 
analysis of their specificity towards those substrates has become an important focus of 
current research (24). Two main approaches have been commonly used for this purpose: 
(i) gel-based methods where complex mixtures are separated and identified by mass 
spectrometry (MS) analysis, (ii) N- and C-termini based proteomics strategies where 
cleaved substrate is enriched for MS analysis (25, 26). To gain functional information on 
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large numbers of protein, library-based approaches have been developed such as mixture-
based peptide libraries (27) and multiplex substrate profiling (28).  
1.2.4. Regulation and activation 
Peptidases are highly regulated in the cell because they catalyze essentially 
irreversible reactions and must respond to specific cellular cues temporally and spatially. 
The known regulation mechanisms for peptidases include gene expression, post-
translational modifications, zymogen activation via limited proteolysis, cellular 
localization, co-factors, allosteric mechanisms, endogenous peptidase inhibitors and 
degradation (13, 29, 30). Protein reservoir of the encoded genome can be extensively 
diversified by regulated peptidase mechanisms. How peptidase gene expression is 
controlled is generally not known, but notable exceptions include matrix metalloproteases 
that are implicated in cancer (31).  
Inactive zymogens can be activated by either autocatalysis or catalysis via a 
different peptidase. For example, presenilin performs autocatalysis to become active and 
process amyloid precursor protein which plays important role in Alzheimer’s disease (32, 
33). Blood coagulation cascade involves sequential serine protease activation (34). 
Dysregulation of peptidases can lead to cell death; apoptosis can occur when pro-growth 
cell cycle proteins are not properly degraded (35).  
1.3. Intramembrane peptidases 
Intramembrane peptidases (IPs), of particular interest in this thesis, act within the 
hydrophobic cell membrane to cleave transmembrane helices. Intramembrane proteolysis 
was first observed less than three decades ago (36). Soluble and intramembrane 
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peptidases are similar in their requirement of substrate recognition before processing. 
However, data to date indicate that compared to soluble peptidases which cleave their 
substrates within seconds, IPs cleave substrates on a timescale of minutes (37, 38). The 
details of IP biochemistry are limited but their malfunction is associated with pathologies 
such as Alzheimer’s and Parkinson’s diseases (39, 40). More details on classes of IPs and 
their proposed mechanisms are presented in Chapter 2.  
Although the structures of some IPs have been solved and increasing number of 
studies have been conducted to understand their mechanism of action (41-44), there are 
still many open questions: (i) how do IPs recognize their substrates and distinguish them 
from other transmembrane helices, (ii) what is the rate limiting step responsible for the 
slow kinetics, (iii) what kind of conformational changes occurs on enzyme and/or 
substrate for substrate recognition and processing, (iv) how do substrates gain access to 
the hydrophilic catalytic site, (v) how do disease-related mutations affect the mechanism, 
(vi) how does the membrane environment such as lipids affect the cleavage. 
1.4. Non-peptidase homologs 
1.4.1. Similar structures but different chemical reactions 
Peptidases are classified based on their evolutionary and structural relationships 
(18), not explicitly by the reactions they catalyze (Section 1.2.1). For example, MEROPS, 
a peptidase database regularly updated and very useful for many researchers worldwide 
(45), clusters homologous sequences expected to share a similar structure and/or catalytic 
type. Due to advances in genome sequencing, functional characterization of hypothetical 
proteins encoding predicted peptidases lags behind the availability of their corresponding 
translated nucleotide sequences and phylogenetic analysis (46). By noting the 
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replacement of key active site residues, some uncharacterized enzymes can be annotated 
as non-peptidases homologs (47), but because it is not possible to identify substrates from 
primary sequence or even atomic structure, there exist sequences within peptidase 
families that perform chemistry other than peptide bond hydrolysis. 
1.4.2. An example: 5-nitroantranilic acid aminohydrolase (5NAA-A) 
5NAA-A is a metallopeptidase family member that has evolved to hydrolyze a 
toxic nitroaromatic compound, 5-nitroantranilic acid (5NAA), to 5-nitrosalicylic acid 
(5NSA) (48). As discussed in Chapter 6, we characterized 5NAA-A 
biochemically/biophysically and solved its structure in various states (49). Its sequence, 
structure, and biochemical characterization confirm that 5NAA-A belongs to the 
MEROPS M20 metallopeptidase family as a non-peptidase homolog (50) and evolved 
from a common ancestor (51). The closest structural homologues are other M20 family 
members carboxypeptidase G2 (root mean squared deviation (R.M.S.D.): 5.04 Å, 
(sequence similarity ~35%) (16), N-acetyl-L-citrulline deacetylase (ACD, R.M.S.D.: 4.32 
Å) (52), and N-succinyl-L,L-diaminopimelic acid desuccinylase (SDAD, R.M.S.D.: 5.66 
Å) (53) (Figure 1.3). However, 5NAA-A harbors key distinctions leading to its unique 





Figure 1.3. Monomer superposition of MEROPS M20 family members: 5NAA-A 
(orange), carboxypeptidase G2 (yellow, PDB ID: 1CG2), N-acetyl-L-citrulline 
deacetylase (blue, ACD, PDB ID: 2F7V), and N-succinyl-L,L-diaminopimelic acid 
desuccinylase (purple, SDAD, PDB ID: 3IC1).  
 
By phylogenetic analysis, we identified additional MEROPS M20 non-peptidase 
homologs that likely harbor mononuclear metal binding sites and hydrolyze other 
aromatic substrates of potential environmental or synthetic interest (Chapter 6). It appears 
likely that many additional rare and unusual non-peptidase homologs are involved in 
catabolic pathways for the great diversity of natural organic compounds in our ecosystem 
(54).  
1.5. Thesis objectives 
1.5.1. Development of single chain antibody fragments (scFvs) for membrane 
protein co-crystallization 
Structural and biochemical/biophysical characterization of membrane proteins is 
challenging due to their hydrophobic content. In chapter 2, I present methods used to 
prepare an archaeal signal peptide peptidase (SPP), ortholog of an intramembrane 
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peptidase in humans that plays essential roles in immune response and surveillance. 
Several optimization strategies ranging from molecular cloning to purification to 
detergents were employed to obtain high yield, pure and active SPP for further 
characterization. 
The next objective was to develop antibody fragments specific to a short peptide 
epitope that can be easily installed in an extramembranous loops of any membrane 
protein target for facile complexation. These antibody fragments would then aid 
crystallization of membrane proteins by increasing their hydrophilic crystal contact 
interfaces. As presented in chapter 3, several single chain antibody fragments (scFvs) 
were developed from a parent anti-His6 scFv, in collaboration with the lab of Jennifer 
Maynard at University of Texas (UT), Austin. Biophysical properties of parent scFv were 
improved and specificity was then converted to anti-EYMPME (EE). After solving the 
structures of scFvs, rational design was performed to manipulate the crystallization lattice 
to better accommodate a membrane protein of interest. Lessons regarding the challenges 
of controlling crystal lattice contacts were learned from this study.  
In chapter 4, I present results of two test membrane proteins targeted for anti-EE 
scFv complexation and co-crystallization trials: SPP as an α-helical membrane protein 
and E. coli intimin as a β-barrel membrane protein. Only one site-directed-mutagenesis 
step was required to install EE-tag in selected soluble loops. Several parameters were 
optimized including the location of EE-tag and solution complexation to form a tight 
interaction between the anti-EE scFvs and EE-tagged membrane proteins for co-
crystallization trials.  
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1.5.2. Protein engineering and several optimizations for SPP to improve its 
crystallization and diffraction 
In chapter 5, I present my efforts to improve crystallization and diffraction quality 
of SPP crystals. This chapter catalogs the exhaustive efforts to crystallize SPP by itself. 
SPP crystallization was optimized via alterations in detergent/lipid environment, by 
protein engineering, and several other commonly used techniques in the field. 
Unfortunately, although diffraction quality of the crystals was significantly improved by 
my efforts, I determined that the protein crystals were not of SPP but of a contaminant. 
Thus, while I did not solve a high resolution structure of SPP, I learned valuable lessons 
regarding contamination issues for any membrane protein crystallization experiments. 
1.5.3. An on-going structure-function study to understand substrate gating 
mechanism of SPP 
During the course of this thesis work, a 3.8 Å resolution crystal structure of SPP 
in an inactive conformation became available in the literature. Using this structure, 7 
mutants were designed to probe substrate gating in SPP, taking advantage of the lab’s 
expertise in enzyme kinetics and biophysical characterization. I developed a protocol to 
measure substrate binding on-off kinetics by surface plasmon resonance (SPR) to 
differentiate between mutants that reduce activity via impaired substrate binding and 
those for which binding is similar to that of wild-type SPP. Preliminary results are 
presented in chapter 7, which will be repeated and expanded by Swe-Htet Naing, another 
PhD candidate in Lieberman Lab, after my departure. Chapter 7 thus provides a 
perspective on future directions for the project. 
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1.5.4. Structural and biochemical/biophysical characterization of a novel 
metalloenzyme, 5NAA-A, capable of hydrolyzing a toxic, natural 
nitroaromatic compound 
Chapter 6 presents results from a long-standing collaborative side project between 
the Lieberman lab and that of Jim Spain from the School of Civil and Environmental 
Engineering at Georgia Tech. The goal of this project was to structurally and 
biochemically/biophysically characterize a novel metalloenzyme, 5NAA-A, classified 
among metallopeptidases but instead hydrolyzes a toxic natural nitroaromatic compound, 
5NAA to 5NSA. We obtained crystallographic snapshots of the mechanism and explored 




CHAPTER 2: Molecular Cloning, Expression, Purification and Detergent 
Optimization of Signal Peptide Peptidase (SPP) 
2.1. Introduction 
2.1.1. Intramembrane peptidases (IPs) 
Regulated intramembrane proteolysis (RIP) plays various roles in cell signaling 
events that are important for cell proliferation, differentiation, development, and 
metabolism (55). Peptidases involved in RIP are called intramembrane peptidases (IPs). 
IPs cleave within transmembrane region of membrane-bound substrates to release 
cytoplasmic and/or extracellular peptides, which translocate to different parts of the cell 
to perform their corresponding biological response (56). There are four classes of IPs 
identified to date based on their catalytic units (55-57): (i) serine peptidases called 
rhomboids which play roles in the epidermal growth factor receptor pathway (58), (ii) 
zinc metallopeptidases called site-2-proteases (S2P), which are involved in the regulation 
of cholesterol metabolism (59), (iii) glutamate proteases which involve in cell 
differentiation and carcinogenesis (41), and (iv) aspartyl proteases (42) which will be 
discussed in detail in section 2.1.2. These different classes of IPs are not evolutionary 
related but they are all polytopic transmembrane α-helical proteins (Figure 2.1). Despite 
their essential functions in the cell, details of their biochemistry, mechanism and substrate 




Figure 2.1. The proposed catalytic mechanisms and overall structures of intramembrane 
proteases (IPs). Glutamate IP (MmRce1, PDB ID 4CAD) (41), serine IP (GlpG, PDB ID 
2O7L) (58), aspartyl IP (PSH, PDB ID 4HYC) (42) and zinc metalloprotease S2P 
(ZMPSTE24, PDB ID 4AW6) (59). Structures are viewed parallel to the membrane, 
oriented from the ER lumen (top) to the cytoplasm (bottom). Reprinted by permission 




2.1.2. Intramembrane aspartyl proteases and SPP 
Intramembrane aspartyl proteases (IAPs) includes presenilin and Signal Peptide 
Peptidase (SPP) (33, 60). It has been shown that mutations in presenilin are related to 
early onset Alzheimer’s disease (AD) (32). Presenilin is the catalytic subunit of γ-
secretase, it sequentially cleaves amyloid precursor protein (APP) to generate different 
amyloid β (Aβ) peptides that is deposited in the brain of AD patients. Presenilin is very 
similar to SPP in structure, with 9 transmembrane helices but opposite topology (Figure 
2.2). Their active sites include the same conserved motifs (“YD” and “GXGD”) and it 
was shown that they are inhibited by the same active-site directed compounds (61). 
Unlike SPP, presenilin performs self-cleavage to become catalytically active (57). 
 
Figure 2.2. Intramembrane aspartyl proteases. (A) Presenilin is the catalytic component 
of γ-secretase complex (inset). It cleaves APP to form Aβ peptides. (B) SPP processes 
signal peptides following signal peptidase (SP) cleavage. Reprinted by permission from 




SPP is an IAP with orthologs found from human to archaea (62). In eukaryotes, 
after signal peptidase cleaves the signal peptide of a nascent protein, SPP cleaves type-2 
signal peptides from the endoplasmic reticulum (ER) membrane. SPP plays key roles in 
immune surveillance; it processes peptides such as those from newly synthesized major 
histocompatibility complex (MHC) class I molecules (63) to form histocompatibility 
antigen HLA-E epitopes which are presented on the cell surface for signaling natural 
killer cells that protein synthesis is proceeding normally (64). Also, SPP is known to 
process N-terminal domain of hepatitis C virus for virus maturation (65). 
2.1.3. Chapter overview and publications 
Detailed biochemical and structural investigation of membrane proteins are 
challenging compared to soluble proteins due to their lower protein expression levels and 
need for detergent and/or lipids in the downstream processes (66). Because of its 
important role in the cleavage of diverse signal peptides and similarity to presenilin, SPP 
is an attractive target for structural and functional studies. In this chapter, methods 
applied to optimize SPP expression and purification are discussed. 
Two co-author manuscripts were published based on work presented here. First, a 
book chapter was published in Methods in Molecular Biology volume titled Heterologous 
Expression of Membrane Proteins: Methods and Protocols, 2nd edition (67). Second, a 
manuscript about a novel SPP peptide cleavage assay was published in ACS Chemical 




2.2.1. Molecular cloning of archeal SPP orthologs 
Several archeal SPP orthologs were cloned by Dr. Raquel Lieberman during her 
post-doctoral studies. Among those constructs, Haloarcula marismortui SPP (mSPP) and 
Halobacterium salinarum SPP (hSPP) were chosen for further studies. Methanoculleus 
marisnigri JR1 SPP (MCMSPP) was cloned separately. Genomes were obtained from 
ATCC (http://www.atcc.org/). Signal sequence prediction (Signal-3L) (69) was 
performed to detect possible signal sequences, N-terminal 23 amino acids of MCMSPP 
were predicted as signal sequence. The target SPP sequences were amplified by PCR and 
cloned into pET-22b(+) vector (Novagen) via restriction sites NcoI and SalI (Figure 2.3). 
While cloning of MCMSPP without predicted signal sequence (MCMSPP ΔN23) 
worked, the one with predicted signal sequence (full-length MCMSPP or MCMSPP) did 
not work with conventional cloning techniques. Therefore, Jennifer Johnson (former PhD 
graduate from Lieberman Lab) applied a Restriction Free (RF) cloning method (70) to 
obtain MCMSPP. Construct sequences were confirmed by DNA sequencing (MWG 
Operon). Primers for MCMSPP cloning are presented in Table 2.1. 
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Figure 2.3. Molecular cloning of archeal SPP orthologs in pET-22b(+) vector via NcoI 
and SalI restriction sites. There is an N-terminal pelB leader sequence for periplasmic 
membrane insertion and a C-terminal hexahistidine tag for Ni2+-affinity purification (67). 
 
Table 2.1. Primers for molecular cloning of MCMSPP. Cloning of full-length MCMSPP 
only worked with RF cloning. 
Constructs Forward (F) and Reverse (R) Primers (5’-3’) 
MCMSPP F: GTGGACCATGGGGATGCAGATACGCGACTGGCTGC 
R: GTACGTGTCGACGAAAGGAAGCCACGAAAACGAACC 
MCMSPP (RF cloning) F: CGCTGCCCAGCCGGCGATGGCCATGCAGATACGCGACTGG 
R: GCATCGGCATGACGAGGACGATAGCGATGATCTGGACGAAC 
MCMSPP ΔN23 F: GTGGACCATGGGGATCGTCCTCGTCATGCCGATGC 
R: GTACGTGTCGACGAAAGGAAGCCACGAAAACGAACC 
 
2.2.2. Cell growth and protein expression 
A standard heat-shock plasmid transformation into E.coli Rosetta 2 (DE3) cells 
were performed and plated onto an agar plate containing 60 µg/mL ampicillin (plasmid 
resistance) and 34 µg/mL chloramphenicol (cell resistance). After overnight (16-18 
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hours) incubation at 37°C, a single colony was chosen for expression immediately or the 
plate was wrapped with a parafilm and stored in the 4°C refrigerator up to one week. 
1x200 mL Luria-Bertani (LB, Fisher) broth in a 500 mL Erlenmeyer flask and 
6x1-L LB broth in 2 L flasks were autoclaved and 60 µg/mL ampicillin and 34 µg/mL 
chloramphenicol were added to each flask when cool. A single colony from 
transformation plate were added into 5 ml LB broth with appropriate antibiotics (starter 
culture) in the morning and incubated at 37°C for 6-8 hours with shaking at 225 RPM. 
200ml LB broth was inoculated with the starter culture and incubated at 37°C for 16-18 
hours with shaking at 225 RPM. The next morning, each of 6 1-L cultures were 
inoculated with 10 mL of the 200 ml culture. For each 1 L culture, starting optical density 
at 600nm (OD600) should be less than 0.1. 1-L cultures were incubated at 37°C with 
shaking at 225 RPM, and OD600 was checked regularly. When OD600 reached 0.6-0.8 
(usually takes 3-4 hours), the incubation temperature was reduced to 18°C and shaking 
was continued for one hour to allow the temperature to equilibrate. Protein expression 
was induced by the addition of 0.5 mM IPTG (Calbiochem) to each culture and shaking 
was continued at 225 RPM at 18°C for 16-20 hours. 
After expression for 16-20 hours, the cells were harvested by centrifugation at 
4200 x g for 10 minutes. Cell pellet was put in a small plastic bag and flash-frozen in 
liquid nitrogen. They were stored at -80°C freezer until further use. 
2.2.3. Membrane isolation 
7-8 g of frozen cell paste was resuspended in a 50 mL conical tube on ice by 
adding 25-30 mL lysis buffer (50 mM HEPES pH 7.5, 200 mM NaCl, Roche complete 
EDTA Free Protease Inhibitor - 1 tablet to 50 mL buffer). Frequent gentle pipetting was 
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done with a 25 mL serological pipette until the mixture was fully resuspended and 
homogeneous. Resuspended cells were lysed using a chilled French press equipment at 
1300 psi pressure. The cells were passed through the French press at least twice to ensure 
complete cell lysis.  
Cellular lysate was centrifuged at 5000 x g for 15 minutes at 4°C. Supernatant 
was transferred in a new centrifuge tube and centrifuged again. This centrifugation step 
was repeated until no further pellet was discernible (usually 3 times). Final supernatant 
was transferred to an ultracentrifuge tube and centrifuged at 120,000 x g for 45 minutes at 
4°C. The supernatant was discarded and the membrane pellet was placed in a 7 mL 
Dounce homogenizer with 7 mL lysis buffer (without protease inhibitor). The membrane 
pellet was resuspended with the loose plunger first for 6 times, then the tight plunger for 
10 times. The resuspended membrane pellet was ultracentrifuge again at 120,000 x g for 
45 minutes at 4°C. The supernatant was discarded and the pelleted membrane was 
transferred into a tared microcentrifuge tube in ~0.4 mg aliquots. Its mass was recorded, 
around 0.9-1.2 g of membrane was typically obtained from 7-8 g lysed cells. Membranes 
were flash-frozen in liquid nitrogen and stored at -80°C freezer until protein purification. 
2.2.4. Protein purification from membranes 
Frozen membrane (0.4-0.5 g) was resuspended in 7 mL membrane resuspension 
buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 20 mM imidazole) by dounce 
homogenizer with loose plunger first, then the tight plunger. An amount of the desired 
detergent (mostly n-dodecyl β-D-maltoside (DDM, Anatrace)) was weighed out equal to 
the mass of membrane. The detergent was dissolved in enough membrane resuspension 
buffer to make a final 1% solution. For 0.4 g membrane, 0.4 g detergent was added to 33 
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mL membrane resuspension buffer, where the last 7 mL would be the resuspended 
membrane solution. The resuspended membrane was added to the detergent solution and 
rocked gently at 4°C for 1 hour. Once solubilization is complete the solution appears 
translucent. Solubilized membrane was centrifuged at 120,000 x g at 4°C for 45 minutes 
to remove any unsolubilized material. Any remaining pellet was discarded and the 
supernatant was used for purification.  
Protein-detergent solution was loaded into a superloop appropriate for the total 
volume. With ÄKTA Fast Liquid Chromatography (FPLC) instrument (GE Healthcare), 
the protein was purified over a 1 mL Ni2+-affinity sepharose chromatography column 
(GE Healthcare) using Buffer A (50 mM HEPES pH 7.5, 500 mM NaCl, 20 mM 
imidazole, 0.1% DDM) for the wash and Buffer B (50 mM HEPES pH 7.5, 500 mM 
NaCl, 500 mM imidazole, 0.1% DDM) for protein elution using a gradient elution. The 
wash step after sample injection was 0% buffer B before but it was changed to 5% buffer 
B after we discovered a contamination issue (see Chapter 5). The protein amount was 
monitored by tracking the absorbance at 280 nm. Eluted protein was concentrated to 
appropriate volume by 50K MWCO Amicon filter for size-exclusion chromatography 
(SEC) using gel filtration buffer (20 mM HEPES pH 7.5, 250 mM NaCl, 0.05% DDM). 
HiPrep 16/60 Sephacryl S-300 (S300) or Superose 12 10/300 GL (S12) (GE Healthcare) 
was used as gel filtration column on an ÄKTA FPLC system. Protein concentration was 
measured by absorbance at 280 nm using a calculated extinction coefficient. Sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and coomassie staining 
was used to assess the purity of the protein. 
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2.2.5. Detergent exchange by gel filtration 
After protein purification by Ni2+-affinity chromatography, the sample was 
divided into equal volumes, ~250 µL each, to test different detergents by gel filtration. 
S12 column was equilibrated on an ÄKTA FPLC system with at least two column 
volumes of gel filtration buffer with corresponding detergents (Anatrace). Each gel 
filtration buffer contained 2 x the critical micelle concentration (CMC) of corresponding 
detergent. Used detergents include Fos-Choline-12 (FC-12), N,N-dimethyldodecylamine-
N-oxide (LDAO), Lauryl Maltose Neopentyl Glycol (LMNG), 
Polyoxyethylene(8)dodecyl Ether (Anapoe-C12E8), n-octyl-b-D-glucopyranoside (OG), 
n-Nonyl-β-D-Glucopyranoside (NG), n-Nonyl-β-D-Maltopyranoside (NM), n-decyl-β-D-
maltopyranoside (DM) and n-dodecyl- β-D-maltopyranoside (DDM). 
After equilibrating with two column volumes of buffer to remove the prior 
detergent, the 250 µl sample was injected onto the column. Absorbance at 280 nm was 
tracked for protein elution. Elution peak shape and intensity was compared. High 
intensity, Gaussian peaks were desirable because it may show that protein in 
corresponding detergent is monodisperse. The size of the protein based on elution volume 
should also be considered, because it may indicate oligomeric state or protein-detergent 
complex (PDC) size. Further experiments (filter MWCO optimization, activity assay, 
thermal melt, crystallization, etc.) were conducted with eluted proteins. 
2.2.6. Protein stability analysis by Circular Dichroism (CD) melt 
Each protein sample was concentrated using a 50K MWCO Amicon filter to 8-10 
µM. CD spectra and thermal melt were acquired on a Jasco J-810 spectropolarimeter 
equipped with Neslab RTE 111 circulating water bath and a Jasco PTC-4245/15 
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temperature control system. CD spectra were taken at room temperature for both gel 
filtration buffer (blank) and protein sample in gel filtration buffer. CD thermal melt was 
performed utilizing a 1 °C/min increase in temperature from 4 to 90°C. Both CD spectra 
and thermal melt (temperature points for every 2°C) were acquired with 15 averaged 
scans from 300 to 200 nm at a 200 nm/min scan rate, using a 0.1-cm cuvette. 
For each sample, the temperature versus the normalized molar ellipticity was 
plotted at the minimum wavelength (222 nm for -helical proteins). Molar ellipticity was 
calculated from equation: Φ = Mres x Φobs / 10 x d x c, where Mres is the mean residue 
mass calculated from the protein sequence; Φobs is the observed ellipticity (degrees) at 
wavelength 222 nm; d is the path length (cm), and c is the protein concentration (g/ml). 
The melting temperature (Tm) was determined using molar ellipticity values recorded at 
222 nm via sigmoidal dose-response analysis using GraphPad Prism 5 software. High 
protein stability (high Tm) is desired; detergents that maintain high stability to the protein 
of interest can be used for further study.  
2.2.7. Concentrator Molecular Weight Cut-Off (MWCO) optimization by protein 
quantification and Thin Layer Chromatography (TLC) 
For each purified protein in each detergent to be tested, gel filtration elution peak 
was pooled, the protein concentration was measured by absorbance at 280 nm using a 
calculated extinction coefficient. 0.45 mL of the protein sample was put into each 0.5 mL 
MWCO 10K, 30K, 50K, and 100K Amicon filter. The samples were centrifuged at 8500 
x g, 4°C until less than 50 µL remains on top of the filter. The total volume and protein 
concentration of each concentrated sample (concentrate) were measured. Any protein loss 
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was calculated for each filter by comparing protein amount on top of the filter with 
starting protein concentration. 
Bottom portion of each filter (filtrate) was placed into a new 0.5 mL 10K Amicon 
filter. They were centrifuged at 8500 x g, 4°C until less than 50 µL remains on top of the 
filter. This concentrated all the detergent that passed through the initial filter so that it can 
be visualized on a TLC plate. Both concentrate and filtrate samples were kept for further 
TLC assay. 
Detergent standards were prepared for a standard curve in the gel filtration buffer, 
including points above and below the expected detergent concentration. For example, 
standards of 0.25%, 0.5%, 1.0%, 2.0% (w/v) were prepared for an expected concentration 
of 0.5-1.0% corresponding detergent. 5 µL of each of the detergent standards, concentrate 
and filtrate samples were spotted onto the baseline of a silica 60 TLC plate. Pencil can be 
used to draw a straight line at the baseline (3 cm from the bottom of the plate) for aligned 
sample spotting and there should be at least 1 cm between sample spots. All samples 
were allowed to dry for at least 30 minutes at room temperature. Dried TLC plate was 
then placed into a TLC chamber containing about 0.5 inch solvent 
(chloroform:methanol:ammonium hydroxide, 63:35:5, v/v/v). The solvent was allowed to 
run at least half way up the plate. The TLC plate was removed from the chamber and the 
solvent on the plate was allowed to evaporate in open air for approximately 5 minutes. 
Dried TLC plate was placed in an iodine chamber (I2) and allowed to stain for at least 5 
minutes. The TLC was removed from the chamber and imaged immediately. The 
detergent amount was quantified by densitometry of the detergent spots using 
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ImageQuant, ImageJ, or Photoshop. Unknown detergent concentrations in concentrate 
and filtrate samples were estimated by using the detergent standard curve.  
Optimal filter MWCO was determined by comparing the protein loss with the 
detergent loss for corresponding protein-detergent complex. The filter with the least 
detergent in the sample and the least protein loss should be the best choice. 
2.3. Results 
2.3.1. Archeal SPP orthologs 
In higher eukaryotes, proteins might need post-translational modifications to be 
functional and active. This makes their recombinant bacterial expression challenging. In 
this thesis, archeal SPP orthologs were chosen to be expressed in E.coli. Archeal SPPs 
can be studied as a model system to higher eukaryotic SPPs and presenilin. 
Three archeal SPPs were chosen: Haloarcula marismortui SPP (mSPP), 
Halobacterium salinarum SPP (hSPP) and Methanoculleus marisnigri JR1 SPP 
(MCMSPP) (Figure 2.4). mSPP and hSPP were already cloned by Dr. Raquel Lieberman 
during her post-doctoral research. MCMSPP was cloned separately with Jennifer 
Johnson, a former lab member after a publication on MCMSPP was published (71). 
pet22b-(+) was chosen as expression plasmid which has N-terminal pelB sequence and 
C-terminal hexahistidine tag (Figure 2.3). N-terminal pelB is a leader sequence and it 
directs the recombinantly expressed protein to the membrane. Hexahistidine tag was used 
to purify the protein. During molecular cloning step, structure of MCMSPP was not 
known yet. Therefore, signal sequence prediction servers were used to predict a possible 
signal sequence on the N-terminal (67). Both constructs with and without predicted signal 
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sequence, MCMSPP and MCMSPP ΔN23 respectively, were cloned into the plasmid for 
expression and purification of MCMSPP. After crystal structure of an archeal SPP 
became available (PDB ID 4HYC) (42), it was revealed that predicted signal sequence 
was actually a part of TM1 of MCMSPP. Therefore, all efforts were focused on 
MCMSPP afterwards.  
 
Figure 2.4. Multiple sequence alignment of MCMSPP, mSPP, hSPP and crystal structure 
sequence of MCMSPP (4hyc_chainA_p001, PDB ID: 4HYC). Alpha-helix and beta sheet 




2.3.2. SPP expression, membrane isolation and purification 
Three parameters were optimized for SPP expression: (i) induction temperature 
and duration, (ii) cell line, (iii) culture media. Induction at 18°C for 16-18 hours yielded 
more cell paste and higher protein expression than that of 37°C for 4-5 hours. E.coli 
Rosetta 2 (DE3) gave better protein expression than E.coli C43 (DE3). Although Luria-
Broth (LB) and Terrific Broth (TB) gave similar cell growth curves (Figure 2.5), protein 
yield was higher with LB. This optimized protocol (Chapter 2.2.2) was used for all SPP 
orthologs. 2.5-3 g of cell paste was typically obtained from 1 L cell culture. 
 
Figure 2.5. Cell growth curves for MCMSPP/E.coli Rosetta2 (DE3) in different media. 
 
Membranes were isolated from the cell paste as described in the methods section. 
A wash step was performed for the pelleted membrane to eliminate residual protease 
inhibitor. 0.9-1.2 g membrane was typically obtained from 7-8 g cell paste. Because 
membrane isolation itself takes a whole day, harvested membranes were always flash-
frozen before resuspension and detergent solubilization. 
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SPP solubilization was performed with two different detergents: DDM and FC-
12. They both solubilized SPP orthologs well enough for further purification steps. For 
purification, both DDM and FC-12 was tested. However, DDM was used for most of the 
purification protocols because FC-12 has not been successful for protein crystallization 
compared to DDM (72). For the last step of purification, SEC was used to exchange 
detergents. A variety of detergents (see Chapter 2.2.5) were tested to determine which 
detergent will be the most suitable for the final protein sample to be used in further 
structural and biochemical studies. First parameter to check was the shape of elution peak 
in SEC. mSPP with EE-tag (mSPP-EE1, Chapter 4) was chosen as a representative result 
(Figure 2.6). Gaussian-like peaks were preferred because it is an indicator of 
homogenous monodisperse SPP solution. 
 
Figure 2.6. A representative example of detergent exchange by SEC. (A) SEC elution 
profile of mSPP-EE1 with 5 different detergents on Superose 12 column (B) SDS-PAGE 
of mSPP-EE1 in different detergents: 1) after Ni2+-affinity purification with FC-12, after 




2.3.3. Stability of SPP orthologs in different detergents 
Stability analysis of SPP orthologs in different detergents were determined by CD 
thermal melt (Figure 2.7). Melting temperatures were calculated based on the melting 
curves. Some melting curves did not reach plateau due to the apparent high stability of 
membrane proteins and/or only partial unfolding in detergent micelles, extrapolation was 
performed to calculate their melting temperatures. 
 
Figure 2.7. A representative example of CD thermal melt for stability determination. (A) 
CD thermal melt of mSPP-EE1 in different detergents. (B) Calculated melting 
temperature from CD thermal melt. 
 
2.3.4. Detergent quantification and concentrator MWCO determination 
Analysis of detergent quantity in the final sample was performed by TLC. Our 
aim was to eliminate as much empty detergent micelles as possible while retaining 
maximum amount of protein in the sample. Four different concentrator MWCO sizes 
were tried (10K, 30K, 50K, 100K, K: kDa). Both top (concentrate) and bottom (filtrate) 
of concentrator were analyzed by TLC for detergent quantification and UV-Vis 
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absorbance (at 280 nm) for protein quantification (Figure 2.8). 50K amicon filter was 
chosen for further use because it lost excess detergent and kept protein better than others. 
 
Figure 2.8. A representative example of concentrator MWCO determination. (A) DDM 
detergent quantification of mSPP-EE2 samples in different concentrators by TLC 
analysis: 1) 3% DDM standard 2) 10K top 3) 30K top 4) 50K top 5) 100K top 6) 10K 
bottom 7) 30K bottom 8) 50K bottom 9) 100K bottom. (B) Protein percentages of mSPP-
EE2 samples in different concentrators by absorbance analysis. 
 
2.4. Discussion 
In this chapter, three SPP orthologs were chosen to be expressed and purified for 
further biochemical and structural experiments. Several optimizations were performed to 
get better quality protein. Archeal SPP orthologs were chosen due to their ease of 
production in E.coli expression system. Cell growth and protein expression protocol was 
optimized to get highest yield of corresponding protein.  
Membrane proteins need detergent for purification due to their hydrophobic 
nature. Different detergents were tested for initial solubilization and final protein sample. 
For solubilization, mostly DDM was tested first because it has been widely and 
successfully used for many other membrane proteins (73). Monodispersity and stability 
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are important parameters for downstream experiments (74). Detergent exchanges were 
performed at the last step of purification, SEC. Monodispersity was estimated from the 
shape of elution peak, gaussian peak shaped elution profile is an indication of 
monodispersity. For stability analysis, CD thermal melt was used. Melting temperature is 
a measure of protein stability which is related to crystallization propensity for structural 
studies (75). LMNG gave the highest stability to mSPP-EE1 according to CD melt data 
(Figure 2.7) but its SEC peak was in the void volume (Figure 2.6) meaning that its PDC 
size is higher than separation range of S12 (~300 kDa for globular proteins). 
Detergent amount in the final sample is also important because excess detergent 
might interfere with crystallization (76). Different MWCO sizes of concentrator filters 
were tested. Concentrator with 50K MWCO was chosen for further experiments with 
DDM because it eliminated most of the excess detergent according to TLC analysis and it 
kept the protein better than 100K filter which lost more than half of the loaded protein 
(Figure 2.8).  
Before TLC, we tried to use contact angle measurement (77) for quantification of 
detergent amount in the final sample (data not shown). However, we had many technical 
difficulties with the instrument which was located in another research lab (Behrens lab at 
Georgia Tech). In addition to those methods, there are several other techniques to 
determine detergent concentration such as refractive index, phenol-sulphuric acid assay 
for sugar-based detergents, molybdate assay for phosphate-containing detergents, 
radiolabeling, gas chromatography coupled with mass spectrometry, and nuclear 
magnetic resonance (78, 79). TLC was the most convenient method because it uses little 
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amount to sample, it works with most of the detergents and materials needed are not 
expensive. 
Our method to determine stabilizing detergent was challenging because 
expression, purification, and CD melt should be performed for each SPP ortholog-
detergent combination. There are other methods that can be used to make it more high-
throughput such as fluorescent size exclusion chromatography (FSEC) with a GFP-fused 
protein (80, 81). In this method, protein even need not be purified but a fluorescence 
detector is required in line with the SEC column. Another method uses buried cysteines 
in your protein (if any) to perform high-throughput thermal unfolding experiment with N-
[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM). CPM fluoresces 
upon reaction with thiol group on the cysteine which reveals with thermal unfolding (82).  
This chapter summarizes our efforts to get higher yield, stability and quality SPP 
protein. We optimized our SPP expression and purification protocol accordingly, and this 





CHAPTER 3: Development of Engineered Single Chain Antibody Fragments 
(scFvs) as Crystallization Chaperones for Membrane Proteins 
3.1. Introduction 
3.1.1. The use of crystallization chaperones for membrane protein crystallization 
Macromolecular crystallization requires the association of weak, but specific, 
intermolecular interactions into a repeated lattice array, and is often the rate limiting step 
to structure determination by X-ray crystallography (83).  
Although crystallization and structure determination of proteins is successful in 
many cases, numerous techniques have been implemented in which target proteins are 
modified to enhance crystallizability. The most well-known example is membrane 
proteins. Membrane proteins have a variety of essential functions in the cell, which are 
important from both biological and therapeutic standpoints. However, structure 
determination of membrane proteins is still challenging due to their hydrophobic nature. 
Techniques such as chaperone-based crystallization, tailoring the lipid and/or detergent 
environment, covalent modification, and mutagenesis studies have emerged to make 
crystallization of a target membrane protein tractable (84-86).  
Chaperone-based crystallization uses co-crystallization chaperones that assist in 
the crystallization of a target membrane protein which present few surface polar residues 
to form crystal contacts (86). The addition of a chaperone protein can sequester 
aggregation-prone hydrophobic regions and can serve to immobilize flexible regions (87, 
88). Structure determination of a G-protein coupled receptor (GPCR) using a fused T4 
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lysozyme in place of a flexible loop and a nanobody chaperone specific for the GPCR 
demonstrates the utility of this approach (89).  
3.1.2. Antibody fragments as crystallization chaperones 
Antibody fragments are the most commonly used chaperones for membrane 
protein crystallization (85, 86, 90). They include Fab fragments, single chain antibody 
fragments (scFvs) (Figure 3.1) and nanobodies (89-92). Although antibody fragment 
production is straightforward, it is still expensive and time-intensive (86). Additionally, 
produced antibodies are usually specific to a target protein; a more general approach 
would be beneficial. Our potentially generalizable approach uses engineered single chain 
antibody fragments (scFvs) specific to a short peptide epitope that can be inserted into 
any extramembranous loop of target membrane protein. Tight binding of engineered scFv 
variants to the membrane protein would provide a more hydrophilic crystal contacts 
leading to more stable crystal lattices, and better diffracting crystals.  
 
Figure 3.1. Fab and scFv antibody fragments derived from full Immunoglobulin G (IgG) 




3.1.3. Chapter overview and publications 
To date, successful crystallization chaperones have been target-specific, limiting 
the generality of the chaperone method, as a new chaperone must be identified for each 
new target. Chaperone-assisted crystallization has the potential to become a general 
platform, however, if chaperones can be engineered for high affinity to a specific short 
peptide epitope that can be easily installed into any target protein of interest (Figure 3.2). 
We believe that an ideal chaperone toolbox would include multiple hypercrystallizable 
chaperones, each with specificity for a discrete epitope, versatile crystal contact 
interfaces and a predictable crystallization lattice to accommodate client proteins of 
various sizes. Exquisite control over crystallization may not be easily achievable, but for 
our set of engineered crystallization chaperones discussed in this chapter, we 
hypothesized that systematically exploring crystallization propensities may reveal 
governing principles and improved chaperones.  
 
 
Figure 3.2. Target protein specific versus peptide epitope specific scFvs. 
 
Here, we used a combination of computational analysis, protein design, 
crystallization, and structure determination to investigate the extent to which protein 
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crystallization may be controlled by tuning the energetics of intermolecular contacts 
within a highly conserved (sequence identity ≥ 85%) set of murine scFvs that are 
candidate crystallization chaperones. We previously engineered the anti-hexahistidine 
(His6) scFv 3D5 (94, 95) to enhance its biophysical properties and affinity for the 
hexapeptide EYMPME (EE-tag) (95), a process which inadvertently resulted in a new 
crystal lattice employing variable heavy chain (VH) complementarity determining region 
(CDR) residues in a crystal contact. In this study, we systematically altered specific 
amino acid residues mediating these new crystal contacts in an attempt to restore the 
original 3D5 lattice, which does not use CDR residues in major crystal contacts. The 
experimentally prepared variants retain some crystal contact interfaces of the original 
parent 3D5 antibody, and in some cases even use the same residues for contacts; yet, 
lattices were altered. Taken together, our results underscore the challenges of directing a 
particular lattice in hypercrystallizable proteins such as this family of scFvs, but suggest 
that this plasticity could be an advantage for their use as crystallization chaperones. 
In this work, protein engineering and design were mostly done by Maynard Lab at 
UT Austin, crystallization and structure determination were performed by Lieberman Lab 
and thermodynamic calculations were done by Truskett lab at UT Austin. This work was 
published in Proteins: Structure, Function and Bioinformatics in 2014 (96).  
3.2. Methods 
3.2.1. Molecular biology of scFv chaperones 
Two initial scFv chaperones with enhanced biophysical properties were 
previously derived from 3D5 scFv (94): anti-His6 3D5/His_683 and 3D5/EE_48, which 
has low nanomolar affinity for internal EE-tag (95). Two new scFv variants were 
37 
 
investigated in this thesis: anti-EE 3D5/EE_48.A and anti-EE 3D5/EE_48.K. Those new 
anti-EE variants had mutations which targeted crystal contacts in the lattice formation. 
3D5/EE_48.A harbored the heavy chain amino acid changes S30T and S32A, and 
3D5/EE_48.K harbored S30T and S32K. All scFv chaperones were designed by a 
collaborator, Maynard lab (University of Texas at Austin), they were cloned into the 
SfiI–SfiI site of pAK400 plasmid. Antibody residues are numbered according to the 
Kabat system (see Table 3.1 for light chain and Table 3.2 for heavy chain sequences). 
Design of 3D5/EE_48.A and 3D5/EE_48.K variants were performed by site-directed 
mutagenesis (SDM, Quickchange II, Agilent Technologies) with 3D5/EE_48 as a 
template. Primers for 3D5/EE_48.A scFv and 3D5/EE_48.K variants can be seen in 
Table 3.3. Sequences were verified by DNA sequencing (MWG Operon).  
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Table 3.1. Light chain crystal contact residues of 3D5, 3D5/His_683, 3D5/EE_48, 3D5/EE_48.A, and 3D5/EE_48.K. Residues 
are listed according to the Kabat numbering system. Crystal contact residues are shown in dark grey, and CDR regions 
















































































3D5 M A D Y K D I L M T Q T P S S L P V S L G D Q A S I S C R S S 
3D5/His_683 M A D Y K D I V M T Q T P S S L P V S L G D Q A S I S C R S S 
3D5/EE_48 M A D Y K D I V M T Q T P S S L P V S L G D Q A S I S C R S S 
3D5/EE_48.A M A D Y K D I V M T Q T P S S L P V S L G D Q A S I S C R S S 
3D5/EE_48.K M A D Y K D I V M T Q T P S S L P V S L G D Q A S I S C R S S 
 



































































































3D5 Q S I V H S N G N T Y L E W Y L Q K P G Q S P K L L I Y K V S 
3D5/His_683 Q S I V H S N G N T Y L E W Y L Q K P G Q S P K L L I Y K V S 
3D5/EE_48 Q S I V H S N G N T Y L E W Y L Q K P G Q S P K L L I Y K V S 
3D5/EE_48.A Q S I V H S N G N T Y L E W Y L Q K P G Q S P K L L I Y K V S 
3D5/EE_48.K Q S I V H S N G N T Y L E W Y L Q K P G Q S P K L L I Y K V S 
 






























































































3D5 N R F S G V P D R F S G S G S G T D F T L K I S R V E A E D L 
3D5/His_683 N R F S G V P D R F S G S G S G T D F T L K I S R V E A E D L 
3D5/EE_48 N R F S G V P D R F S G S G S G T D F T L K I S R V E A E D L 
3D5/EE_48.A N R F S G V P D R F S G S G S G T D F T L K I S R V E A E D L 
3D5/EE_48.K N R F S G V P D R F S G S G S G T D F T L K I S R V E A E D L 
 





















































































3D5 G V Y Y C F Q G S H V P F T F G S G T K L E I K R 
3D5/His_683 G I Y Y C F Q G S L V P P T F G A G T K L E L K R 
3D5/EE_48 G I Y Y C F Q G S L V P P T F G A G T K L E L K R 
3D5/EE_48.A G I Y Y C F Q G S L V P P T F G A G T K L E L K R 





Table 3.2. Heavy chain crystal contact residues of 3D5, 3D5/His_683, 3D5/EE_48, 3D5/EE_48.A, and 3D5/EE_48.K. 
Residues are listed according to the Kabat numbering system. Crystal contact residues are shown in dark grey, and CDR 






















































































3D5 Q V Q L Q Q S G P E D V K P G A S V K I S C K A S G Y T F T D 
3D5/His_683 Q V Q L Q Q S G P E D V K P G A S V K I S C K A S G Y T F T D 
3D5/EE_48 Q V Q L Q Q S G P E D V K P G A S V K I S C K A S G Y S L S T 
3D5/EE_48.A Q V Q L Q Q S G P E D V K P G A S V K I S C K A S G Y S L T T 
3D5/EE_48.K Q V Q L Q Q S G P E D V K P G A S V K I S C K A S G Y S L T T 
 


































































































3D5 Y Y M | | N W V K Q S P G K G L E W I G D I N P N N G G T S Y 
3D5/His_683 Y Y M |
 | N W V K Q S P G K G L E W I G D I N P N N G G T S Y 
3D5/EE_48 S G M G V N W V K Q S P G K G L E W L A H I Y W D D D | K R Y 
3D5/EE_48.A A G M G V N W V K Q S P G K G L E W L A H I Y W D D D | K R Y 
3D5/EE_48.K K G M G V N W V K Q S P G K G L E W L A H I Y W D D D |
 
K R Y 
 


































































































3D5 N Q K F K G R A T L T V D K S S S T A Y M E L R S L T S E D S 
3D5/His_683 N Q K F K G R A T L T V D K S S S T A Y M E L R S L T S E D S 
3D5/EE_48 N P S L K S R A T L T V D K S S S T V Y L E L R S L T S E D S 
3D5/EE_48.A N P S L K S R A T L T V D K S S S T V Y L E L R S L T S E D S 
3D5/EE_48.K N P S L K S R A T L T V D K S S S T V Y L E L R S L T S E D S 
 














































































































3D5 S V Y Y C E S Q S |
 | | | | | | G A Y W G Q G T T V T V S 
3D5/His_683 S V Y Y C A A S S P Y S M R A A M D Y W G Q G T T V T V S 
3D5/EE_48 S V Y Y C A R R G G S S H Y Y A M D Y W G Q G T T V T V S 
3D5/EE_48.A S V Y Y C A R R G G S S H Y Y A M D Y W G Q G T T V T V S 




Table 3.3. Primers for 3D5/EE_48.K and 3D5/EE_48.A. 
Constructs Forward (F) and Reverse (R) Primers (5’-3’) 
3D5/EE_48.A F: ATGGGTGTGAACTGGGTTAAACAGAGTCCAGG 
R: CCTATAAGTGACTGGTGACGACCATACCCACACTTG 
3D5/EE_48.K F: ATGGGTGTGAACTGGGTTAAACAGAGTCCAGG 
R: CCTATAAGTGACTGGTGATTCCCATACCCACACTTG 
 
3.2.2. Protein expression and purification 
For all scFv chaperones, a standard heat-shock plasmid transformation into E. coli 
C43 (DE3) cells were performed and it was plated in an agar plate containing 34 µg/mL 
chloramphenicol (plasmid resistance). Luria-Bertani (LB, Fisher) and Terrific Broth (TB, 
Fisher) cultures used for the rest of the protocol contain the same antibiotic content. After 
overnight (16-18 hours) incubation of the agar plate at 37°C, a single colony was chosen 
for expression immediately or the plate was wrapped with a parafilm and stored in the 
4°C refrigerator up to one week. 
A single colony from transformation plate were added into 5 ml LB broth (starter 
culture) in the morning and incubated at 37°C for 6-8 hours with shaking at 225 RPM. 
The starter culture was inoculated into 500 mL TB in a 2 L baffled flask and grown 
overnight at 25°C with shaking at 225 RPM. Next morning, cells were pelleted at 4200 x 
g for 10 minutes at 4 °C, then the cell pellet was resuspended in 500 mL fresh TB in 2 L 
flask and incubated for 1 hour at 25 °C, 225 RPM. Protein expression was induced by the 
addition of 1 mM IPTG (Calbiochem) to each culture and shaking was continued at 225 
RPM at 25°C for 4-5 hours. The cells were harvested by centrifugation at 4200 x g for 10 
minutes. Cell pellet was put in a small plastic bag and flash-frozen in liquid nitrogen. 
They were stored at -80°C freezer until further use. 
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Cell pellet was resuspended in 10 mL resuspension buffer (0.1 M Tris pH 8.0, 0.75 M 
sucrose) per gram of cell pellet. 10 mg lysozyme (Sigma-Aldrich) was dissolved in 1ml 
resuspension buffer per gram of cell and it was added to resuspension. 7.5 mL of 1 mM 
EDTA were added slowly per gram of cell. The resuspension was stirred for 1 hour at 4 
°C, then 1 mL of 0.5 M MgCl2 was added per gram of cell and stirring continued for an 
additional 1 hour. After centrifuging for 20 minutes at 47,800 x g, supernatant was 
subjected to Ni2+-affinity chromatography on an ÄKTA FPLC system (GE Healthcare) 
with wash buffer (20 mM Tris pH 8, 500 mM NaCl, 20 mM imidazole) and elution buffer 
(20 mM Tris pH 8, 500 mM NaCl, 500 mM imidazole). Gradient elution (0-60% elution 
buffer) was used to elute corresponding scFv chaperone. scFv was further purified by 
preparative size exclusion chromatography using a Superdex 75 16/600 column (GE 
Healthcare) equilibrated with HBS buffer (50 mM HEPES pH 7.5, 150 mM NaCl) on an 
ÄKTA FPLC system. Both monomer and dimer peaks were collected and pooled 
together for further analysis and/or crystallization (see section 3.3.5). 
3.2.3. Biophysical characterization 
Protein purity and size were assessed by standard reducing sodium-dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Qualitative analysis of the 
oligomeric state distribution in solution at equilibrium (scFv monomer-to-dimer ratio) 
was determined by calculating the area under each elution peak from size exclusion 
chromatography using Unicorn software (GE Healthcare).   
Protein solubility was determined by quantifying the concentration of soluble 
protein after concentration of the protein to ~20 mg/mL, incubation for four days at 4 °C, 
and centrifugation to pellet insoluble material. Thermal stability was evaluated by 
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differential scanning fluorimetry (DSF) (97). Briefly, purified protein (20 μl of 200μM) 
or buffer blank were mixed with Sypro Orange (1 μl of a 1:1000 dilution; Molecular 
Probes), heated in a Real Time PCR machine (ViiaTM7; Applied Biosystems) at 
increments of 0.96°C/min from 25°C to 90°C and analyzed with ViiaTM7 software 
(Applied Biosystems) for the melting temperature (Tm), the midpoint of unfolding. 
Protein solubility and thermal stability experiments were performed by the collaborator, 
Maynard lab (University of Texas at Austin). 
3.2.4. Protein crystallization 
Initial crystallization conditions for 3D5/His_683 were identified by sparse matrix 
screening (Hampton Research HR2-139 and HR2-138). For 3D5/EE_48.A and 
3D5/EE_48.K, we initially used conditions that resulted in diffraction quality crystals of 
the parent 3D5/EE_48 scFv, but included several optimization steps to increase the 
diffraction quality of the daughter scFvs. Variables optimized included protein 
concentration, protein:drop ratio, temperature, buffer concentration, salt, and 
polyethylene glycol (PEG) molecular mass in the mother liquor. Ultimately, the best 
crystals of 3D5/His_683 (8 mg/ml in 10 mM HEPES pH 7.5, 150 mM NaCl, HBS) were 
grown at room temperature with 0.2 M KI, 0.001 M Guanidinium HCl, 18% PEG 8000 
(Hampton Research).  These crystals appeared in 2-3 days and grew to a maximal size of 
120-150 μm within 1 week. Crystals of 3D5/EE_48.K (7.5 mg/ml in HBS) were grown at 
4°C with 0.1 M Tris pH 8.5, 0.2 M Li2(SO4), 3% 6-aminohexanoic acid, 24% PEG 8000; 
crystals appeared in 4-5 days and grew to a maximal size of 30-40 μm within 2 weeks. 
Crystals of 3D5/EE_48.A (7.5 mg/ml in HBS) were grown at 4°C with 0.1 M BisTris pH 
6.5, 0.2 M Mg(OAc)2, 21% PEG 8000, crystals appeared in 4-5 days and grew to a 
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maximal size of 20-30 μm within 3-4 weeks. All crystals were grown utilizing a 1:1 
reservoir:protein ratio. David Heaner, Jr. (former undergraduate researcher in Lieberman 
Lab) helped with some of listed crystallization experiments. 
3.2.5. Data collection, structure determination, and refinement 
Crystals were mounted in nylon loops and flash-cooled with liquid nitrogen prior 
to synchrotron X-ray data collection. Glycerol was used as a cryo-protectant by 
supplementing the reservoir conditions with 30% (v/v) (3D5/His_683), 20% (v/v) 
(3D5/EE_48.A) and 25% (v/v) (3D5/EE_48.K). Data were collected at the Southeast 
Regional Collaborative Access Team (SER-CAT) beamline 22-ID at the Advanced 
Photon Source at Argonne National Laboratory (Darien, IL). Crystallographic data sets 
were processed with HKL2000 (98) and unmerged data were exported for structure 
determination by molecular replacement using Phaser (99). For 3D5/His_683, the search 
model was the 3D5 scFv (PDB ID 1KTR) whereas for 3D5/EE_48.A and 3D5/EE_48.K, 
the 3D5/EE_48 structure (PDB ID 3NN8) was used. The atomic models were fit to the 
respective electron density maps using Coot (100), and then iteratively refined with 
Phenix (101), taking advantage of parameterization specifically designed for low 
resolution structures (102). POLYGON (103) (Phenix) was used to evaluate model 
qualities of all structures and they were in the acceptable range (103, 104). 
Crystallographic statistics are presented in Table 3.4. Atomic coordinates and structure 
factors for 3D5/His_683, 3D5/EE_48.A and 3D5/EE_48.K have been deposited at the 




Table 3.4. Crystallographic data collection and refinement statistics for scFv chaperones. 
 3D5/His_683 (4NKO) 3D5/EE_48.K (4NKM) 3D5/EE_48.A (4NKD) 
Data collection    
   Space group  C2221 C2 F23 
   Cell dimensions    
      a, b, c (Å) 60.59  104.92  284.41 103.26    92.26   142.71 275.67   275.67   275.67 
      α, β, γ (°) 90 90 90 90 110.86  90 90  90  90 
   Resolution (Å)a 42.2  - 3.49 (3.62  - 3.49) 46.1  - 3.71 (3.84  - 3.71) 38.6 - 3.3 (3.42  - 3.30) 
   Rmerge a 0.09183 (0.4878) 0.1049 (0.2206) 0.1131 (0.2985) 
   Rmeas  0.11 0.13 0.12 
   I/σI a 12.00 (2.97) 11.85 (4.30) 20.21 (6.97) 
   Completeness (%)a 93.10 (95.17) 84.81 (82.24) 99.96 (100.00) 
   Multiplicity a 3.3 (3.5) 2.0 (1.9) 7.6 (7.6) 
Refinement    
   Resolution (Å) 42.22 - 3.49 46.13  - 3.71 38.60-3.30 
   No. of reflections 11089 11363 26045 
   Rwork/Rfree 0.3084/0.3441 0.2636/0.2820 0.1950/0.2313 
   No. of molecules    
      Protein residues 708 944 944 
   B-factor protein (A2) 90.4 84.2 50.0 
   R.m.s deviations (rmsd)    
      Bond lengths (Å)  0.004 0.003 0.003 
      Bond angles (°) 1.25 0.87 0.94 
   Ramachandran    
      Favored (%) 92 95 97 
      Outliers (%) 1.6 0.75 1.0 




3.2.6. Computational analyses 
PDBe Protein Interfaces, Surfaces and Assemblies (PDBePISA) (105) was used 
to rank and analyze crystal lattice contacts by surface area and energy, as well as catalog 
critical amino acids in crystal contacts based on their formation of H-bond or salt bridge 
interactions. After excluding peptide binding (ID4 and ID5 of 3D5) and the native heavy-
light chain interface (ID1 of all scFv variants) within the scFv monomer, identified by the 
Complexation Significance score (CSS), the top three interfaces were considered major 
crystal contacts and used for further analysis.  
To assess the overall thermodynamic stability of each scFv in its native or the 
3D5 lattice, the three refined EE-peptide binding scFv monomer structures were fit into 
the P3221 space group using secondary structure matching in Coot (106). The overall 
free energy of each lattice was assessed by summing the energetic contributions of major 
crystal contacts, identified by PDBePISA as those with a surface area >50 Å2 or ΔG > 
0.84 kJ/mol and excluding biological interfaces.  The free energy contributions of each 
contact are calculated as ΔGcontact = ΔGinterface + ΔGH-bonds + ΔGsalt bridges, with ΔGinterface = 
the solvation free energy gain upon formation of the interface, calculated as difference in 
total solvation energies of isolated and interfacing structures, and the contributions of 
each hydrogen bond and salt bridge assessed at 2.09 and 1.25 kJ/mol respectively. The 
total free energy of lattice formation per scFv was obtained by dividing the energies by 
the number of monomers in each asymmetric unit. Thermodynamic stability calculations 





3.3.1. Analysis of first-generation scFv chaperones (3D5/His_68, 3D5/EE_48) 
The anti-His6 3D5 scFv framework was selected as the initial basis for our 
crystallization chaperone toolbox since it is one of the few scFvs that does not use CDRs 
in major crystal contacts, instead directing these towards a large solvent cavity that could 
accommodate a membrane protein (94, 95). Anti-His6 3D5/His_683 varies from the 
parent 3D5 by 13 amino acid residues in the VH CDR3 loop (Table 3.2) and it was shown 
that its biophysical characteristics are better than 3D5 (95). On the other hand, 
3D5/EE_48 was engineered by further manipulating VH CDRs to convert its specificity 
from anti-His6 to anti-EE (Figure 3.3). 3D5/EE_48 was previously crystallized under 
identical conditions as 3D5, but used the cubic space group F23 as opposed to the P3221 
space group used by 3D5 (95). Lattice analysis reveals that 3D5 (Figure 3.4a) and 
3D5/EE_48 (Figure 3.4b) both present large solvent channels, but are in distinct 
arrangements.  
 






Figure 3.4. Crystal lattices of scFv variants described in this chapter. (A) 3D5, (B) 
3D5/EE_48, (C) 3D5/His_683, (D) 3D5/EE_48.A, (E) 3D5/EE_48.K. Lines indicate 
solvent channels, with diameters listed. 
 
Highly soluble 3D5/His_683 variant readily grew crystals in a variety of 
conditions. The final optimized 3D5/His_683 crystals grew in conditions reminiscent of, 
but different from, 3D5. No crystals were obtained in the original 3D5 conditions. The 
best diffracting crystals grew with a higher protein concentration and growth temperature, 
in a cocktail containing no buffer and a very low concentration of the denaturant 
guanidinium hydrochloride. The 3D5/His_683 structure was solved in space group C2221 
(Table 3.4). In this lattice, a pair of three nearly identical scFv molecules in the correct 
asymmetric unit is related by a two-fold rotation, but the structure could not be refined in 
a hexagonal lattice (P6522 or P6122 with one molecule in the asymmetric unit). These 
crystals exhibit significant pseudomerohedral twinning as identified by Xtriage within 
Phenix (107). Dozens of crystals were tested for space group assignment and reduced 
twin fraction, but no differences were detected. Lattice analysis reveals that the 
3D5/His_683 lattice does not harbor an analogous large channel like 3D5 or 3D5/EE_48 
to accommodate a client protein (Figure 3.4C). Although 3D5/His_683 does exhibit 
excellent biophysical properties (95) (see section 3.3.5), due to the combination of the 
crystal properties and disadvantages of targeting a pH-sensitive, C-terminal His6 tag for 
48 
 
chaperoning, 3D5/His_683 was not considered further for membrane protein 
complexation (Chapter 4).  
3.3.2. Structure and crystal lattice analysis of first-generation scFvs 
Though they crystallize in different space groups, structures of the scFv 
monomers 3D5, 3D5/EE_48, and 3D5/His_683 are nearly superimposable (overall root 
mean squared deviation is ~ 1 Å), indicating there are no lattice-induced deformations 
(Figure 3.5A). PDBePISA crystal contact analysis (Table 3.5) reveals one common 
interface among the three structures (Figure 3.5B). This contact relies on polar 
interactions between C-terminal Lys and Arg residues within variable light chain (VL) 
and other nearby residues of the VH domain, which sometimes also involves a Gly from 
the linker region, depending on the variant (Table 3.5, Table 3.1, and Figure 3.5C). In 
3D5, this contact is ranked third (ID3) and involves a surface area of 305.6 Å2. It is 
likewise ID3 in 3D5/His_683 and ID4 in 3D5/EE_48. Unlike 3D5, which utilizes 
predominantly VH-VL protein contacts (Figure 3.6A), those in 3D5/EE_48 involve 
residues in symmetry related VH domains, whereas for 3D5/His_683 there is a VH-VH 




Figure 3.5. Common features among scFv variants. (A) Superposition of 3D5, 
3D5/His_683, 3D5/EE_48, 3D5/EE_48.A, 3D5/EE_48.K monomers. (B) Common VH-
VL crystal contact interface of aforementioned five structures (VL in grey, VH in black). 
(C) Close up view of contact in (B) for 3D5 (PDB code 1KTR) and 3D5/EE_48 (PDB 





Table 3.5. PDBePISA analysis of all scFv variants described in this study. In all variants, ID1 is the native VL-VH binding 







VH Contacts that formed H-bonds/salt bridges VL Contacts that formed H-bonds/salt bridges 
3D5 
ID2 467.1 11.3 T57, V71, D72, K73, S74 N30, K50, N53, R54 
ID3 305.6 -5.0 D11, Y91, Q105, T108 K107, R108 
ID6 160.0 10.0 n/a Q42, R108 
3D5/His_683 
ID2 465.4 -2.1 D31, Y32, N52, S99 n/a 
ID3 353.0 -12.1 Q6, D11, Y91, Q105, G106, T108 L106, K107, R108, G109 (linker), G110 (linker) 
ID4 185.3 -2.5 n/a S65, S67, D70 
3D5/EE_48 
ID2 465.4 3.3 K57, R58, S65, T68 n/a 
ID3 305.6 -16.3 P9, K19, S30, S32, D72, K73, S75, T77, Y79, 
S98 
n/a 
ID4 393.0 -10.5 Q6, D11, Y91, Q105, T108 L106, K107, R108, G110 (linker) 
3D5/EE_48.A 
ID2 409.5 -15.5 P9, S21, T30, A32, T77, Y79, S98 n/a 
ID3 406.7 2.1 S65 n/a 
ID4 363.7 -12.6 Q6, D11, Q105, T108 K107, R108, G110 (linker) 
3D5/EE_48.Ka 
ID2 483.7 -1.3 K23, S28, T30, D56, K57, Y59, K64, S65, S74, 
R82A 
n/a 
ID3 356.3 -8.4 Q6, S7, D11, Q105, T108 K107, R108, G109 (linker), G110 (linker) 
ID4 226.0 -9.2 S98, Y100B N28, N30 











3.3.3. Rational design and analysis of second-generation scFvs (3D5/EE_48.A 
and 3D5/EE_48.K) 
On the basis of the disparate crystal contacts found among 3D5 and the two first-
generation scFvs (3D5/His_683 and 3D5/EE_48), residues were identified which, upon 
substitution with another residue, might restore the desirable 3D5 lattice (Figure 3.4A) 
via the original contacts (Figure 3.6A). Such residues were those involved in hydrogen 
bonding and/or salt bridge interactions spanning the intermolecular interfaces of 3D5, 
3D5/His_683 and 3D5/EE_48, but were not involved in the common crystal contact 
described above (Table 3.5, Table 3.6 and Table 3.2).  
Five VH residues, Ser 30, Ser 32, Lys 57, Arg 58, and Ser 65, were evaluated for 
their contributions to the respective crystal contact for each protein, and extent of 
accessible and buried surface areas. The top two residues, VH Ser 30 and VH Ser 32, 
found in 3D5/EE_48 ID3 and not predicted to interact with peptide (95), were then 
selected for mutation (Table 3.6). In 3D5/EE_48, Ser 30 occurs one residue before the 
start of VH CDR1 (Kabat numbering) and participates in hydrogen bonding interactions 
with Thr 77 and Tyr 79 of a neighboring VH domain via the Ser 30 side chain and main 
chain, respectively (Figure 3.6B). In this position in the structures of 3D5 and 
3D5/His_683 there is a Thr, which is not involved in a crystal contact (Table 3.5 and 
Table 3.2). VH Asp 72 and VH Lys 73 are involved in both 3D5 and 3D5/EE_48. Thus, 
by making the conservative S30T substitution, we expected to remove the 3D5/EE_48-
specific Ser 30 interactions in favor of the desired VH-VL contact. In addition, in 
3D5/EE_48, Ser 32 participates in hydrogen bonding interactions with the main chain 
carbonyl of Lys 19 from a neighboring VH domain (Figure 3.6B). We reasoned that 
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replacement of Ser 32 with Ala would remove the side chain interaction, or substitution 
with Lys would disrupt the side chain interaction as well as increase entropy, making this 
contact less likely to form. Reversion to the Tyr 32 found in 3D5 and 3D5/His_683 did 
not seem prudent because while Tyr 32 does not form a crystal contact in the 3D5 
structure, it does participate in a crystal contact in 3D5/His_683 and Tyr residues 
commonly mediate antibody-ligand interactions (Table 3.5 and Table 3.2) (108). In sum, 
our second-generation scFv chaperone candidates are the double mutants 3D5/EE_48.A 





Figure 3.6. Outcome of rational design efforts. (A) Desired VH-VL lattice contact in 3D5 
(ID2). (B) 3D5/EE_48 contact selected for mutagenesis (ID3) (C) Interface of 
3D5/EE_48.A ID2 similar to 3D5/EE_48 ID3. (D) Comparison of 3D5/EE_48 ID2 (left) 
and 3D5/EE_48.A ID3 (right). (E) Interface ID2 formed in 3D5/EE_48.K (F) Interface 
ID4 formed in 3D5/EE_48.K. L: light chain, H: heavy chain. 3D5/EE_48.K interfaces are 




Table 3.6. Comparison of average solvent accessible surface areas of selected crystal 
contact residues. 
Rank Residue Kabat # PDBePISA 
Interface 
ASAa BSAb % buried areac 
1 
Ser 30 ID3/7 46.1 44.7 96.9 
Ser 30 ID3/8 47.1 45.1 95.7 
    Average 46.6 44.9 96.3 
2 
Ser 32 ID3/7 88.7 81.8 92.2 
Ser 32 ID3/8 82.0 76.0 92.6 
  Average 85.4 78.9 92.4 
3 
Ser 65 ID2/5 91.8 83.5 91.0 
Ser 65 ID2/5 92.4 86.3 93.4 
Ser 65 ID2/6 94.1 86.5 92.0 
Ser 65 ID2/6 82.3 73.3 89.1 
    Average 90.1 82.4 91.4 
4 
Lys 57 ID2/5 68.9 55.4 80.4 
Lys 57 ID2/5 79.3 59.9 75.4 
Lys 57 ID2/6 69.6 50.6 72.8 
  Average 72.6 55.3 76.2 
5 Arg 58 ID2/5 151.6 68.0 44.8 
aSolvent-accessible surface area in Å2, average values are in bold. 
bSolvent-accessible surface area that is buried upon interface formation, in Å2, average values are in bold. 
cBuried area percentage (BSA/ASA*100) , average values are in bold. 
 
3.3.4. Structure and crystal lattice analysis of second-generation scFvs 
3D5/EE_48.A crystallizes in a cocktail nearly identical to that of 3D5 and 
3D5/EE_48, but produces smaller crystals (20-30 μm in the largest dimension) than 3D5 
(70 μm) (94) and 3D5/EE_48 (40-60 μm) (95). As with 3D5/EE_48 and 3D5/His_683, 
the scFvs are all readily superimposable (Figure 3.5A). Crystals of 3D5/EE_48.A belong 
to the same space group as 3D5/EE_48, namely, F23, with a similar 50Å solvent channel 
present in the lattice (Figure 3.4D). Interestingly, while VH Ser 30 of 3D5/EE_48 and VH 
Thr 30 of 3D5/EE_48.A are within essentially the same contacts in the two structures 
(Figure 3.6B ,C), VH Ala 32 of 3D5/EE_48.A now torques the crystal contact to form a 
hydrogen bonding interaction with VH Ser 21 via the main chain of VH Ala 32 (Figure 
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3.6C), instead of interacting with VH Lys 19 as seen for VH Ser 32 in 3D5/EE_48 (Figure 
3.6B). Notably, VH Ser 21 is not a contact residue in 3D5/EE_48 (Figure 3.6B). 
Comparison of the second common contact (ID2 in 3D5/EE_48 and ID3 of 
3D5/EE_48.A, Figure 3.6D) also reveals an apparent slippage between residues 
interacting across the contact. The only residue to form a contact at this interface in 
3D5/EE_48.A is VH Ser 65, which interacts with a symmetry-related VH Ser 65, 
compared to four additional contacts in the same interface of 3D5/EE_48 (Figure 3.6D). 
Thus, the two amino acid substitutions were not sufficient to alter the crystal lattice but 
did change the lattice contacts.  
By comparison, crystallization of 3D5/EE_48.K was successful under different 
conditions; in spite of considerable effort, no crystals were obtained in the condition used 
for 3D5. For 3D5/EE_48.K, the combination of higher protein concentration with a 
cocktail composed of monovalent rather than divalent salt, and higher pH, promoted 
crystal growth. The crystals belong to space group C2 (Figure 3.4E), and like those of 
3D5/His_683 (Figure 3.4C), do not harbor a wide channel within the lattice. In the 
3D5/EE_48.K structure, there are three main crystal contacts: (1) a hybrid interface (ID2, 
Table 3.5, Figure 3.6E) between the top two contacts seen in 3D5/EE_48 and ID2 in 
3D5 (Table 3.5, Figure 3.6A, B, D left panel) (2) the common VH-VL interface (ID3) 
seen among all structures (Table 3.5, Figure 3.5B for overlay, Figure 3.5C close up of 
3D5 and 3D5/EE_48), and (3) a new crystal interface (ID4) involving VH CDR3 and VL 
CDR1 (Figure 3.6F) proximal to ID2. Residues participating in 3D5/EE_48.K ID4 are 
located within VH CDR3, the most important loop for peptide recognition, and VL CDR1 
(Figure 3.6F). One ID4 residue, VL Asn 30, participates in the desirable common contact 
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in the 3D5 lattice (Figure 3.6A). In the hybrid contact of ID2, VH Thr 30, one of the two 
residues altered in second generation variants due to its lack of involvement in contacts in 
the 3D5 or 3D5/His_683 lattices, participates in stabilizing interactions with the carbonyl 
oxygens of VH Lys 64 and VH Ser 65, both of which are residues within VH CDR2 
(Figure 3.6E). In turn, VH Ser 65 is stabilized by VH Ser 28, an interaction not observed 
in 3D5/EE_48 or 3D5/EE_48.A (Figure 3.6D). Residue 28 is an invariant serine within 
the EE-binding scFvs, a threonine in 3D5 and 3D5/His_683, and did not previously 
participate in crystal contacts (Table 3.2). Tyr 59 from VH CDR2, which is unchanged in 
the structures under discussion and not previously in a crystal contact, forms a main-
chain H-bonding interaction with the carbonyl group of VH Ser 74 in a neighboring 
molecule (Figure 3.6E); VH Ser 74 is a contact residue in 3D5 (Figure 3.6A) but not in 
3D5/EE_48 or 3D5/EE_48.A (Figure 3.6B, C). Another commonality between the 
desired 3D5 contact and ID2 of 3D5/EE_48.K is the involvement of the residue at 
position 57 of VH, which is a Thr in 3D5 and Lys in 3D5/EE_48.K (Figure 3.6A, E). 
Finally, a side-chain Lys-Asp salt bridge is present in both lattices (VL K50-VH D72 of 
3D5 and VH K23-VH D56 of 3D5/EE_48.K), although specific residues are different 
(Figure 3.6A, E).  
3.3.5. Biophysical characterization of second-generation scFvs 
The minor changes in amino acid composition for 3D5/EE_48.A and 
3D5/EE_48.K led to alterations in biophysical properties compared to first-generation 
chaperones 3D5/EE_48 and 3D5/His_683 (Table 3.7). Although all client proteins were 
purified in adequate yield for downstream experiments (Figure 3.7), the typical yield 
from cell growth of 3D5/EE_48.A was somewhat lower than 3D5/EE_48, and better 
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yield was obtained for 3D5/EE_48.K. Solubility was reduced for both new EE variants, 
but thermal stability was improved over 3D5/EE_48. Because solubility and yield are two 
very important factors for co-crystallization trials, 3D5/EE_48 and 3D5/EE_48.K are 
determined as the most promising anti-EE scFv crystallization chaperones (Chapter 4). 
Yield of 3D5/EE_48.A is very low to continue with downstream co-crystallization 
experiments, improvement of its yield through expression and purification optimization 
would not be a good effort since its low solubility (3mg/ml) would be another limiting 
factor for co-crystallization. As analyzed by size exclusion chromatography (SEC), the 
scFv variants 3D5/His_683 initially purify as a mixture of a monomer and dimer but to 
differing extents (Figure 3.7A). The anti-EE scFvs exhibit a higher monomer:dimer ratio 
compared to anti-His 3D5/His_683 and 3D5 (95) (Table 3.7), and the monomeric protein 
is stable once purified. Overall, the use of protein engineering has led to scFv variants 
with enhanced biophysical characteristics compared to 3D5. 
Table 3.7. Biophysical characteristics of scFv variants. 
  3D5/His_683a 3D5/EE_48a 3D5/EE_48.A 3D5/EE_48.K  
Expression level (mg/l culture) 8.5 2.1 0.5 3.6 
Solubility (mg/ml) 16.6 12.8 3 6.8 
Melting temperature (°C) 53.6  ± 0.0   47.2  ± 0.3 51.75 ± 0.1 51.3±0.2 
% Monomeric protein 62 79 72 75 
Kd (nM), MBP-KEE (χ2) ND 166 (0.031) 100 (0.029) 147 (0.020) 
a Pai, J. C., Culver, J. A., Drury, J. E., Motani, R. S., Lieberman, R. L., and Maynard, J. A. 
(2011) Conversion of scFv peptide-binding specificity for crystal chaperone development, 





Figure 3.7. Biophysical characterization of second-generation scFv variants. (A) 
Oligomeric state (dimer:monomer)  analysis of purified scFvs by size exclusion 
chromatography on Superdex 75 column. (B) Size and purity analysis of scFvs by SDS–
PAGE.  
 
3.3.6. Computational energetics analysis 
To date, we have not crystallized our engineered anti-EE scFv variants in the 3D5 
crystal lattice of P3221 even though the residues mediating these interactions are 
conserved. To gain insight into why this may be the case, one of our collaborators, 
Truskett Lab at UT Austin, superimposed each engineered scFv onto the 3D5 lattice and 
computed the free energies for each lattice (Table 3.8). Comparable free energies are 
calculated among the anti-EE scFv variants in the hypothetical P3221 lattice, similar to 
the value for 3D5. When compared to the experimentally-obtained lattices on a per-
asymmetric unit basis, P3221 is consistently less favorable, indicating that 
thermodynamics do contribute to lattice choice. However, when compared per scFv 
molecule, free energy values corresponding to the experimental lattices are either very 
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similar (3D5/EE_48 and 3D5/EE_48.K) or somewhat less favorable (3D5/EE_48.A) than 
P3221 (Table 3.8).  











3D5 P 3221 -18.8 1 -18.8 
3D5/EE_48 F23 -70.3 4 -17.6 
 P 3221 -15.9 1 -15.9 
3D5/EE_48.A F23 -59.8 4 -15.0 
  P 3221 -29.7 1 -29.7 
3D5/EE_48.Kb C121 -109.6 4 -27.4 
  P 3221 -25.5 1 -25.5 
a Experimentally observed lattice in bold.  
b Based on a low resolution (3.71Å) structural data. 
3.4. Discussion 
We were motivated to understand crystallization behavior of highly similar scFvs 
as part of our effort to develop peptide-specific crystallization chaperones. Ideally, our 
anti-EE chaperones would template a porous three dimensional lattice using contacts 
remote from CDRs, in a manner suitable to immobilize an EE-tagged client protein for 
structure determination. We attempted to combine our knowledge of the crystallization 
propensity of 3D5, 3D5/His_683 and 3D5/EE_48 to redirect second-generation anti-EE 
scFvs to the 3D5 lattice, which uses largely non-CDR residues for contacts and whose 
lattice includes a wide ~75 Å diameter channel. Side chain entropy has been shown to be 
the principal negative correlate of crystallization, with charged residues the least likely to 
participate in crystal contacts (109). In the case of proteins that do not crystallize in their 
native state, mutation of key high-entropy side chains has been highly successful in 
identifying crystallizable variants (110). Thus, we used similar considerations of contact 
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residue contributions to buried and accessible surface area, as well as to surface entropy. 
The variants 3D5/EE_48.A and 3D5/EE_48.K retained potent EE binding affinity but 
crystallized in different, non-3D5 lattices. In the case of 3D5/EE_48.A, the lattice of 
3D5/EE_48 was retained with minor modifications in crystal contacts. Our result for 
3D5/EE_48.A is consistent with general observations from Surface Entropy Reduction 
(SER), namely that the substitution of Ser for Ala removes the polar side chain 
interaction and leads instead to a stereochemically constrained backbone interaction that 
likely contributes to hydrophobic stabilization in the water-depleted crystal contact 
environment (110). By contrast, our attempt to use SER underpinnings to kill a contact by 
introducing a lysine residue led to an unexpected result. The offending crystal contact 
from 3D5/EE_48 was altered, but a new hybrid contact was generated that incorporated 
some, but not all, of the desired parent contacts.  
Our study demonstrates that the disruption of just one intermolecular contact can 
be sufficient to modify the lattice if more than one protein-protein interaction is available 
for crystallization. Such crystallization variability has been explored in classically studied 
proteins like lysozyme (111-114) and ribonuclease A (115), but few studies strategically 
attempt mutagenesis to alter the crystal lattice to a desired one starting from first 
principles. In one study, structures of A. cellulolyticus coh1 mutants were solved as part 
of an effort to generate a protein-based lattice capable of templating nanocomposite 
materials or as an immobilized catalyst (116). In this case, surface lysine residues were 
eliminated by replacing them with alanine or tryptophan. Although not a typical residue 
employed in SER (110), the latter mutant resulted in a crystal lattice with higher porosity 
and solvent content than the parent, with the Trp playing a key contact role (116). For 
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coh1, the presence of a surface-exposed Trp residue did not cause problems in terms of 
protein yield or solubility. In a second example, an alternative lattice was a serendipitous 
outcome of attempts to revert the oligomeric state of sweet potato β-amylase from 
monomer to the tetramer found in another ortholog (117). As in the case of our scFvs, 
residues comprising the 3D5 lattice contact were not mutated in our scFv variants to 
resurrect the desired crystal contacts. However somewhat different crystal 
contacts/interfaces were obtained, this shows that our scFv chaperones have versatile 
crystal contacts available for alternative lattice formations.  
A major challenge in directing a particular crystal lattice is that beyond a general 
preference for amino acids with low entropic contribution (110, 118), physicochemical 
characteristics common to protein crystal contacts are not obvious (112, 119). In our 
system, one possible explanation for the observed lattice alterations is the length and 
flexibility of surface loops. Both 3D5/His_683 and 3D5/EE_48 have VH CDR3 loops that 
are seven residue longer, while the 3D5/EE_48 VH CDR1 is two residues longer, than in 
3D5. These additional residues do not appear to directly influence crystal contacts, 
however, as just one of these additional residues (VH Ser 98 in 3D5/EE_48 and VH Ser 99 
in 3D5/His_683) is involved in a crystal contact. Notably, while 3D5 exhibits the typical 
surface area for crystal packing of 100-500 Å (112) with a corresponding lattice free 
energy per asymmetric unit on the low end of published values (G0= ~-25-40 kJ/mol) 
(83, 120), those for our engineered anti-EE variants are higher in terms of contact surface 
areas, and are more energetically favorable per asymmetric unit. Viewed on a per-scFv 
basis, however, the free energies are roughly comparable; suggesting that lattice choice 
may be influenced by the crystallization pathway. Specifically, the additional residues in 
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our EE variants may direct crystal nucleation through repulsive or attractive events on the 
pathway to crystallization, such as by releasing key bound water molecules (120). The 
pathway may also be influenced by the composition of the mother liquor (113, 115) or 
the presence/absence of a ligand/binding partner.  
Although controlling the crystallization lattice by rational design may not be 
achievable, our scFv platform holds considerable promise for crystallization chaperoning. 
As evidenced by this study, our hypercrystallizable scFv molecules have multiple well-
ordered surface patches available for crystal contacts, including those utilized in 3D5 that 
would not interfere with epitope binding; indeed the presence of a bound ligand may 
independently direct lattice formation to that used by 3D5.  In addition, our protein 
engineering efforts have led to a high affinity binding site, capable of complexation with 
a purified, detergent-solubilized, EE-tagged membrane protein (Chapter 4). Our 
chaperone discovery approach has advantages over current ligand specific library 
panning or hybridoma technologies in which numerous antibodies are evaluated for their 
ability to co-crystallize with a single client protein. With our approach, a single (or a few) 
chaperone(s) can be engineered for optimal crystallizability, expanded to nanobody 
and/or Fab platforms, and then used to co-crystallize a wide variety of client proteins 
simply by installing the hexapeptide epitope, the placement of which the researcher has 
complete control.  
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CHAPTER 4: Progress Towards Complexation and Co-crystallization of scFv 
Variants with EE-tagged Membrane Proteins 
4.1. Introduction 
4.1.1. Membrane protein crystallization challenge 
Although membrane proteins are essential in many cellular functions and nearly 
one third of all encoded genes belongs to membrane proteins, their structural 
characterization is highly underrepresented. Less than 1% of unique protein structures in 
Protein Data Bank (PDB, www.rcsb.org) are membrane proteins 
(http://blanco.biomol.uci.edu/mpstruc/). The main reason behind this is their high 
hydrophobic content which makes crystallization challenging.  
There are two main approaches to help membrane proteins to crystallize: (i) 
engineering membrane protein itself (121, 122) or tailoring its lipid or detergent 
environment (84), (ii) use covalent or non-covalent crystallization chaperones (85, 86). 
The most common technique that has been used is chaperone approach. Crystallization 
chaperones increase the hydrophilic surface available to form crystal contacts and 
therefore the likelihood of growing well-ordered and diffracting crystals. Covalent 
crystallization chaperones are usually inserted in one of the soluble loops of membrane 
proteins, one common example for this is lysozyme which is a highly-expressed, soluble 
and hypercrystallizable protein (123). Non-covalent crystallization chaperones form a 
tight complex with target membrane protein. Antibody fragments are the most common 
non-covalent chaperones because of their high affinity interactions (85, 86). However, 
these approaches suffer from the need to identify a new chaperone specific for each new 
target protein to be crystallized. In our approach, we developed a generalized approach to 
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crystallize any membrane protein by altering a nonessential hydrophilic loop to harbor a 
short peptide epitope with high affinity for antibody crystallization chaperones. We chose 
EE-tag as the epitope which is a six amino acid long peptide EYMPME. 
4.1.2. Advantages of EE-tag (EYMPME) 
EE-tag was chosen as epitope due to its promising characteristics which would 
form a tight complexation (124). Tyrosine can form both hydrophobic and H-bond 
interactions which usually dominate protein-protein interactions. Proline can restrict 
conformational flexibility of the epitope, and two charged residues, glutamates, can form 
electrostatic interactions.  
As described in Chapter 3, scFv antibody fragments were engineered for binding 
interaction to EE epitope while trying to retain the scaffold of parent 3D5 scFv known to 
use crystal contacts remote from the epitope binding site. We expect that our tightly 
bound scFv chaperone would immobilize EE-tagged membrane protein loop and provide 
a stable crystal lattice, leading to high quality diffracting crystals. 
4.1.3. Chapter overview and publications 
Membrane proteins are hard to crystallize and the developed techniques use target 
protein specific approaches to tackle this problem. In this chapter, a new method was 
tested as a more generalizable approach which used the high affinity interaction of anti-
EE scFvs with EE-tagged membrane proteins. This chapter reports the successful tight 
complexations of several anti-EE scFv fragments with EE-tagged test membrane 
proteins. Both -helical and -barrel membrane proteins were tested for proof-of-concept 
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anti-EE scFv complexation. EE-tagged SPP and intimin were chosen as -helical and -
barrel membrane proteins respectively.  
The results from this chapter were published in Proteins: Structure, Function and 
Bioinformatics in 2014 (96). Another co-author paper which uses the same approach with 
anti-EE Fab antibody fragment was published in 2015 (125). 
4.2. Methods 
4.2.1. Site Directed Mutagenesis (SDM) for EYMPME (EE) tag substitution on 
extramembranous loops of membrane proteins 
EE-tag epitopes were incorporated into proteins of interest via SDM 
(Quickchange II, Agilent Technologies) and verified by DNA sequencing (MWG 
Operon). Extramembranous loop between transmembrane helix (TM) 6 and 7 were 
chosen for EE-tag incorporation of SPP because it is the longest loop in all three chosen 
archeal SPP orthologs. EE-tags were installed on various locations of TM6-TM7 loops of 
MCMSPP, mSPP and hSPP except mSPP-EE3 whose EE-tag was installed on TM8-TM9 
loop (Figure 4.1, Table 4.1). First EE-tagged SPP, mSPP-EE, was generated by Jeff 
Culver, a former Lieberman lab member, and it was also located in the TM6-TM7 loop 
(Figure 4.1, Table 4.1). Naming of EE-tagged MCMSPPs were shortened as MCM-
EE(x) where (x) is the corresponding number of the EE-tagged variant. 
E. coli intimin with the expression plasmid was generously provided by Dr. Susan 
K. Buchanan (NIH) (126). The EE-tag was incorporated into an extramembraneous loop 
in wild-type intimin (WT-intimin) between residues 314–321 via SDM (Table 4.2). More 
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details on EE-tag position optimization of intimin can be found in undergraduate thesis of 
David Heaner, a former undergraduate researcher in Lieberman lab. 
 
Figure 4.1. Multiple sequence alignment of TM6-TM7 loop locations of Haloarcula 
marismortui SPP (mSPP), Halobacterium salinarum (hSPP) and Methanoculleus 
marisnigri JR1 SPP (MCMSPP). Loop was highlighted for MCMSPP. EE-tag 



























































































Table 4.2. Primers for EE-tag incorporation into WT-intimin. 








4.2.2. Purification of scFv fragments and EE-tagged membrane proteins 
EE-tagged SPP was purified as described in Chapter 2.2 and scFv fragments 
(3D5/EE_48, 3D5/EE_48.A 3D5/EE_48.K) were purified as described in Chapter 3.2. 
EE-tagged intimin (intimin-EE) was expressed and purified as previously described for 
WT-intimin (126). More details on EE-tag position optimization and purification of 
intimin can be found in undergraduate thesis of David Heaner, a former undergraduate 
researcher in Lieberman lab. 
4.2.3. Complexation of scFv fragments with EE-tagged membrane proteins 
EE-tagged SPP was purified as described in Chapter 2.2 and scFv fragments 
(3D5/EE_48, 3D5/EE_48.A 3D5/EE_48.K) were purified as described in Chapter 3.2. 
EE-tagged intimin (intimin-EE) was expressed and purified as previously described for 
WT-intimin (126). More details on EE-tag position optimization and purification of 
intimin can be found in undergraduate thesis of David Heaner, a former undergraduate 
researcher in Lieberman lab. 
The (SPP-EE)-scFv interaction was evaluated by size-exclusion-chromatography 
(SEC) using an ÅKTA FPLC instrument equipped with HiPrep 16/60 Sephacryl S-300 
column (GE Healthcare) equilibrated with 20 mM HEPES pH 7.5, 250 mM NaCl, 0.05% 
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n-dodecyl-b-D-maltopyranoside (DDM, Anatrace), at 4°C. Wild-type or EE-tagged SPP 
was mixed in a 1:1 molar ratio with scFv and incubated for 1 hour on ice before injection. 
Elution fractions for each peak were analyzed with reducing SDS–PAGE. 
The (intimin-EE)-scFv interaction was evaluated by SEC using an ÅKTA FPLC 
instrument equipped with a Superose 12 GL 10/300 column (GE Healthcare) equilibrated 
with 50 mM Tris pH 7.5, 200 mM NaCl, 0.01% Na Azide, 0.05% DDM, at 4°C. Wild-
type or EE-tagged intimin was mixed in a 1:1 molar ratio with scFv and incubated for 3 
hours on ice before injection. Elution fractions for each peak were analyzed with 
reducing SDS–PAGE. 
4.2.4. Co-crystallization trials of scFv fragments with EE-tagged membrane 
proteins 
After careful consideration of all SPP orthologs (Chapter 2), biophysical 
characteristics of scFv variants (Chapter 3), EE-tag positions and binding properties of 
SPP orthologs to scFv variants (Chapter 4), co-crystallization trials were focused on 
complexes of mSPP-EE and MCM-EE2 with 3D5/EE_48 or 3D5/EE_48.K (Table 4.3). 
Sparse matrices were prepared in 96-well format using the Art Robbins Crystal Gryphon 
instrument. Sparse matrix conditions were commercial screens purchased from Hampton 
Research, Emerald Biosystems, Rigaku, and Molecular Dimensions. If any crystal hit 
was observed in any sparse matrix trays, optimization trays were manually prepared in a 
24-well format. 
Two different methods were used to prepare protein sample to set up co-crystal 
trays: (i) concentrating complex peak from SEC with 10K MWCO amicon  filters, (ii) 
directly mixing SPP and scFv in 1:1 molar ratio and incubating them on ice for 1 hour. 
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The latter method was mostly used for crystal trays that were set up. In total, 52 sparse 
matrix and manual optimization trays were set up for (SPP-EE)-scFv complexations and 
65 trays were set up for (intimin-EE)-scFv complexations. More details on co-
crystallization trials of EE-tagged intimin with scFv fragments can be found in 














WT mSPP Yes Yes Yes (-control) Yes (-control) - 
mSPP-EE Yes No Yes Yes Yes 
mSPP-EE1 Yes Yes Yes No No 
mSPP-EE2 Yes Yes Yes No No 
mSPP-EE3 Yes No Yes No No 
WT hSPP Yes Yes No No - 
WT-MCM Yes Yes Yes (-control) Yes (-control) - 
MCM-EE1 Yes No Yes Yes  No 
MCM-EE2 Yes Yes Yes Yes Yes 
MCM-EE3 Yes No Yes Yes  No 
 
4.3. Results 
4.3.1. Selection of EE-tagged membrane protein candidates based on SEC 
complexation performances 
3D5/EE_48 and 3D5/EE_48.K were complexed with mSPP-EE and all three 
MCM-EE variants (Table 4.3). Their SEC profiles were compared and best SPP 
candidates were chosen. Figure 4.2 shows the comparison of 3D5/EE_48.K 
complexations with WT-MCM/MCM-EE1/MCM-EE2/MCM-EE3. According to this 
comparison, MCM-EE2 was the best candidate for 3D5/EE_48.K complexation because 
intensity of its complex peak (around 60 ml) was higher and intensity of unbound 
3D5/EE_48.K peak (around 90 ml) was lower than others. These peak intensities showed 
that more complex formed with MCM-EE2. Peak around 37 ml was void volume for this 
column and it might show the aggregated or higher molecular weight species but its 




Figure 4.2. SEC complexation profile overlays of WT-MCM/MCM-EE1/MCM-
EE2/MCM-EE3 with  3D5/EE_48.K on a HiPrep 16/60 Sephacryl S-300 column. y-axis 
is absorbance reading at 280 nm in mAU from AKTA FPLC instrument and x-axis is the 
elution volume in ml. 
 
4.3.2. Complexation of EE-tagged SPP with anti-EE scFv fragments 
Co-elution of 3D5/EE_48.K and MCM-EE2 was seen by SEC combined with 
SDS–PAGE analysis (Figure 4.3). There is a shift in the complexation peak (around 60 
ml) towards the higher molecular weight (lower the elution volume, higher the molecular 
weight) for MCM-EE2 & 3D5/EE_48.K complex compared to negative control (WT-SPP 
& 3D5/EE_48.K). SDS-PAGE gel of corresponding fractions confirmed co-elution of 
3D5/EE_48.K and MCM-EE2 in the complexation peak while WT-SPP and 




Figure 4.3. Overlay of MCM-EE2 & 3D5/EE_48.K (black) with WT-SPP & 
3D5/EE_48.K (red) upon mixing and fractionation by SEC on a HiPrep 16/60 Sephacryl 
S-300. SDS–PAGE analysis of corresponding elution profiles are on the right; top: 
MCM-EE2 & 3D5/EE_48.K, bottom: WT-SPP & 3D5/EE_48.K. 
 
4.3.3. Complexation of EE-tagged intimin with anti-EE scFv fragments 
Co-elution of 3D5/EE_48.K and intimin-EE was seen by SEC combined with 
SDS–PAGE analysis (Figure 4.4). There is a shift in the complexation peak (around 12 
ml) towards the higher molecular weight for intimin-EE & 3D5/EE_48.K complex 
compared to negative control (WT-intimin & 3D5/EE_48.K). This was also concomitant 
with a reduction in the height of the elution peak corresponding to unbound 
3D5/EE_48.K (around 14 ml) when compared to the negative control. SDS-PAGE gel of 
corresponding fractions confirmed co-elution of 3D5/EE_48.K and intimin-EE in the 




Figure 4.4. Overlay of intimin-EE & 3D5/EE_48.K (black) with WT-intimin & 
3D5/EE_48.K (red) upon mixing and fractionation by SEC on a Superose 12 GL 10/300 
column. SDS–PAGE analysis of corresponding elution profiles are on the right; top: 
intimin-EE & 3D5/EE_48.K, bottom: WT-intimin & 3D5/EE_48.K. 
 
4.3.4. Co-crystallization trials 
More than 50 co-crystal trays were set up for mSPP-EE/MCM-EE2 and 
3D5/EE_48 and 3D5/EE_48.K complexes. Although there were some possible crystal 
hits, either they could not be reproduced with manual optimization trays or they were salt 
crystals confirmed by their diffraction pattern. After this, crystallization efforts were 
directed towards MCM-EE2 which formed diffracting reproducible crystals (Chapter 5). 
Most of intimin-scFv or intimin-Fab co-crystal trays were prepared and screened 
by David Heaner, a former undergraduate researcher in Lieberman lab. David focused 
more on intimin-Fab co-crystallization due to the fact that purified scFvs were mixtures 
of monomers and dimers (Chapter 3) while Fab was mostly monomer and we could not 
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anticipate the effect of this in complexation and co-crystallization. Around 65 co-crystal 
trays were prepared for intimin-scFv and intimin-Fab complexes and more details can be 
seen in David Heaner’s undergraduate thesis. 
4.4. Discussion 
Hybridoma technology and phage display are the most common techniques to 
generate antibody fragments specific to membrane protein of interest (127, 128). 
Although those approaches are widely used, they are still time-intensive, costly and a 
new antibody fragment needs to be generated for each new target protein. Another non-
covalent chaperone that has been used in membrane co-crystallization is Designed 
Ankyrin Repeat Proteins (DARPins) (129, 130). DARPins are derived from ankyrin 
repeat which is 33 amino acid motif and shown to direct protein-protein interactions in 
the cell (129). Directed evolution strategies are used to generate DARPins specific for a 
target protein (130). All of those co-crystallization chaperone approaches suffer from 
targeting only single membrane protein of interest. Our generalizable approach use 
antibody fragments specific to a short peptide epitope which can be tightly complexed 
with any membrane protein with the epitope installed in one of its soluble loops. 
The feasibility of our chaperone approach was demonstrated here by solution 
complexation of 3D5/EE_48.K with MCM-EE2 and intimin-EE, which are 
representatives of -helical and -barrel test membrane proteins respectively. To the best 
of our knowledge, this was the first demonstration of a rationally designed non-covalent 
complex between a candidate crystallization chaperone and a membrane protein 
harboring an installed internal peptide tag. 
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It was our hope that with our approach, a single (or a few) chaperone(s) can be 
engineered for optimal crystallizability, and then used to co-crystallize a wide variety of 
client proteins simply by installing the hexapeptide epitope via a single step.  Because of 
its higher solubility and expression level, 3D5/EE_48 and 3D5/EE_48.K were assessed 
for complexation with proof-of-concept membrane proteins (Chapter 3). EE-tag was 
introduced into various positions of extramembraneous loops of candidate membrane 
proteins using just one round of site-directed-mutagenesis (SDM). EE-tag insertion did 
not change expression and purification characteristics of any test membrane proteins. The 
effect of EE-tag position was assessed by their complexation performances to anti-EE 
scFvs. It was shown that positions close to the middle region of loops are best for better 
complexation (mSPP-EE, MCM-EE2 and intimin-EE, section 4.2.1). Middle positions 
probably expose the EE-epitope towards the solution better for tight scFv binding 
interaction.  
Although we set up many co-crystallization trays, we could not obtain any co-
structures. To understand why the co-crystallization trials have not been successful in 
spite of the demonstrated favorable solution properties, we performed molecular 
dynamics in collaboration with Gumbart lab at Georgia Tech. WT-intimin and intimin-
EE were first modelled and allowed to equilibrate over 50 ns. In comparison to WT-
intimin, intimin-EE showed increased flexibility in residues 314–321, where the EE tag 
was substituted. Conformational flexibility is known to preclude crystallization, binding 
of antibody fragments to this floppy region might deter crystal contact formation and 
ultimately co-crystallization. More details on this result can be found in Jennifer 
Johnson’s (former Lieberman lab member) PhD thesis and published work (125). 
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CHAPTER 5: Optimization and Protein Engineering for SPP to Improve its 
Crystallization and Diffraction: Lessons Learned from Contamination of 
Acriflavine resistance protein (AcrB) of E.coli 
5.1. Introduction 
Proteins with increased solubility and stability are less prone to interactions 
leading to undesirable off-pathways of aggregation or precipitation (131, 132). 
Biophysical properties can be improved through the use of libraries (121), modification 
of environment (86), optimization of target constructs to remove flexible regions (133), 
which reduces the probability of unproductive contacts, and truncation of loops that 
reduce conformational heterogeneity which also helps crystallization.  
Reducing flexibility of extramembranous loops in membrane proteins is important 
for their crystallization because these soluble loops are expected to form the main crystal 
contacts if there are no available hydrophilic extracellular domains (133, 134). SPP does 
not have extracellular domains, but it has a very long loop between transmembrane (TM) 
helix 6 and 7 (Chapter 4). In the published crystal structure of SPP, this loop is not visible 
likely because Li, et al. used limited proteolysis approach to delete it in order to enhance 
crystallization (42) and thus could explain why the structure is in an inactive 
conformation. 
5.2. Chapter overview and publications 
In this chapter, several techniques were used in an attempt to enhance the 
crystallization of MCMSPP (Chapter 2). After getting the first crystal hit of MCMSPP, 
we optimized purification, crystallization, and post-crystallization steps to 
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reproduce/optimize crystals and improve its diffraction resolution. We also changed 
detergent environment of MCMSPP to lipidic cubic phases (LCP) and bicelles which 
would provide more native-like environment for crystallization. 
Because initial crystals could not be reproduced without zinc salts, we 
hypothesized that zinc binding could be important for crystal contact interface. A zinc 
binding motif, HEXXH, was engineered into a soluble loop to make this possible 
interface even stronger which would improve crystallization properties. 
We tried to shorten one of the longest extramembranous loops of MCMSPP by 
deleting amino acids step-by-step. By doing so, we aimed to observe the difference in 
crystallization properties of those SPP variants based on length of its loop. There are 
some conserved residues in the corresponding loop, we tried not to delete those residues 
to keep any important interactions. Activity assays were also done to test activity of those 
SPP variants to make sure they would crystallize in an active conformation. 
Unfortunately, once the crystals were large and abundant enough to be visualized 
by silver staining after SDS-PAGE analysis, we learned that instead of crystallizing 
MCMSPP, we crystallized an E. coli membrane protein contaminant, acriflavine 
resistance protein (AcrB) which is a multidrug efflux pump. Because low amounts of 
AcrB nonspecifically binds to the Ni2+-affinity column, we changed our constructs and 
purification protocol in hopes of eliminating this contaminant from our final protein 
sample. A TEV-cleavage site was added before C-terminal His6-tag and a second affinity 
purification step was added to eliminate co-purified AcrB. A final strategy to remove 




A book chapter was published in Methods in Molecular Biology volume titled 
Heterologous Expression of Membrane Proteins: Methods and Protocols, 2nd edition, in 
collaboration with former Lieberman lab member Dr. Jennifer Johnson (17). This 
manuscript covered some of the lessons learned from this study especially AcrB 
contamination issues. 
5.3. Methods 
5.3.1. MCM-EE2 crystallization trials 
MCM-EE2 (Chapter 4) was first crystallized in MembFac sparse matrix 
(Hampton Research). Rod-shaped crystal hits were observed in H9 well with 7.3 mg/ml 
MCM-EE2 (0.1 M sodium cacodylate pH 6.5, 0.2 M zinc acetate, 9% PEG8k, 1:1 drop 
ratio). 
In total, ~150 sparse matrix and manual crystallization trays were set up. In 
addition to protein engineering and environment optimization efforts, several other 
optimizations were done to improve crystallization as listed below: 
 Concentration of protein (4 – 32 mg/ml) 
 Different salt concentration in gel filtration (GF) buffer (50, 100, 150 mM NaCl) 
 Concentration of each crystallization solution component 
 Different polyethylene glycols (PEGs) for crystallization solution (PEG 400, 
1000, 3000, 3350, 4000, 6000, 10000, 20000, PEG monomethyl ether 500, 2000)  
 Different pHs for crystallization solution using suitable buffers (pH 5.5 - 8.5) 
 Different salts (magnesium acetate, calcium acetate, ammonium acetate, lithium 
acetate, sodium acetate, ferric ammonium citrate, cobalt chloride, nickel sulfate, 
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copper acetate, cadmium chloride) and different zinc salts (zinc chloride, zinc 
nitrate) for crystallization solution 
 Different temperatures for crystal tray incubation (4 °C, 20 °C, 16 °C and room 
temperature). 
 Different detergents in GF buffer (Fos-choline-12, n-Dodecyl-β-D-
Maltopyranoside, n-Decyl-β-D-Maltopyranoside, CYMAL-5, Lauryl Maltose 
Neopentyl Glycol, n-Dodecyl-N,N-Dimethylamine-N-Oxide, n-Nonyl-β-D-
Glucopyranoside, n-Nonyl-β-D-Maltopyranoside, n-Octyl-β-D-Glucopyranoside, 
Anapoe-C12E8 from Anatrace). Minimum detergent amount which is 2x critical 
micellar concentration (CMC) for each detergent was used. 
 Concentrator filter MWCO (10K, 30K, 50K, 100K) for final protein sample 
(Chapter 2) 
 Different size-exclusion-chromatography (SEC) columns for GF: Superose 12 
10/300 GL (S12) and HiPrep 16/60 Sephacryl S-300 HR (S300) 
 Additive screens (additive screen and detergent screen from Hampton Research) 
 Dehydration and glutaraldehyde-annealing of crystals right before flash-freezing 
 Heavy metal and inhibitor (ZLL2-ketone) soaking of the crystals 
5.3.2. Crystallization trials with bicelles and Lipidic Cubic Phases (LCPs) 
Bicelles were prepared as described in Ujwal, et al. (135), using 1,2-Dimyristoyl-
sn-Glycero-3-Phosphocholine (DMPC, Anatrace) and 3-[(3-Cholamidopropyl) 
dimethylammonio]-2-Hydroxy-1-Propanesulfonate (CHAPSO, Anatrace). A molar ratio 
of 2.8:1 (DMPC:CHAPSO) was chosen to prepare stock bicelle concentrations  at 10%, 
20% and 40%. Final protein sample for crystallization was prepared with 4-fold dilution; 
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one unit of bicelle stock was added to 3 units of purified concentrated protein sample on 
ice. All three stocks were used to do 4-fold dilution to obtain protein samples with final 
protein concentration of 18 mg/ml and final bicelle concentrations of 2.5%, 5% and 8%. 
Crystal trays were prepared on ice to maintain the fluidity of the bicelles. Crystal trays 
were incubated at 4, 20, or 37 °C. All crystal trays were imaged with the Rigaku Minstrel 
DT Benchtop protein crystal drop imager and recorded in CrystalTrak software. 
Lipid cubic phase (LCP) crystallization trays were prepared in the Center for 
Structural Biology at The University of Alabama Birmingham. A total of 4 sparse matrix 
trays were prepared using the 1:1 direct mix method. In the final protein sample, 
protein:monoolein volume ratio was 60:40 and they were mixed by syringe lipid mixer 
(Hamilton Company) (136). Sparse matrix screens used were Cubic Phase I, Cubic Phase 
II, MB Class I and MB Class II (Molecular Dimensions). Hampton Research LCP 
sandwich plates were used and crystallization drops were prepared with the assistance of 
an Art Robbins Gryphon LCP instrument. The incubation temperature for the LCP trays 
was 20°C. All crystal trays were imaged with the Rigaku Minstrel DT Benchtop protein 
crystal drop imager and recorded in CrystalTrak software. 
5.3.3. MCM-EE2 protein engineering via Site Directed Mutagenesis (SDM) to 
improve crystallization 
5.3.3.1. Step-by-step TM6-TM7 loop shortening 
The loop connecting TM6 and TM7 is the longest within SPP; in MCMSPP it is 
37 residues long (Figure 5.1). This loop in MCMSPP was shortened step-by-step by 
SDM. At every step, 4 non-conserved amino acids in the loop were deleted from either 
MCM-EE2 or MCM-EE2-TEV construct (Table 5.1, Chapter 4, section 5.3.3.3). The 
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conserved predicted β-strand (“IMVVVP”) at the start of this loop (Figure 5.1) as well as 
the EE-tag (“EYMPME”), were retrained (Chapter 4). The template used for all 
constructs was either the plasmid for ΔN23 or full-length MCM-EE2 in pet22b(+) 
plasmid (Chapter 2, Chapter 4, Figure 5.2). Construct sequences were confirmed by 
DNA sequencing (MWG Operon). Primers for all loop shortening steps are listed in 
Table 5.1. 
 
Figure 5.1. Multiple sequence alignment of TM6-TM7 loops of SPP from different 
organisms. The loop of MCMSPP was shown with an arrow. Conserved predicted β-
sheet and EE-tag position for MCM-EE2 construct were highlighted in yellow and blue 




Table 5.1. Primers for stepwise MCM-EE2 loop shortening. E denotes for EE2, T 
denotes for TEV cleavage site, S denotes for loop shortening, the number after S denotes 
for number of rounds of 4 amino acid deletions (e.g. 1 denotes for 4 amino acids deletion, 
and 2 denotes for another 4 amino acids deletion after 1st round which is 8 amino acids in 
total) 












































5.3.3.2. “HEXXH” motif on TM6-TM7 loop 
The “HEXXH” peptide motif (where X is any amino acid) is known to form α-
helix and accommodate zinc metal binding (137). From the initial crystallization efforts, 
it was shown that Zn2+ was essential for crystal formation. Therefore, we decided to 
substitute EE-tag region of ETS4 construct (Figure 5.2) with a “HEXXH” motif where X 
is any amino acid. “EYMPME” was mutated to “HELTHK”, LT was chosen for XX 
region because it was common in natural α-helical HEXXH motifs, last amino acid of 
EE-tag, E, was mutated to K because WT MCMSPP originally had K in that position 
(Figure 5.2). Construct sequences were confirmed by DNA sequencing (MWG Operon). 
Primers can be seen in Table 5.2. 
Table 5.2. Primers for “HELTHK” motif substitution of ETS4. EE-tag (“EYMPME”) 
motif of FLETS4 was mutated into “HELTHK”. Zn in the naming denotes for possible 
zinc binding property of “HELTHK” motif. 








5.3.3.3. Tobacco etch virus (TEV) protease cleavage site construct and its 
additional purification step 
TEV protease cleavage site (“ENLYFQS”) was inserted before C-terminal 
hexahistidine (His6) tag by SDM. Primers for TEV cleavage site insertion can be seen in 
Table 5.3. Figure 5.2 shows which SPP variants were used for TEV cleavage site. 




Table 5.3. Primers for TEV cleavage site incorporation into SPP variants. Both insertion 
and substitution were made in two rounds of SDM for conversion of “KLAAALE” to 
“ENLYFQSALE”. 
Constructs Forward (F) and Reverse (R) Primers (5’-3’) 













For MCMSPP variants containing a TEV cleavage site, removal of the 
hexahistidine tag was performed after the first Ni2+-affinity purification step (see Chapter 
2.2.4). The protein was buffer-exchanged using 50K MWCO Amicon Ultra centrifugal 
filter into gel filtration buffer to remove excess imidazole. TEV protease (~1.8 mg/ml in 
phosphate buffered saline, pH 7.5, 20% glycerol, stored at -80 °C freezer) was directly 
added to protein sample in a 1:1 TEV:MCMSPP variant mass ratio. The cleavage 
reaction was allowed to proceed at 4 °C for 16-20 hours and the sample was re-purified 
over a Ni2+-affinity chromatography column, collecting the flowthrough and discarding 
protein that bound to the column (TEV protease and contaminants). Cleaved protein was 
concentrated and the gel filtration step was performed as in Chapter 2.2.4. 
5.3.3.4. Modified T4 lysozyme fusion protein (mT4L) as a covalent 
chaperone for MCMSPP 
Inspired by work of Kobilka in crystallizing GPCRs, a modified T4 lysozyme 
fusion (mT4L) was inserted into the TM6-TM7 loop of MCMSPP (138). A plasmid with 
mT4L sequence was ordered from Eurofins Genomics (Table 5.4). SacI and NheI 
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restriction sites were designed the N-term and C-term of ordered mT4L plasmid 
respectively. The same restriction sites were mutated via SDM into the ETS3 plasmid 
between the conserved -strand and the start of TM7 (Table 5.4, Figure 5.1, Figure 5.2). 
Both mT4L and mutated ETS3 plasmids were double-digested with SacI and NheI, 
digested plasmids were cut/purified from the agarose gel and standard ligation protocol 
(NEB) was performed to obtain final SPP-mT4L plasmid (Table 5.4). Construct 
sequence was confirmed by DNA sequencing (MWG Operon). 
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5.3.4. Activity assays for MCM-EE2 shortened loop variants 
Ren390FRET (R-E(EDANS)-IHPFHLVIHT-K(DABCYL)-R, Anaspec) was 
dissolved in DMSO (500 µM stock concentration). Freshly purified WT-MCM, ETS3 or 
ETS4 protein (0.5, 1, 2, 5 µM) in 10 mM sodium phosphate, pH 7.2, 150 mM NaCl 
(PBS), 0.05% (w/v) DDM and Ren390FRET (10 µM) in PBS with 0.05% (w/v) DDM, 
were mixed by gentle pipetting in a 96-well black-bottomed non-binding plate (Corning) 
and sealed with optical adhesive film (MicroAmp). The fluorescence values were 
monitored every 2 min for 1 hour at 37°C in a Synergy 2 plate reader (BioTek, filters 
λex= 360 ± 40 nm, λem= 485 ± 20 nm). A blank was prepared without the enzyme and it 
was subtracted from the data. Initial velocities were calculated by the slope from the 
linear regression of data acquired in the first 20 minutes (AFU/min). 
5.3.5. Protein expression with E. coli BL21(DE3) ΔAcrB 
In an attempt to circumvent the AcrB contamination problem completely, we 
obtained the E.coli knock-out strain BL21(DE3) ΔAcrB from Dr. Edward Yu (Iowa State 
University) (139). AcrB is not essential in E.coli cell system. I used the same expression 
and purification protocol as explained in Chapter 2. 
5.3.6. Two-dimensional (2D) crystallization efforts 
In collaboration with Schmidt-Krey lab in School of Biology, 2D-crystallization 
trials of SPP for electron crystallography were performed. I purified different variants of 
SPP as in Chapter 2. Schmidt-Krey lab members, Maureen Metcalfe and Kasahun 
88 
 
Neselu, conducted 2D-cystallization trials and negative-staining visualization in the 
electron microscope.  
Initially Ms. Metcalfe tested both purified mSPP and MCMSPP (Chapter 2). 
MCMSPP was identified as the more promising homolog due to its reproducible 
incorporation into lipid vesicles. Thereafter, electron crystallization trials focused on 
MCMSPP. Parameters tested to improve 2D crystals of MCMSPP include lipid-to-
protein ratio, dialysis buffer content and pH, protein concentration, different fractions 
form SEC elution, purification protocol, and temperature. Additional experimental details 
can be found in Ms. Metcalfe’s Master’s thesis.  Larger crystals with ordered areas and 
lower mosaicity are the main areas of improvement in this ongoing project to solve a high 
resolution structure of SPP in a native-like lipidic environment. 
5.4. Results 
5.4.1. MCM-EE2 crystallization 
Our main goal was to co-crystallize EE-tagged SPP with anti-EE scFv (Chapter 4) 
but in addition to that, I set up some sparse matrix screens with left-over MCM-EE2 from 
co-crystallization trays. After 3-4 days, I had a crystal hit (Figure 5.3A). The hit 
condition was optimized several times by manual crystallization trays (section 5.3.1, 
Figure 5.3B). After getting crystals reproducibly, we decided to focus on MCM-EE2 
crystallization in hopes of improving these crystals for structure determination. The same 





Figure 5.3. First crystal hit of MCM-EE2. (A) Crystal hits in H9 well of MembFac 
sparse matrix under UV imaging. Crystals are circled in red. H9 well solution is 0.1 M 
NaCacodylate pH 6.5, 0.2 M  Zn(OAc)2, 9% PEG 8000. 7.3 mg/ml MCM-EE2 was 
mixed with the solution in 1:1 ratio. (B) Optimization of sparse matrix crystal hit by 
manual crystal tray. Rod-shaped crystals are white under UV imaging. Well solution is 
0.1 M NaCacodylate pH 6.5, 0.3 M  Zn(OAc)2, 5% PEG 8000. 7.1 mg/ml MCM-EE2 
was mixed with the solution in 1 µL : 1 µL ratio. 
 
 
Figure 5.4. Representative purification flow of MCM-EE2 for crystallization 
optimization trials. (A) HisTrap purification with 0-60% gradient elution. Elution peak 
(1) are pooled and concentrated to ~250 µL for SEC. (B) SEC with S12 column, second 
peak (2) is pooled and concentrated for crystallization trials. (C) SDS-PAGE of HisTrap 
(1) and S12 (2) elution fractions. SPP band appears just below the 31 kDa band of 
molecular weight marker. 
 
With optimization of the hit condition, the crystals got bigger and were subjected 
to X-ray diffraction data collection. These crystals diffracted to at best 12 – 7 Å (Figure 
5.5) and were sensitive to radiation damage; the diffraction pattern decreased in intensity 
and diffraction limit, and the spots became very smeary during attempted data collection. 
Collected data were not of sufficient quality to determine the space group or unit cell 
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parameters. On the basis of these results, we decided to focus our optimization efforts on 






Figure 5.5. Representative MCM-EE2 crystal diffraction. (A) MCM-EE2 crystal flash-
frozen in a nylon loop for X-ray diffraction. The crystal is grown in solution of 0.1 M 
NaCacodylate pH 6.5, 0.3 M  Zn(OAc)2, 5% PEG 8000 and cryo-protectant is the same 
solution supplemented with 25% glycerol. 10 µM beam size is represented as green circle 
on the crystal. (B) X-ray diffraction pattern of the crystal. Diffraction spots are observed 
up to 7 Å resolution. 
 
5.4.2. Optimization of MCM-EE2 crystals  
As summarized in Section 5.3.1, many parameters were tested in attempt to 
improve diffraction quality of MCM-EE2 or its variants. Many of optimization strategies 
were also employed with promising engineered MCM-EE2 variants (Section 5.3.3). 
Figure 5.6 shows a representative result from filter MWCO and detergent additive screen 
optimization efforts. All crystals obtained throughout this optimization process were rod-
shaped and improvement criteria were based on morphology (longer and thicker), which 
were expected to diffract to higher resolution. 
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Throughout the optimization process, zinc ions and a buffer of pH 6.5 were 
required to grow crystals; when I changed salt, no crystals grew. Crystals did not grow at 
all or were very small when the buffer used was lower or higher than pH 6.5. Additive 
screens and the post-crystallization optimizations (dehydration, annealing, and heavy 
metal/inhibitor soaking) did not have any substantial change in the crystallization. Crystal 
size and diffraction quality were improved with higher protein concentration in the 
crystal drop: the length of crystal became longer than 100 μm and they became thicker 
when the protein concentration was greater than or equal to 15 mg/ml. 
 
Figure 5.6. Representative crystal images from optimizations of filter size and detergent 
additive screen. MCM-EE2 protein is concentrated by (A) MWCO 10K and (B) 50K 
amicon filter for additive detergent screening. Various crystal hits in different additive 
detergents are shown. Crystallization condition is 0.1 M NaCacodylate pH 6.5, 0.3 M  
Zn(OAc)2, 6% PEG 8000. Protein : additive detergent : crystallization solution volume 




Data collected on these larger crystals diffracted to ~4.5 Å resolution (Figure 
5.7). Although radiation damage precluded collection of a complete dataset, we were able 
to index the initial frames obtained. Unfortunately, a search of the refined space group 
and unit cell dimensions matched with AcrB structures deposited in the Protein Data 
Bank (PDB). Though documentation as such is scant, AcrB is a relatively common 
contaminant in membrane protein crystallization trials. AcrB crystallizes even at 
picogram levels where it is not visible by SDS-PAGE (140-142). Based on this result, we 
inferred our protein crystals were AcrB and we turned our efforts to eliminate AcrB 
contamination (sections 5.4.3, 5.4.5, 5.4.6).  
 
Figure 5.7. Better diffraction of optimized crystals informed that crystals might belong to 
AcrB contaminant according to its unit cell dimensions and angles. (A) Representative 
optimized crystal. (B) Crystal in the nylon loop ready for X-ray diffraction. (C) 
Diffraction of the crystal up to 4.5 Å resolution. (D) Space group, unit cell dimensions 




5.4.3. Protein engineering efforts to improve crystallization of MCM-EE2 
5.4.3.1. Introduction of a TEV cleavage site to remove His6 tag from 
MCM-EE2 
When contaminant proteins like AcrB bind to Ni2+-affinity columns and do not 
separate by SEC, removal of the hexahistidine (His6) tag from the purified protein of 
interest followed by an additional purification step should eliminate the contaminant. We 
engineered a TEV cleavage site (“ENLYFQS”) before the C-terminal His6 tag of MCM-
EE2 (section 5.3.3.3). The purification protocol changed accordingly (Figure 5.8); after 
overnight TEV cleavage, the mixture was applied to the Ni2+-affinity column. Uncleaved 
MCM-EE2 and AcrB are expected to bind the column whereas the flow-through fractions 
contain cleaved MCM-EE2 for further purification by gel filtration: the cleaved MCM-
EE2 should be contaminant-free after this step. All other protein engineering efforts and 
crystal optimizations were done with the TEV-cleavable MCM-EE2 variant after AcrB 
contamination problem came to light. 
 
Figure 5.8. TEV cleavable His6 tag variants and their purification flow. (A) Ni
2+-affinity 
purification (buffers as in section 2.2.4) with 0-60% gradient elution. Elution peak (2) is 
pooled and buffer-exchanged into gel filtration buffer for overnight TEV protease 
cleavage at 4 °C in 1:1 ratio. (B) Another Ni2+-affinity purification (buffers as in section 
2.2.4) was run with injection of TEV digested protein, flow-through (3) is concentrated to 
~250 µL for SEC. (C) SEC with S12 column, second peak (4) is pooled and concentrated 
for crystallization trials. (D) SDS-PAGE of clarified cell lysate (1), Ni2+-affinity (2, 3) 
and S12 (4) elutions. SPP band shows up under marker band of 31 kDa. TEV cleaved 





5.4.3.2. Introduction of zinc binding motif to MCM-EE2 
On the basis of our observation that rod-shaped crystals only grew in the presence 
of zinc ions, leading us to think that zinc was required to form a crystal contact, we 
attempted to engineer a zinc binding motif in the extramembraneous TM6-TM7 loop. We 
hypothesized that crystallization would be enhanced by installing an explicit zinc binding 
motif (HEXXH, section 5.3.3.2) to form an additional Zn-dependent crystal contact. 
However, this alteration did not have any effect on crystallization or quality of 
diffraction. Later, we inferred that rod-shaped crystals were probably AcrB. 
5.4.3.3. Shortening of loop connecting TM6-TM7 
An early concern about SPP crystallization was the long loop between TM6-TM7 
(section 5.3.3.1). Long and flexible loops are expected to impede crystallization due to 
heterogeneity in conformation. The TM6-TM7 loop of MCM-EE2 was shortened step-
by-step and subjected to sparse matrix crystallization trials. To evaluate whether the loop 
affects SPP activity, we conducted a diagnostic continuous FRET activity assay with 
ETS3 and ETS4, and compared activity that of WT MCMSPP (Figure 5.9). Notably, the 
shortened loop variants had higher initial velocities than WT MCMSPP (Figure 5.9), 




Figure 5.9. Preliminary activity assay for WT-MCM, ETS3 and ETS4. (A) FRET assay 
to determine velocities for different concentrations of enzyme (0.5, 1, 2, 5 μM) with 10 
μM Ren390FRET substrate. (B) Calculated initial velocities in AFU/min. This data was 
obtained with one batch of each protein as triplicates in the plate. 
 
Crystallization trials of the variants containing shortened TM6-TM7 loops 
resulted in new hits with diamond-shaped morphologies (Table 5.5). Optimizations 
proceeded as listed in section 5.3.1. Figure 5.10 depicts a representative crystal and 
diffraction limit of ~6 Å resolution. A data set was collected from one of the optimized 
crystals, but again it turned out to be AcrB which we solved by molecular replacement 
(143). Although we thought that we eliminated the AcrB contamination by using TEV-
cleaved constructs, it was probably still in our sample in low amounts which would be 
enough for its crystallization (141). Later, we confirmed presence of AcrB by silver-
stained SDS-PAGE gel which has higher sensitivity than that of coomassie-stained 
(section 5.4.5). 
In parallel with the process of shortening the TM6-TM7 loop, we generated 
another variant with covalently attached lysozyme (mT4L-SPP, section 5.3.3.4). 
Lysozyme is known to help improve crystallization of membrane proteins due to its 
hypercrystallizability. A recent paper from Kobilka lab demonstrated the utility of a 
modified T4 lysozyme in improving their diffraction quality of a GPCR compared to that 
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of wild-type T4 lysozyme (138). Although I screened many different crystallization 
conditions through sparse matrices, mT4L SPP did not yield any crystals other than those 
that had morphology consistent with AcrB contaminant crystals. 
Table 5.5. New crystal hits with different crystal morphologies after SPP protein 
engineering efforts. 
Crystal images under UV light Variant Crystallization solution 
  
MCM-EE2 First crystal hit with rod-shaped 
morhology 
0.1 M NaCacodylate pH 6.5 
0.3 M  Zn(OAc)2 
6% PEG 8000 
 
ETS1 MemGold 
0.04 M Tris pH 8 
0.04 M NaCl 




0.1 M HEPES pH 7 
0.2 M NaCl 




Sodium Phosphate pH 6.2 
0.02 M NaCitrate 




0.02 M Na Citrate pH 5.6 
0.1 M NaCl 




0.025 M HEPES pH 7.5 
0.2 M NaCl 




Table 5.5. Continued   
 
ETS2 MemGold 
0.1 M Tris pH 8 
0.15 M NaCl 




0.1 M HEPES pH 7 
0.2 M NaCl 




0.1 M HEPES pH 7.5 




0.4 M Ammonium acetate pH 8 




Figure 5.10. Representative diamond-shaped ETS3 crystal diffraction. (A) Crystal flash-
frozen in a nylon loop for X-ray diffraction. The crystal is grown in solution of 0.4 M 
Ammonium acetate pH 8, 15% PEG MME 2000 and cryo-protectant is the same solution 
supplemented with 20% glycerol. 50 µM beam size is represented as green circle on the 
crystal. (B) X-ray diffraction pattern of the crystal. Diffraction spots are observed up to 6 
Å resolution. Structure was solved with the collected dataset by molecular replacement 




5.4.4. Crystallization trials with bicelles and LCPs 
Due to the fact that excess detergent in the crystallization solution can interfere 
with membrane protein crystallization, alternative crystallization methods were 
attempted. These alternative methods included DMPC/CHAPSO detergent bicelles, and 
lipidic cubic phase (LCP) (135, 136, 144). Both the bicelle and LCP techniques utilize 
lipids that form bilayers which would mimic natural lipidic environment. 
Bicelle crystallization trials with sparse matrix screens were performed for MCM-
EE2 and ETS3 variants; neither gave crystal hits. Some of the drops contained 
precipitation over time (Figure 5.11). LCP crystallization trials were performed for 
MCM-EE2 and cleaved MCM-EE2-TEV variants but again no crystals were identified. 
Figure 5.12 shows a representative image of an LCP crystallization tray and one of the 
drops in the tray.  
 
Figure 5.11. Representative images for crystal drops of bicelle crystallization trays over 





Figure 5.12. LCP trays. (A) LCP sandwich plates ready to be imaged by Rigaku Minstrel 
DT instrument. (B) Representative zoomed-in crystal drop in the LCP tray. Protein-
monoolein mixture is the small circle inside the crystallization solution from the sparse 
matrix (big circle). 
 
5.4.5. Confirmation of AcrB contamination  
 
Although almost two years were devoted to optimizing crystallization conditions 
and SPP constructs, we were unable to fully remove E. coli AcrB. Neither removing the 
hexahistine tag from MCM-EE2 and additional purification steps, nor other protein 
engineering efforts, proved successful. AcrB was not prominent in SDS-PAGE analysis 
of purified enzyme when stained by coomassie but AcrB was confirmed with the more 
sensitive silver-staining protocol when harvested crystals were evaluated by SDS-PAGE 




Figure 5.13. Silver-stained SDS-PAGE for ETS4 protein and harvested crystals. 28 rod-
shaped ETS4 crystals were harvested and washed 2 times with GF buffer before loading 
into the SDS-PAGE. When compared to the TEV-cleaved ETS4, crystals give two bands 
higher in molecular weight than that of ETS4. The lower band (between 97 and 116 kDa 
band) corresponds to AcrB molecular weight (110 kDa) and the upper band could be the 
aggregated form of the AcrB protein which could not enter to the resolving gel. 
 
5.4.6. Protein expression in E. coli BL21(DE3)ΔAcrB 
After facing AcrB crystallization twice, we decided to express our protein in an 
AcrB knock-out E. coli strainBL21(DE3)ΔAcrB (139), a kind gift from Dr. Yu (Iowa 
State University). I performed pilot expression trials with both WT-MCM and mT4L-
SPP. Yield for cells expression WT-MCM was very low and enzyme could not be 
purified to any appreciable levels (Figure 5.14). At this point, we decided to halt SPP 





Figure 5.14. Purification flow of WT-MCM expressed in E.coli BL21(DE3) ΔAcrB. (A) 
HisTrap purification with 0-60% gradient elution. Elution peak (17-22) are pooled and 
concentrated to ~250 µL for SEC. (B) SEC with S12 column, peak fractions are 
concentrated for SDS-PAGE. (C) SDS-PAGE of cell lysate, HisTrap and S12 fractions. 
Samples are not pure and three bands show up between 31-45 kDa. All purification 
buffers contain DDM detergent. 
 
5.4.7. 2D crystallization efforts in collaboration with Schmidt-Krey Lab 
In collaboration with Schmidt-Krey Lab, we have been trying to crystallize SPP 
in 2-dimensional (2D) lipid vesicles. For initial screening, dialysis and negative staining 
have been performed. I provided 8 batches of WT-MCMΔN23, WT-MCM or WT-MCM-
TEV (Table 5.6) When we learned that N-terminal 23 amino acids belong to the 
transmembrane helix 1 of SPP (Chapter 2), we decided to continue all 2D-crystallization 
experiments with full-length (WT-MCM). We tried to see if SEC column would make 
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any difference in 2D-crystallization by altering the separation of PDC from empty 
micelles. Both S12 and S300 columns were tested with WT-MCM and S12 gave better 
crystals, so we decided to continue with the S12 column. We also tested WT-MCM-TEV, 
and we concluded that removing C-terminal His6 tag did not have any discernible effect 
on 2D-crystallization. Therefore, all experiments were focused on WT-MCM. Early in 
the project, I had pooled fractions from SEC elution peak for 2D crystallization trials, but 
an optimization parameter has been keeping fractions separate. There is an overlap 
between the elution of purified protein and empty micelle; thus each fraction has a 
different detergent:protein concentration, which could affect crystallization. Indeed, 
Kasahun discovered a difference in crystal quality depending on fraction (fraction 
number 11 from S12 column was the best), so fractions have not been pooled in 
subsequent 2D-crystallization trials. Finally, the purification protocol was changed with 
5% buffer B wash after sample loading to eliminate further AcrB contamination (Chapter 
2.2.4) 
More details on results of dialysis and 2D-crystallization experiments can be 
found in Schmidt-Krey lab documents: Maureen Metcalfe’s master thesis and Kasahun 
Neselu’s laboratory notebooks. Thus far, varying lipid-to-protein ratio, dialysis solution, 
temperature, etc., has resulted in larger ordered areas (>1 μm) with lower mosaicity 
(Figure 5.15). The next phase of the project will be determining the structure by cryo-




Table 5.6. Protein samples provided to Schmidt-Krey Lab for WT-MCM 2D-
crystallization efforts. 
Date Dialysis and negative-staining by SPP variant SEC column and its fractions 
12/13/13 Maureen Metcalfe WT-MCM ΔN23 S300, pooled fractions 
05/01/14 Maureen Metcalfe WT-MCM ΔN23 S300, pooled fractions 
07/01/14 Maureen Metcalfe WT-MCM S300, pooled fractions 
10/08/14 Maureen Metcalfe WT-MCM S12, pooled fractions 
02/04/15 Maureen Metcalfe WT-MCM-TEV S12, pooled fractions 
05/13/15 Kasahun Neselu WT-MCM-TEV S12, pooled fractions 
12/03/15 Kasahun Neselu WT-MCM S12, separate fractions 
03/14/16 Kasahun Neselu WT-MCM S12, separate fractions* 
* 5% buffer B wash step was used after sample loading during Ni2+ affinity purification 
 
 
Figure 5.15. Representative 2D-crystallization results of WT-MCM. (A) Vesicles formed 
after 12 days of dialysis. (B) Vesicles zoomed-in. (C) Live Fast Fourier Transform (FFT) 
image from the part of the vesicles show good mosaicity. 
 
5.5. Discussion 
In this chapter, I cataloged efforts to improve crystallization and diffraction of 
SPP by optimization of crystallization environment and by protein engineering. I faced 
AcrB contamination twice and could not eliminate this problem while retaining SPP 
expression levels required for structure determination. Several other research labs also 
crystallized AcrB instead of their desired his-tagged membrane protein (140-142). AcrB 
contamination was not evident in the literature until very recently; emerging evidence 
suggests that ~45% of all membrane protein crystallization trials produce crystals of 
AcrB even when AcrB is not visible by SDS-PAGE (141). Psakis, et al. report that AcrB 
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can crystallize in a variety of different crystallization conditions and suggest that the 
stress of target protein overexpression might up-regulate AcrB expression. They also 
propose that crystallization of AcrB in very low quantities (scale of picograms) could 
happen by its phase-transition of the detergent/lipid content instead of oversaturation due 
to the crystallization components (141). 
Many important lessons were learned from this study. During crystallization of 
any membrane protein of interest, it is always important to check if crystal morphologies 
are similar to known AcrB crystals (141) and if their unit cell dimensions/angles and 
space groups match with those of AcrB. Even though AcrB is invisible in the SDS-PAGE 
of the final protein sample, more sensitive methods such as silver-staining should be used 
to determine the purity of the membrane protein and to identify contaminants like AcrB 
before valuable time and resources are wasted. The same caution should be taken with 
2D-crystallization experiments (145). During our 2D-crystallzition efforts, we used to see 
low amounts of high-contrast regions among vesicles. This was strange because SPP did 
not have any known extracellular region which would result in crystals with high 
contrast. Luckily, we did not focus our efforts on these high-contrast vesicles, which we 
infer by comparison to published data (145), was probably AcrB. 
During loop shortening studies, we found out that two variants with the shortest 
TM6-TM7 loop, ETS3 (12 amino acid deletion) and ETS4 (16 amino acid deletion) were 
catalytically faster than WT-MCM (Figure 5.9). ETS4 was even faster than ETS3, this 
might mean that shorter the loop is, faster the enzyme is. Because the two catalytic 
aspartates are located in TM6 and TM7, shortening the TM6-TM7 loop may bring the 
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catalytic aspartates closer to each other, reducing the numbers of inactive conformations 
accessible to the enzyme.  
 Because of the challenges at the crystallization level of membrane proteins, 
research has been done to alter the chemical environment of membrane proteins. Lipid 
and cell membrane mimics can stabilize membrane proteins and increase the chance of its 
crystallization, both in 3D and 2D. Lipidic environments such as LCP and bicelles have 
been developed (135, 136, 144) and they have been successfully used in the structure 
determination of some membrane proteins including many G-protein Coupled Receptor 
proteins (GPCRs) (146). Although their broad utility still needs to be confirmed with 
more unique membrane protein structures, they hold promise to tackle membrane protein 
crystallization challenge.  More perspectives on membrane protein structure 
determination are discussed in Chapter 7. 
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6. CHAPTER 6: Enzymatic Hydrolysis of 5-nitroanthranilic acid by Metal-
dependent Nucleophilic Aromatic Substitution 
6.1. Introduction 
6.1.1. Nitroaromatic compounds and their biodegradation pathways 
A vast number of synthetic and natural organic compounds found in the biosphere 
(54, 147). Nitroaromatic compounds, widely synthesized and used industrially for dyes, 
pesticides, explosives and solvents, are particularly toxic and recalcitrant to degradation 
(148-150). Nitro substituents are deactivating meta directors in electrophilic aromatic 
substitution reactions, and can form a stable Meisenheimer complex when found ortho or 
para to a leaving group in nucleophilic aromatic substitution (SNAR) (148-150). Bacteria 
from areas contaminated with synthetic nitroaromatics have evolved degradation 
pathways in which the nitro group is first converted to nitrite, amine, hydroxylamine, 
keto or hydroxyl by oxygenases or nitroreductases; then ring fission leads to 
intermediates that can enter central metabolism (148-150). Naturally occurring nitro-
containing compounds are produced in animals, plants, fungi, and microbes (150-152), 
but documentation of their catabolism is scant (150). Discovery of the enzymatic 
mechanisms for synthesis and biodegradation of such compounds would extend our 
understanding of metabolic diversity for the prediction and control of their ecological 
impacts.  
 There is a growing awareness of the potential use of rhizospheric or endophytic 
bacteria as biocontrol agents to enhance resistance to plant pathogens (153-155), 
including Streptomyces scabies (156), which causes potato scab (157), a disease of 
worldwide economic importance (158). The primary phytotoxin, thaxtomin, is a family of 
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5-nitrotryptophan-containing cyclic dipeptides. Among the additional metabolites 
secreted by S. scabies is 5-nitroanthranilic acid (5NAA), the nitrated analog of the 
tryptophan biosynthesis intermediate chorismate, which is degraded by Bradyrhizobium 
sp. JS329, a bacterial strain isolated from potato field soil (159). The ecological role of 
Bradyrhizobium sp. JS329 is not currently known, but by eliminating a component of the 
S. scabies chemical arsenal, Bradyrhizobium sp. JS329 might protect itself and plants 
from disease (147, 160). In contrast to the processes known to biodegrade xenobiotic 
nitroaromatic compounds, the nitro group is not the initial target for the biodegradation of 
5NAA. Instead, 5-nitroanthralinate aminohydrolase (D3WZ85, E.C. 3.5.99.8, 5NAA 
deaminase, 5NAA-A) performs a unique deamination reaction whereby the amino group, 
which is para to the nitro substituent, is hydrolyzed to form 5-nitrosalicylic acid (5NSA) 
and the nitro group remains intact. Next, ring fission is catalyzed by 5NSA dioxygenase 
and the nitro group is eliminated by downstream reactions (48) (Figure 6.1). Whereas 
DNA deaminases and other hydrolases can remove amino groups from aliphatic and 
heterocyclic compounds (161), 5NAA-A is the first described hydrolase that can remove 




Figure 6.1. Proposed biodegradation mechanism of 5NAA 
6.1.2. Chapter overview and publications 
The study in this chapter was a collaboration project with Spain Lab in School of 
Civil and Environmental Engineering. They discovered a new bacterial strain named 
Bradyrhizobium sp. JS329 in potato soil and found enzymes encoded its genome which 
can biodegrade a natural nitroaromatic compound, 5NAA (48, 159). The first step in 
biodegradation pathway is catalyzed by 5NAA-A, a metalloprotease family member that 
converts 5NAA to 5NSA (Figure 6.1). 
Here, we report the crystal structures of this enzyme in the apo, 5NAA-bound, 
5NSA/Mn2+-bound 5NAA-A, and Meisenheimer complex intermediate/Zn2+- bound 
5NAA-AR289A, as well as characterize metal binding and substrate preferences that tailor 
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5NAA-A for its unprecedented active site chemistry. We obtained snapshots of its 
mechanism from its structures in various states. 5NAA-A, an octamer that can use a 
variety of divalent transition metals for catalysis, employs a novel nucleophilic aromatic 
substitution mechanism. Unexpectedly, the metal binding site in 5NAA-A is labile. 
5NAA-A is specific for 5NAA and cannot hydrolyze other tested derivatives, which are 
likewise poor inhibitors. The 5NAA-A structure and mechanism expanded our 
understanding of the chemical ecology of an agriculturally important plant and pathogen, 
and will inform bioremediation and biocatalytic approaches to mitigate the environmental 
and ecological impact of nitroanilines and other challenging substrates.  
 The manuscript of this study was submitted to Nature Chemical Biology in March 
22nd, 2016 and it was sent out for review on March 30th, 2016. Mostly positive reviews 
came back with a couple of requests for additional experiments on May 3rd, 2016. During 
writing process of this thesis chapter, we did additional experiments, revised our 
manuscript and submitted revisions to Nature Chemical Biology 
6.2. Methods 
6.2.1. Molecular biology 
5NAA-A was cloned into a pET-30 Xa/LIC vector (Novagen). 5NAA-A variants 
were generated by site-directed mutagenesis (SDM, QuickChange Lightning Kit, Agilent 
Technologies) using the 5NAA-A pET-30 Xa/LIC vector as template. Primers were 
designed with the assistance of PrimerX (Bioinformatics.Org), and synthesized by MWG 
Operon. Sequences of all the constructs were confirmed by DNA sequencing (MWG 
Operon). Primer sequences for reported 5NAA-A variants were shown in Table 6.1. 
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Table 6.1. Primers for 5NAA-A variants. 
Mutant Oligonucleotide Primers 
H86A Forward: 5'-AGCCTGTCCTTCAACAGTGCGCTCGACACGATCATGGCG-3' 
Reverse: 5'-CGCCATGATCGTGTCGAGCGCACTGTTGAAGGACAGGCT-3' 
E196A Forward: 5'-GCTCTCGTCGCGGCGGCGACGAACTTC-3' 
Reverse: 5'-GAAGTTCGTCGCCGCCGCGACGAGAGC-3' 
E158A Forward: 5'-CTGCAGTCTGTGGCGCGATTGACTGCGAGCCG-3' 
Reverse: 5'-CGGCTCGCAGTCAATCGCGCCACAGACTGCAG-3' 
N124A Forward: 5'-TCTACGGCTATAGTGTTGTGGCGTGTAAGGGTCCTATGGCGTG-3' 
Reverse: 5’-CACGCCATAGGACCCTTACACGCCACAACACTATAGCCGTAGA-3' 
Y223A Forward: 5'-CCGGGCCGTCCCGCGCGACGCCCTACGTGCC-3' 
Reverse: 5'-GGCACGTAGGGCGTCGCGCGGGACGGCCCGG-3' 
Y223F Forward: 5'-GGCCGTCCCGCTTTACGCCCTACGT-3' 
Reverse: 5'-ACGTAGGGCGTAAAGCGGGACGGCC-3' 
R289A Forward: 5'-GCGGCGTGCCCTACAAGATTTATGCGTTTCCAGAGCTCT-3' 
Reverse: 5'-AGAGCTCTGGAAACGCATAAATCTTGTAGGGCACGCCGC-3' 
R373A Forward: 5'-GGAGTGCAGCATGTGGGCGGACACGAATCCCTACA-3' 
Reverse: 5'-TGTAGGGATTCGTGTCCGCCCACATGCTGCACTCC-3' 
D88A Forward: 5'-TTCAACAGTCATCTCGCGACGATCATGGCGCGCG-3' 
Reverse:  5'-CGCGCGCCATGATCGTCGCGAGATGACTGTTGAA-3' 
D88N Forward:  5'-CTTCAACAGTCATCTCAACACGATCATGGCGCG-3' 
Reverse:  5'-CGCGCCATGATCGTGTTGAGATGACTGTTGAAG-3' 
V247K Forward:  5'-TGCGTATGGCCAAGCTCAAAGAGGCGCTGGAGGAATG-3' 
Reverse:  5'-CATTCCTCCAGCGCCTCTTTGAGCTTGGCCATACGCA-3' 
 
6.2.2. Protein expression and purification 
5NAA-A and 5NAA-A variants were expressed in competent E. coli Rosetta 2 
(DE3) cells. A single transformed colony was inoculated into a selective 20 mL Luria-
Bertani culture (LB, Fisher, supplemented with 34 μg/mL chloramphenicol, 50 μg/mL 
kanamycin) and agitated overnight (16-18 hours) at 37°C, 225 RPM.  A starter culture (5 
mL) was used to inoculate 1 L of selective LB media and agitated at 37°C, 225 RPM 
until an optical density at 600 nm of 1.0-1.5 was reached. The cell cultures were cooled 
with shaking at 225 rpm at 25°C for 1 hour, then induced with 0.5mM isopropyl β-D-
thiogalactopyranoside (IPTG, Calbiochem), and allowed to grow overnight (16-18 hours) 
at 25°C, shaking at 225 RPM. Cells were pelleted (3000 x g, 10 minutes, 4°C) and 
subsequently flash-frozen with liquid nitrogen and stored at -80°C.  
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The selenomethionine derivatized enzyme (5NAA-A SeMet) was generated by 
transforming the pET-30 Xa/LIC plasmid into competent E. coli T7 Express Crystal cells 
(New England Biolabs) following the protocol published by Lambert et al. (162). Briefly, 
a single transformed colony was inoculated into 10 mL selective minimal media (5x M9 
salts (163), 0.4% glucose, 1 mM MgSO4, 0.1 mM CaCl2, 0.0002% ferric ammonium 
citrate, 34 μg/mL chloramphenicol, 50 μg/mL kanamycin) containing 50 μg/mL L-
methionine. The starter culture was agitated at 225 RPM at 37°C for 2 hours, followed by 
inoculation at a 1:100 dilution into the selective 1 L minimal media expression media 
containing 50 μg/mL L-methionine. When an optical density at 600 nm of 0.6-0.8 was 
reached, cells were pelleted and resuspended into fresh selective minimal media with no 
L-methionine and shaken at 225 RPM, 37°C, for 2.5 hours. L-selenomethionine was then 
added to the cell culture to a final concentration of 50 μg/mL; after 30 minutes with 
agitation, cells were induced with 0.5 mM IPTG, and then allowed to grow overnight 
(16-18 hours) at 25°C, with 225 RPM agitation. Cells were pelleted by centrifugation 
(3000 x g, 10 minutes, 4°C) and subsequently flash frozen with liquid nitrogen and stored 
at -80°C. 
Cell pellets were suspended in Ni2+-affinity purification wash buffer (50 mM 
HEPES pH 7.5, 500 mM NaCl, 40 mM imidazole, 10% glycerol) containing 0.5x Roche 
Complete EDTA-free Protease Inhibitor and lysed by two passages through a French 
Press (13000 psi). Cellular debris was removed by ultra-centrifugation (162,000 x g, 45 
minutes, 4 °C). The supernatant loaded onto a 1 mL Ni2+-affinity purification column 
(GE Healthcare) on an AKTA FPLC system (GE Healthcare), equilibrated with wash 
buffer. Pure protein was eluted with a gradient from 40-500 mM imidazole by AKTA 
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FPLC system, elution buffer was exchanged with Factor Xa cleavage buffer (50 mM Tris 
pH 7.5, 100 mM NaCl, 5 mM CaCl2) using an Amicon 10K MWCO filter (EMD 
Millipore). The N-terminal hexahistidine tag was removed by incubation with Factor Xa 
(Roche, 50:1 mass ratio) for 20 hours at 4°C. The digestion mixture was applied to a re-
equilibrated 1 mL Ni2+-affinity purification column, the flow-through fractions 
concentrated in an Amicon 10K MWCO filter, and the concentrate then loaded onto a 
HiLoad 16/600 Superdex 75 prep grade column (GE healthcare) equilibrated with gel 
filtration buffer (50 mM Bicine pH 7.0, 150 mM NaCl). The gel filtration buffer was 
selected by assessing 5NAA-A SeMet thermal stability in a range of buffers with various 
pHs using differential scanning fluorimetry as described previously (164). The fractions 
containing 5NAA-A were concentrated in an Amicon 10K MWCO filter for further use. 
Protein purity was assessed by 12% SDS-PAGE analysis with Coomassie staining. 
Protein concentrations were measured by absorbance at 280 nm using molar extinction 
coefficient (74,461.88 M-1 cm-1) determined by total amino acid analysis (Molecular 
Structure Facility, University of California, Davis) and molecular weight (42,832.31 
g/mol). The molecular mass of purified 5NAA-A was estimated by size exclusion 
chromatography using a Superdex-200 10/300 GL column (GE Healthcare) equilibrated 
with 5NAA-A gel filtration buffer and calibrated using a gel filtration calibration kit (GE 
Healthcare). 5NAA-A was analyzed immediately following calibration. The molecular 
weight of 5NAA-A in solution was determined based on the calibration curve, and the 
oligomerization state of 5NAA-A was estimated by this molecular weight divided by the 
calculated mass of a monomer. 
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6.2.3. Circular dichroism (CD) 
CD spectrum and thermal melt were acquired on a Jasco J-810 spectropolarimeter 
equipped with Neslab RTE 111 circulating water bath and a Jasco PTC-4245/15 
temperature control system. CD spectra were taken at room temperature for both gel 
filtration buffer (blank) and 7.8μM WT 5NAA-A sample in gel filtration buffer. CD 
thermal melt was performed utilizing a 1 °C/min increase in temperature from 5 to 91 °C. 
Both CD spectra and thermal melt (every 2 °C) were acquired with 15 averaged scans 
from 300 to 200 nm at a 200 nm/min scan rate, using a 0.1-cm cuvette. The melting 
temperature was determined using ellipticity values recorded at 220 nm via sigmoidal 
dose-response analysis using GraphPad Prism 5 software. 
6.2.4. Activity and inhibition assays 
To assess the activity of 5NAA-A during purification steps, an analytical high-
performance liquid chromatography (HPLC) assay described previously (159, 165) was 
performed by Zohre Kurt (Spain Lab) on a (a) sample after ultracentrifugation, (b) 
sample after the first Ni2+-affinity purification (elution), (c) sample after the second Ni2+-
affinity purification (flow-through), and (d) sample after gel filtration. 5NAA and 5NSA 
content was analyzed by HPLC with an Agilent Eclipse XDB-C18 column (4.6 mm by 
150 mm; 5 μm) by the method described previously (159, 165).  
The chemical structures of substrate 5NAA (Sigma Aldrich) and product 5NSA 
were confirmed by 1H-NMR (Georgia Tech NMR Center). For characterization of 5NSA, 
an overnight reaction (0.25 μM 5NAA-A, 1mM 5NAA, 500 μM Mn(SO4)) was 
performed and 5NSA was purified by HPLC. 5NSA product formation was also 
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confirmed by mass spectrometry (Georgia Tech Bioanalytical Mass Spectrometry 
Facility). 
A spectrophotometric assay was developed to follow depletion of substrate (λmax 
for 5NAA= 374 nm; λmax for 5NSA= 306 nm). Divalent transition metals (MnSO4, 
Zn(OAc)2, CoCl2, CdCl2, NiSO4), FeSO4.7H2O (see below) and divalent alkali metals 
(MgCl2, CaCl2) were screened for 5NAA-A activity. 5NAA (100μM) and varying 
concentrations of metals (0.25 μM, 2.5 μM, 50 μM, 500 μM) were dispensed in a 96-well 
plate (Costar 96-Well EIA/RIA). Freshly purified 5NAA-A enzyme (0.25 μM) in gel 
filtration buffer was added (100 μL total volume) and the reaction mixture was mixed on 
ice by gentle pipetting. The plate was sealed with optical adhesive film (Micro-Amp) and 
the reaction was started at 37°C with a Synergy 2 plate reader (BioTek). Absorbance 
readings were recorded every 3 minutes for 2 hours. 5NAA substrate depletion (374 nm) 
was used for data analysis. For Michaelis-Menten assays, a range of enzyme 
concentrations (0.15 μM, 0.25 μM, 0.5 μM) were tested, and 0.25 μM was selected for 
further assays. Varying concentrations of 5NAA (25-600 μM) and 500 μM MnCl2, 
Zn(OAc)2, or CoCl2 were distributed and the same procedure above was performed. To 
minimize oxidation of Fe2+ during our assay, the 5NAA-A was first dispensed in a 96-
well plate on ice. FeSO4
.7H2O was freshly solubilized as 10mM stock concentration and 
immediately added (500 μM). The assay was terminated after less than 30 min from the 
time the Fe2+ solution was prepared. For all experiments, absorbance readings of 
solutions containing all reagents except enzyme were subtracted from those containing 
enzyme to obtain the signal for 5NAA depletion. 
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Data were fit using the Michaelis−Menten analysis option within GraphPad Prism 
5. The Michaelis−Menten equation is V = Vmax[S]/ (Km + [S]) where V is the initial 
velocity, Vmax is the maximum velocity at infinite substrate concentration, [S] is substrate 
concentration, and Km is the substrate concentration at half maximal velocity. Initial 
velocities were determined by the absorbance reading at 374 nm over the first 15-20 min 
(negative slope of linear regression). Standard calibration curves were plotted with 
substrate controls (0-600 μM) for each assay, then initial velocities were plotted against 
substrate concentrations. Nine replicates were performed for 5NAA-A with MnCl2, 
Zn(OAc)2, six replicates were performed for 5NAA-A with and CoCl2, FeSO4
.7H2O and 
six replicates were performed for all 5NAA-A mutants with MnCl2 or Zn(OAc)2. Fe
2+ 
data did not fit to a Michaelis-Menten model. 
The ability of 5NAA-A to hydrolyze the substrate analogs m-nitrobenzoic acid 
(mNBA, Sigma Aldrich), 4-nitroaniline (4NA, Sigma Aldrich), anthranilic acid (AA, 
Sigma Aldrich), aniline (Alfa Aesar), 2-bromo-5-nitrobenzoic acid (BNBA, Alfa Aesar), 
2,4-dinitroaniline (DNAN, Alfa Aesar), aminoterephthalic acid (ATPA, Oxchem), and 4-
amino-3-nitrobenzoic acid (ANB, Acros), was monitored by a discontinuous enzyme 
activity assay. In an eppendorf tube, 0.25 μM 5NAA-A, either 500 μM MnSO4 or MnCl2, 
and 500-600 μM mNBA, 4NA, AA, aniline, BNBA, DNAN, ATPA or ANB were mixed 
in gel filtration buffer. Substrate 5NAA was used as a positive control. An initial time 
point and an overnight time point (16-18 hours of incubation in a 37°C water bath) were 
taken and the reaction was stopped by mixing a sample of the reaction mixture with 10% 
(v/v) trifluoroacetic acid. The UV-Vis spectra of the reaction mixtures were measured 
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from 300-500 nm by a BioTek Synergy 2 plate reader to detect any depletion of the 
respective substrate analog.  
Three analogs were tested for inhibition of 5NAA-A. 4NA was dissolved in 
water, BNBA and ANB were dissolved in 100% (v/v) and 50% (v/v) DMSO 
respectively. Concentration of purified 5NAA-A (0.25 μM) was kept constant and 
concentrations of analogs varied from 0.125 μM (0.5x enzyme) to 1000 μM (4000x 
enzyme). Enzyme, 500 μM Zn(OAc)2 and corresponding analogs were incubated at room 
temperature for 30-60 min. 5NAA substrate (100 μM) was added and the reaction started 
as described previously. Only DMSO at highest concentrations of 4NA and BNBA 
reactions was added in one of the positive controls (5NAA-A with substrate 5NAA) to 
show that it has no effect on the reaction. Data were fit by the half maximal inhibitory 
concentration (IC50) within GraphPad Prism 5. 
6.2.5. Crystallization 
Conditions for (co)-crystallization of 5NAA-A with substrate analogs and/or 
metal were initially identified by commercial sparse matrix screening (Hampton Index 
HT and Rigaku Wizard 1 & 2) and further optimized. 5NAA-A SeMet crystals (9.4 
mg/mL protein in 50 mM Bicine pH 7.0, 150 mM NaCl) were grown by the sitting-drop 
method at room temperature in 1.07 M NaH2PO4, 0.83 M K2HPO4. Crystals of 5NAA-A 
(7 mg/mL protein in 50 mM Bicine pH 7.0, 150 mM NaCl) with 5NAA (0.22 mM) were 
grown by the sitting-drop method at room temperature in 1.27 M NaH2PO4, 0.63 M 
K2HPO4. Crystals of 5NAA-A (5.8 mg/mL protein in 50 mM Bicine pH 7.0, 150 mM 
NaCl) with MnCl2 (16 mM) and 5NSA (0.16 mM, Eastman) were grown by sitting-drop 
method at room temperature in 0.1 M sodium cacodylate pH 6.5, 0.75 M trisodium 
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citrate. Crystals of 5NAA-AR289A (5.8 mg/mL protein in 50 mM Bicine pH 7.0, 150 mM 
NaCl) with Zn(OAc)2 (12 mM) and 5NAA (0.22 mM) were grown by sitting-drop 
method at room temperature from a solution containing 0.1 M sodium cacodylate pH 6.5, 
0.65 M trisodium citrate.  
6.2.6. Data collection and structure determination 
Crystals of 5NAA-A SeMet, 5NAA-A with 5NAA, 5NAA-A with Mn2+/5NSA, 
and 5NAA-AR289A with Zn
2+/5NAA were cryo-cooled in a solution containing the 
corresponding reservoir solution supplemented with 10% ethylene glycol, 16.6% 
glycerol, 23% glycerol, and 20.5% glycerol, respectively. Diffraction data were collected 
at beamline 22-ID of the Southeast Regional Collaborative Access Team (SER-CAT) at 
the Advanced Photon Source, Argonne, Illinois. Data were indexed, integrated, scaled 
and processed using HKL2000 (166). The initial structure (5NAA-A SeMet, apo) was 
solved by multiwavelength Se anomalous phasing using AutoSol(167) and the remaining 
structures (5NAA-A with 5NAA, 5NAA-A with Mn2+/5NSA and 5NAA-A R289A with 
Zn2+/5NAA) by molecular replacement using Phaser(168), using the 5NAA-A SeMet 
model. The models were iteratively built and refined using Coot(106) and 
Phenix.refine(107). eLBOW(169) within Phenix was used to generate ligand restraints of 
5NAA, 5NSA, and the 5NAA intermediate (Tet, (R)-1-carboxy-2-amino-2-hydroxy-5-
nitro-cyclohexa-1,4-diene) from coordinates generated using Coot. Readyset (107) within 
Phenix was used to generate metal coordination restraints. With the exception of two 
loops in apo 5NAA-A (residues 91-108 and 393-397, and see below), polypeptide chains 
were readily traced from residues 6-425; electron density for the remaining N-terminal 
residues varied among monomers and structures. 5NSA was modeled in all eight 
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protomers in the Mn2+/5NSA structure. Tet was only well-resolved in six protomers of 
5NAA-AR289A with Zn
2+/5NAA. Water molecules are only modeled in the 2.2 Å 
resolution structure where they were visible. Crystallographic statistics for all four 





Table 6.2. Crystallographic data collection and refinement statistics for 5NAA-A 
structures. 
Data Collection  SeMet Apo 5NAA-bound Mn2+/5NSA-
bound 
Zn2+/Tet-bound 
λ (Å)  0.9793 1.0000 1.0000 1.0000 
Space group I422 C2221 C2221 C2221 
Mol/ASU 4 8 8 8 








α, β, γ (°)  90 90 90 90 90 90 90 90 90 90 90 90 
Resolution (Å)*  78.54 - 2.54 
(2.60 - 2.54) 
46.28 - 3.22 
(3.34 - 3.22) 
49.83 - 2.89 
(2.99 - 2.89) 
37.16 - 2.20 
(2.28 - 2.20) 
Completeness (%)*  94.83 (71.63) 93.87 (84.91) 92.23 (77.04) 98.31 (98.46) 
Wilson B-factor (Å2)  25.35 42.37 51.28 27.80 
Rsym*  0.11 (0.63) 0.12 (0.58) 0.11 (0.47) 0.10 (0.45) 
Redundancy* 10.8 (4.0) 6.7 (5.4) 5.2 (4.7) 5.7 (4.6) 
I/σ(I)*  10.41 (1.77) 9.59 (3.59) 11.63 (2.97) 14.63 (3.19) 
Refinement 
Resolution (Å)  78.54  - 2.75  46.28 - 3.22 49.83  - 2.89 37.16  - 2.20 
No. reflections  86420 87398 119036 281745 
Rwork/Rfree 0.17/0.21 0.18/0.22 0.18/0.22 0.17/0.20 
RMS (bonds) (Å)  0.014 0.013 0.014 0.008 
RMS (angles) (°)  1.37 1.35 1.32 1.12 
Number of protein 
atoms 
12290 25816 25593 25900 
Number of ligand 
atoms 
5 104 112 140 
Average B-factor (Å2) 26.0 33.0 39.1 32.3 
Ramachandran Analysis 
Favored (%) 96.2 95.8 94.8 96.3 
Allowed (%) 3.6 3.9 4.6 3.2 
Outliers (%) 0.2 0.3 0.6 0.4 
* Highest resolution shell values are in the parenthesis 
 
6.2.7. Isothermal titration calorimetry (ITC) measurements 
For ITC data shown, 5NAA-A was prepared in gel filtration buffer at 6.4 μM in 
1.8 ml aliquots. Stock solutions of 1 mM 5NAA, 1 mM 5NSA, 3.5 mM ANB, 3.2 mM 
4NA, 100 mM Zn(OAc)2 and 100 mM MnCl2 were diluted to 0.15 mM with gel filtration 
buffer accordingly. All samples were degassed extensively on a vacuum line (MicroCal 
120 
 
ThermoVac) before ITC measurements (MicroCal VP-ITC). In a typical experiment, an 
automated sequence of 30 injections of 9 μL of sample was applied to the protein in the 
sample cell with 6 min between injections to allow for equilibration. The reaction 
solution was stirred at 270 RPM, and the temperature of the chamber was maintained at 
25°C. Several ITC parameters were varied in an attempt to detect a heat of binding of 
metal ion to 5NAA-A, including changing the enzyme concentration (7.8 μM), metal ion 
concentration (250, 500 μM), salt (e.g. ZnCl2), and for the experiment in which 5NAA-A 
was preincubated with 5NAA, time of incubation (1 h). 
Data were analyzed with the Origin 7.0 software package from MicroCal, using 
one-site binding model. A background correction was applied to each experiment by 
subtracting the average of the last four injections. Background corrections were in 
accordance with control experiments (gel filtration buffer). A non-linear least squares 
method was used to obtain one-site model best fit parameters for the number of binding 
sites, n, the association constant, Ka, and the change in enthalpy, ΔH°. The dissociation 
constant, Kd was calculated by taking the inverse of Ka. 
6.2.8. Total reflection x-ray fluorescence (TXRF) measurements 
TXRF measurements were performed with a Bruker S2 Picofox TXRF (Bruker 
Instruments, Inc.). Quartz glass disks were used as sample carriers (Bruker Instruments, 
Inc.). The excitation settings were 50 kV and 750 mA. Measurements were performed by 
signal integration over 1000 seconds. Quantification of the analytes was performed by 
Bruker S2 Picofox TXRF software. After overnight dialysis of apo 5NAA-A against 
either Mn2+ or Zn2+ (50x excess of protein concentration) by 10K Slide-A-Lyzer Dialysis 
Cassette, the protein solution was re-run on Superdex-200 10/300 GL column with gel 
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filtration buffer to remove excess metal. Such experiments were performed twice, and 
quantification was based on the known quantity of the internal standard gallium (1 ppm) 
and amount of protein (5NAA-A) to calculate metal:protein ratio. For determination of 
manganese and zinc amount in E.coli and Bradyrhizobium sp. JS329 cell lysates, 
different concentrations of MnCl2 and ZnCl2 (0.1, 10, 1000 μM) were analyzed with 
TXRF along with samples to plot standard curve.  
6.2.9. Size-exclusion chromatography - small angle x-ray scattering (SEC-
SAXS) 
SEC-SAXS experiments were performed and analyzed by Srinivas Chakravarthy 
at BioCAT (beamline 18ID, Advanced Photon Source at Argonne National Labs). The 
basic setup for SEC-SAXS was based on the pioneering experiment of this kind (170). 
The camera included a focused 12 keV (1.03 Å) X-ray beam, a 1.5 mm quartz capillary 
sample cell, a sample to detector distance of ~3.5 m, and a Pilatus 3 1M detector 
(Dectris). The q-range sampled was ~0.0042-0.38 Å-1. In order to ensure sample 
monodispersity, we used an in-line SEC setup, which included an AKTA FPLC system 
with a Superdex-200 Increase 10/300 GL column (GE Healthcare). The elution trajectory 
after the UV monitor was redirected to the SAXS sample flow-cell. One second 
exposures were collected every 2 seconds during the gel-filtration chromatography run. 
Appropriate exposures were averaged and used as the buffer curve for each run, and the 
exposures during elution (co-incident with the UV peak on the chromatogram) were 
treated as protein+buffer curves. Data were corrected for background scattering by 
subtracting the buffer curve from protein+buffer curves. Radius of Gyration (Rg) was 
calculated using Guinier approximation and a P(R) curve, both of which were done using 
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PRIMUS (171). Dmax was also calculated using the P(R) curve and the output was then 
used to calculate molecular envelopes using DAMMIN 9 separate times (172). These 
envelopes were then averaged using DAMAVER and DAMFILT (173). The high 
resolution crystal structure was fit into the envelope using SUPCOMB (174). 
6.2.10. In silico sequence and structure analysis 
Sequence alignments were conducted using CLUSTAL-Omega (175). 
Comparison to known structures in the PDB was performed using BioXGEM (176, 177). 
Interfaces were calculated with PDBePISA (105). Tunnels and channels were evaluated 
in CAVER (178), and homology models were generated in SWISS-MODEL (179). 
Evolutionary analyses were conducted in MEGA6 (180). The 5NAA-A sequence was 
queried against the non-redundant protein sequence database, allowing for up to 20,000 
target sequences. The resultant 2,256 sequences were then aligned using MUSCLE (181). 
The evolutionary history was inferred by using the Maximum Likelihood method based 
on the JTT matrix-based model (182) and the tree with the highest log likelihood (-
372632.2194) is presented. Initial tree(s) for the heuristic search were obtained 
automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise 
distances estimated using a JTT model, and then selecting the topology with superior log 
likelihood value. All positions with less than 95% site coverage were eliminated. That is, 
fewer than 5% alignment gaps, missing data, and ambiguous bases were allowed at any 
position. There were a total of 268 positions in the final dataset. All structure figures 
were generated in PyMOL (www.pymol.org). Unless stated otherwise, interaction 




6.3.1. Overall structure 
The crystal structure of apo 5NAA-A (Selenomethionine (SeMet) derivatized apo, 
2.75 Å resolution, Table 6.2), confirms inferences from sequence that 5NAA-A belongs 
to the MEROPS M20 metallopeptidase family (50) and thus evolved from a common 
ancestor (51). The closest structural homologs are M20 family members: di-zinc 
carboxypeptidase G2 (root mean squared deviation (R.M.S.D.): 5.04 Å, (sequence 
similarity ~35%, Figure 6.2) (16), N-acetyl-L-citrulline deacetylase (ACD, R.M.S.D.: 
4.32 Å) (52), and N-succinyl-L,L-diaminopimelic acid desuccinylase (SDAD, R.M.S.D.: 
5.66 Å) (53) (Figure 6.3), but 5NAA-A harbors key distinctions leading to its unique 
supramolecular arrangement and catalytic site (see below).  
 
Figure 6.2. Sequence alignment of 5NAA-A with carboxypeptidase G2 (PDB ID: 
1CG2). Metal binding/active site residues are highlighted and labeled on top for 5NAA-
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A, bottom for carboxypeptidase G2. Conserved residues: * or green highlight; similar 
residues: :, ., or yellow highlight; non-conserved active-site residues highlighted in red. 
 
 
Figure 6.3. Structural comparison of 5NAA-A and M20 family members 
carboxypeptidase G2 (PDB ID: 1CG2), N-acetyl-L-citrulline deacetylase (ACD, PDB ID: 
2F7V), and N-succinyl-L,L-diaminopimelic acid desuccinylase (SDAD, PDB ID: 3IC1). 
(a) Superposition of monomers. (b) Dimer orientation comparison. (c) Calculated 
interface areas of 5NAA-A, carboxypeptidase G2, ACD, and SDAD. (d) Pairwise 
superposition of metal center residues of 5NAA-A (orange) with (left) ACD (blue), 
(middle) carboxypeptidase G2 (yellow), and (right) SDAD (magenta). Residue labels are 
in black for 5NAA-A and in annotated colors for the others; catalytic glutamates are 
underlined. 
 
Analysis of the crystal lattice and small angle X-ray scattering envelope reveal an 
octamer in which the eight ~43 kDa 5NAA-A protomers are arranged radially around a 
~50 Å diameter solvent channel (Figure 6.4a, b and Figure 6.5) to form a ~350 kDa 
enzyme. The octamer is unique among characterized M20 family members, which are at 
most functional dimers (183). A shift in the relative orientation of the two lobes, labeled 
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“catalytic” and “dimerization” (16), and novel loop configurations, generate two large 
surface areas (Figure 6.3a, b, c). The first “dimerization” interface establishes the 
5NAA-A catalytic center (see below) and is larger than that of carboxypeptidase, ACD, 
or SDAD (Figure 6.4a and Figure 6.3c). The importance of the dimerization interface is 
underscored by the fact that the V247K variant, designed to destabilize this interface, 
could not be purified to appreciable levels (Table 6.3). The second “catalytic” interface 
enables the closed circular arrangement of a tetramer of dimers (Figure 6.4a). 
 
Figure 6.4. Overall structure and substrate binding of 5NAA-A. (a) Octameric crystal 
structure of 5NAA-A, colored by protomer (apo structure shown). Overall dimensions, 
dimerization, and tetramerization interfaces are labeled. The two active sites within a 
dimer are circled. (b) Solution structure of 5NAA-A confirms donut shaped octamer. 
Left: pair distribution P(r) plot with calculated maximum particle size (Dmax) and radius 
of gyration (Rg). Right: SAXS envelope (blue) superimposed with the apo crystal 
structure (red). (c) Substrate binding details. Left: Superposition of apo and 5NAA-bound 
structures in binding pocket. Loop1 (residues 91-108) and Loop 2 (residues 393-397) are 
disordered in the apo structure (red/dark blue) but adopt an ordered conformation when 
5NAA is bound (cyan/grey). Right: 5NAA binding interactions with protein residues, 





Figure 6.5. Small Angle X-ray Scattering (SAXS) analysis. (a) Scattering profile. (b) 
Guinier plot. I(q): scattered intensity, q: scattering vector. 
 
Table 6.3. 5NAA-A mutants, their expression levels, and residual activities. 
Residue 
function/position 
Mutation Activity Test 
Metal binding H86A Soluble expression, inactive 
N124A No soluble expression 
E196A Soluble expression, inactive 
Substrate binding R289A Soluble expression, inactive 
R373A Soluble expression, inactive 
Y223A Soluble expression, inactive 
Y223F No soluble expression 
Catalysis E158A Soluble expression, inactive 
Second shell D88A Precipitation after purification 
D88N Soluble expression, inactive 




6.3.2. Substrate binding 
The co-crystal structure of 5NAA-A with bound substrate (5NAA-bound, 3.2 Å 
resolution, Table 6.2) reveals that 5NAA binds within one catalytic lobe but stabilized by 
a key residue Tyr223, from an adjacent monomer, which provides parallel-displaced π-π 
stacking stabilization (Figure 6.4c). Within the catalytic lobe of one monomer, 5NAA is 
held in place by Arg373 and Arg289, which stabilize the carboxyl and nitro groups, 
respectively, and the side chain of Glu158, which is within hydrogen bonding distance of 
the amino substituent. Asp160 and the main chain of Trp372 also stabilize the 
aforementioned adjacent Tyr223 (Figure 6.6). Alanine variants of Tyr223, Arg289, and 
Arg373, as well as Y223F, are all inactive or not isolated in sufficient yield for further 
characterization (Table 6.3). Two loops disordered in the apo structure are located in this 
region of the catalytic lobe. Substrate binding, even in the absence of metal, organizes 
these loops, primarily by interactions between Tyr288 and Arg98 and between Asp95 and 




Figure 6.6. Selected stabilizing interactions and representative electron density. 
Stabilizing interactions of 5NAA-bound structure; (a) Y223 (b) Loop1 (c) Active site 
second shell interactions. Cyan and grey residues derive from different monomers in the 
dimer. The same interactions were observed for Mn2+/5NSA- and Zn2+/Tet- bound 
structures (not shown). Representative electron densities for Mn2+/5NSA- and Zn2+/Tet- 
bound structures (d) Metal binding residues and 5NSA in the active site of Mn2+/5NSA-
bound structure (e) Metal binding residues and Tet in the active site of Zn2+/Tet-bound 
structure. Final 2Fo − Fc electron density (blue) is contoured at 2.0σ and difference Fo − 
Fc density (green) is contoured at 2.5σ. The Fo − Fc density map was calculated based on 
coordinates of the refined structure refined prior to modeling 5NSA/Tet. 
 
6.3.3. Metal binding 
Adjacent to the 5NAA binding site is a triad of ligands (His86-Glu196-Asn124), in a 
location equivalent to that of the corresponding M20 metalloprotease His2-Glu2-Asp 
metal binding motif. 5NAA-A requires metal ions for hydrolysis (Figure 6.7a, b and 
Figure 6.8a) (48). Coordinating ligands His86 and Glu196 are oriented identically as in 
carboxypeptidase, ACD, and SDAD (Figure 6.3d). Asn124, which replaces the Asp found 
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in dinuclear M20 metalloproteases, cannot act as a bridging ligand. At the position of the 
two remaining ligands that form the second metal binding site in these dinuclear enzymes 
reside residues Ile159 and Gly389 in 5NAA-A (Figure 6.2). Neighboring second shell 
residues such as Asp88 and Glu158 provide hydrogen-bonding stabilization to orient metal 
binding ligands even in the absence of metal (Figure 6.6c). Alanine mutants of His86, 
Glu196, Asn124, Asp88, Glu158, as well as D88N, are not active or result in a misfolded 
protein that cannot be purified for further characterization (Table 6.3). With 5NAA 
bound, there are no obvious tunnels or channels leading to the metal center, and all 
attempts to obtain a structure of holo 5NAA-A have been unsuccessful. 
Several lines of biochemical evidence support a mononuclear, labile, low affinity, 
and promiscuous metal binding site. Rates with Mn2+ and Zn2+ were faster than other 
metal ions tested (Figure 6.7b and Figure 6.8a), but only in the presence of 
unexpectedly high excess of metal over enzyme (Figure 6.7a). Despite optimizing 
numerous parameters, we could not detect heat of binding for either metal ion to 5NAA-
A by ITC (Methods, Figure 6.7c and Figure 6.9a). However, titrating 5NAA alone, or a 
mixture of 5NSA and Mn2+, into 5NAA-A reveals a binding dissociation constant (Kd) in 
the low micromolar range, tighter than that obtained for titrating 5NSA alone (Figure 
6.7d) or a mixture of 5NSA and Zn2+ (Figure 6.7e and Figure 6.9a). In addition, no heat 
of binding was detected when Mn2+ was titrated into a solution of 5NAA-A pre-incubated 
with 5NAA (Figure 6.7f). Finally, even though high activity is measured from E. coli 
clarified cell lysate containing wild-type recombinant 5NAA-A (7.7 nmol/min/mg using 
an end-point assay (159)), all activity is lost at the first affinity chromatography step at 
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Figure 6.7. Biochemical characterization of 5NAA-A and metal dependence of activity. 
(a) Top: Effect of divalent transition or alkaline earth metals on 5NAA-A activity as 
measured by 5NAA depletion (500 μM metal ion, 0.25 μM 5NAA-A). Concentration 
dependence of Mn2+ (middle panel) and Zn2+ (bottom panel) on 5NAA-A activity. 
Triplicate runs are performed for each metal and its concentration (mean ± standard error 
of the mean). (b) Kinetics analysis for 5NAA-A in the presence of activating metal ions 
and representative mutant 5NAA-AR289A. Three triplicate runs are performed for Mn
2+, 
Zn2+ analysis and two triplicate runs are performed for Co2+, Fe2+, Zn2+ and Mn2+ with 
5NAA-AR289A analysis (mean ± standard error of the mean). (c-f), Metal ion, substrate, 
and product binding measured by isothermal titration calorimetry. Corresponding plots of 
integrated heat versus molar ratio and calculated Kds are shown below raw data (see also 
Figure 6.9). For each experiment, 150 μM of titrant indicated was injected in 9 μl 
aliquots to 6.4 μM enzyme except in (f), where 5NAA-A was pre-incubated with 150 μM 
5NAA at room temperature for 30 min prior to injection of 150 μM Mn2+ aliquots. 
Representative thermograms for each ITC experiment are shown. Each run is repeated 
three times except pre-incubation run which is repeated two times. Parameters shown 





Figure 6.8. Metal content and dependence on enzyme activity. (a) Kinetic parameters of 
5NAA-A with Mn2+, Zn2+ and Co2+. Three triplicate runs are performed for Mn2+, Zn2+ 
analysis and two triplicate runs are performed for Co2+ analysis (mean ± standard 
deviation). (b) Total X-ray Fluorescence (TXRF) data to detect bound metal after 
overnight dialysis of apo 5NAA-A against 50x excess Mn2+ or Zn2+, followed by gel 
filtration. Data for buffer only and apo prior to dialysis are included. The experiment is 
performed twice and a representative result is shown. (c) TXRF analysis of manganese 
and zinc contents of E.coli (DE3) and Bradyrhizobium sp. JS329 clarified cell lysates. 





Figure 6.9. Additional ITC binding data and enzyme inhibition profiles for substrate 
analogs. ITC data; (a) Left: Zn2+ only; Right, pre-mixed 5NSA and Zn2+. (b) 4NA. (c) 
ANB. Raw data and corresponding plot of integrated heat versus molar ratio are 
presented. In each experiment, 6.4μM 5NAA-A was titrated with aliquots of 150 μM 
ligand(s). Representative thermograms for each ITC experiment are shown. Runs of Zn2+ 
and 5NSA+Zn2+ are repeated three times, runs of 4NA and ANB are repeated two times. 
(d) Thermodynamic parameters for ITC experiments with one-site best fit model. 
Parameters are calculated from triplicate analysis (mean ± standard deviation). (e) 
Inhibition profiles of WT 5NAA-A with substrate analogs. Half maximal inhibitory 
concentration (IC50) plots and chemical structures of 4NA, ANB, and BNBA. 
 
 Consistent with biochemical results, we co-crystallized Mn2+ with the product 
5NSA and wild-type 5NAA-A (Mn2+/5NSA-bound, 2.9 Å resolution), and Zn2+, and 
5NAA with the inactive mutant 5NAA-AR289A (Zn
2+/Tet-bound, 2.2 Å resolution), which 
trapped the Meisenheimer intermediate (Tet, (R)-1-carboxy-2-amino-2-hydroxy-5-
nitrocyclohex-1,4-diene, see below) (Table 6.2 and Figure 6.6d, e). The two structures 
confirm the His86-Glu196-Asn124 metal ligand residues. The structures superimpose well 
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with that of 5NAA-bound; the positions of 5NSA, Tet, and metal binding residues are 
within coordinate error (Figure 6.10a), and there are minor variations throughout the 
peptide chain each monomer in the asymmetric units. The coordination geometry for both 
metals is distorted square pyramidal (Figure 6.10a), where the hydroxyl substituent of 
either 5NSA or Tet occupies the fifth coordination site. Thus, the catalytically competent 
metal center has octahedral geometry where the fifth position is occupied by the amino 
group of 5NAA and the sixth coordination site is the water molecule to be activated for 
hydrolysis (Figure 6.10b).  
 
Figure 6.10. Metal coordination, proposed catalytic mechanism and, phylogenetic 
analysis of 5NAA-A. (a) Left: Superposition of metal binding residues of apo 5NAA-A 
(red), 5NAA-bound (cyan), Mn2+/5NSA-bound (magenta) 5NAA-A and Zn2+/Tet-bound 
5NAA-AR289A (yellow). Middle: Coordination environment of Zn
2+/Tet-bound 5NAA-
AR289A shown in two orientations, highlighting stabilization of the intermediate by Glu158. 
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Right: Coordination environment for Mn2+/5NSA-bound 5NAA-A. (b) Proposed 
nucleophilic aromatic substitution mechanism for hydrolysis of 5NAA to 5NSA by 
5NAA-A. (c) Phylogenetic tree (based on protein sequence) zoomed into the region 
closest to 5NAA-A (*). Full phylogenetic tree is available as a separate file from 
Supplementary Information. 
 
6.3.4. Proposed chemical mechanism and substrate specificity 
On the basis of the available structures, we propose that 5NAA-A-mediated 
hydrolysis of 5NAA to form 5NSA occurs by SNAR in a sequence of events that 
parallels, but is distinct from, metal-mediated proteolysis (184) (Figure 6.10b). A water 
molecule is first activated by metal coordination by reducing its pKa, and then 
deprotonated by the general base Glu158. Nucleophilic attack of 5NAA at the electrophilic 
C2 carbon can only occur from a single face, forming the Meisenheimer intermediate 
with (R-) absolute configuration. The now-protonated Glu158 stabilizes the hydroxyl and 
amino groups of the tetrahedral C2 carbon (Figure 6.10a, b). Aromaticity is restored 
concomitant with the release of the ammonia leaving group to form 5NSA. This 
mechanism is distinct from unrelated DNA deaminases (161). Both enzymes activate 
water via a mononuclear metal ion site, but different ligands, coordination environments, 
and active site residues accommodate the purine/pyrimidine and corresponding reactive 
intermediates (185). The metal dependence of 5NAA-A renders it also distinct from 
glutathione-S-transferase and 4-chrlorobenzoyl-CoA dehalogenase, the two other 
enzymes proposed to undergo SNAR (186).  
Interestingly, while the electrons in Tet are expected to be primarily delocalized 
onto the strongly electron withdrawing para nitro group, the ortho carboxy substituent of 
5NAA is also important for catalysis. 5NAA-A was not reactive toward m-nitrobenzoic 
acid, 4-nitroaniline (4NA), anthranilic acid, aniline, 2-bromo-5-nitrobenzoic acid 
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(BNBA), 2,4-dinitroaniline, aminoterephthalic acid, or 4-amino-3-nitrobenzoic acid 
(ANB) (not shown). No binding was detected by ITC for analogs 4NA or ANB (Figure 
6.9b, c), and neither 4NA, ANB, nor BNBA is a competitive inhibitor (Figure 6.9e). The 
result for ANB is particularly surprising because it has both functional groups that in 
5NAA interact with an arginine. Taken together, 5NAA-A exhibits a high level of 
substrate specificity.  
6.3.5. Phylogenetic analysis 
Phylogenetic analysis of the 5NAA-A protein sequence expands our appreciation 
for the breadth of non-peptidase M20 homologs lurking among this protease family far 
beyond deacetylases and desuccinylases (50) (Figure 6.10c). Though numerous 
sequences are annotated as M20 peptidase family members, the number of metal binding 
sites in the active site and biological substrates are generally not known. Manual 
inspection of sequence alignments of closely related species reveals just one other 
sequence, Moorella glycerini hypothetical protein WP_054938065.1, with the signature 
residues for both mononuclear metal ion binding and binding of a nitroaromatic substrate 
(Figure 6.10c and Figure 6.11). The biological relevance of degradation of 5NAA-like 
compounds in this thermophilic, anaerobic, endospore-forming bacterium isolated from a 
hot spring sediment in Yellowstone National Park (187), is a mystery. Review of other 
selected sequences reveals several additional related enzymes from endospore-forming 
bacteria, e.g. Cohnella thermotolerans peptidase M20 WP_051318224 and Nitrospirillum 
amazonense peptidase M20 WP_004272836.1 (Figure 6.10c), which have the same 
5NAA-A metal binding residues and may hydrolyze aromatic substrates (Phe in position 
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of Tyr223) harboring a carboxylate (Arg in position Arg373), but are unlikely to stabilize a 
nitro group (Gly or Ala in place of Arg289) as in 5NAA-A (Figure 6.11).  
 
Figure 6.11. Sample of close homologs of 5NAA-A based on phylogenetic analysis. (a)  
Multiple sequence alignment of 5NAA-A with Moorella glycerini hypothetical protein 
WP_054938065.1, Cohnella thermotolerans peptidase M20 WP_051318224 and 
Nitrospirillum amazonense peptidase M20 WP_004272836.1. Metal and substrate 
binding residues of 5NAA-A are highlighted. Conservation and highlight as in 
Supplementary Fig. 1. (b) Overlay of 5NAA-A structure and homology models of 





Figure 6.12. Circular Dichroism (CD) analysis of WT 5NAA-A. (a) CD spectra (b) CD 
thermal melt with a calculated melting temperature of 74.3°C. 
 
6.4. Discussion 
5NAA-A, a notably stable protein (melting temperature of 74 °C, Figure 6.12), is 
well designed for the key first step in biodegradation of the toxic nitroaromatic substrate. 
5NAA-A must bind 5NAA before cellular nucleophiles like glutathione, found at 
milimolar concentrations in the cell (188), have an opportunity to form covalent adducts. 
Although there are no visible channels to the metal site in the 5NAA-bound structure, 
metal loading in vivo must be facile because the enzyme is active in clarified cell lysates 
of E. coli (above) and Bradyrhizobium sp. JS329 (159). No metallochaperone protein 
sequence is present within the 5NAA-A containing operon (159) and the total cellular Zn 
and Mn levels in Bradyrhizobium sp. JS329 are in the micromolar range, similar to levels 
found in E. coli (Figure 6.8c) (189). The ability of 5NAA-A to function with multiple 
metals suggests that it might rely on available pools of buffered Mn2+ or Zn2+ (190), or 
those of less prevalent transition metal ions, and is suitably flexible in metal ion 
utilization so as not to be affected by fluctuations in any one particular metal.  
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Finally, 5NAA-A expands our knowledge of the largely-uncharacterized 
metalloproteome (191). 5NAA-A would not have been identified as a metal-dependent 
enzyme by proteome-scale studies, which follow metal content during purification. 
Whereas bioinformatics correctly predicted 5NAA-A to be a metal dependent enzyme, 
our findings reinforce the challenges associated with functional annotation of sequences 
from large families in the absence of known biological substrates (192). We identified 
additional M20 non-peptidase homologs that likely harbor labile mononuclear metal 
binding sites and hydrolyze other aromatic substrates of potential environmental or 
synthetic interest. It is not possible to identify substrates from the sequence or structure, 
but it appears likely that many additional rare and unusual enzymes are involved in 
catabolic pathways for the great diversity of natural organic compounds in our ecosystem 
(54).  
6.5. Future directions 
Our cumulative results suggest that a substrate-metal complex likely binds to 
5NAA-A. There is strong precedence for microbes to employ a detoxification strategy in 
which manganese ions form complexes with small organic molecules (193), and a similar 
tactic might be in use by Bradyrhizobium sp. JS329. 
As one of the referees pointed out in their review of our manuscript, one way to 
test the substrate-assisted metal loading is to conduct competition experiments using a 
fluorescence chelator. I have showed that 5NAA can compete out calcein and indo-1 for 
Zn2+. Reported KD for Zn
2+-indo-1 is 0.16 nM (194). This means that 5NAA has a very 
high affinity for Zn2+ with KD being less than 0.16 nM. It is important to keep in mind 
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that KD of 5NAA for Zn
2+ should be equal or lower than free zinc concentration in the 
cell for the efficient catalysis. 
Future directions for this project include understanding the possible molecular 
evolution of 5NAA-A from a metallo-peptidase family. Protein engineering efforts can be 
performed to see if 5NAA-A would revert back and catalyze peptide bond hydrolysis.  
Unusual metal-coordinating Asn can be mutated to more common Asp to see if enzyme 
would catalyze the same reaction with same kinetic parameters and if its affinity for 
metal/substrate would change. Also, active site mutations can be employed to make 
5NAA-A accept/catalyze other nitroaromatic substrates that are environmentally and 
ecologically important.  
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7. CHAPTER 7: Perspectives and Future Directions 
7.1. Perspectives on membrane protein structure determination 
Structures of membrane proteins including Intramembrane Peptidases (IPs) are 
severely underrepresented. As of May 5th, 2016, there were only 615 unique membrane 
protein structures deposited in Protein Data Bank (http://www.rcsb.org/) which has 
118,587 biological macromolecular structures in total 
(http://blanco.biomol.uci.edu/mpstruc/). The main reason for this is the challenge 
associated with crystal growth (Chapter 3).  
Because membrane proteins are hard to crystallize with conventional techniques, 
several new methods to increase the likelihood of obtaining diffraction quality crystals 
have emerged. One particularly exciting technique using free electron X-ray lasers was 
recently developed and it introduced a new concept named femtosecond 
nanocrystallography for membrane protein crystallization (195, 196). This method does 
not need fully-grown crystals, it uses stream of nanocrystals for data collection and 
structure determination. The method thus overcomes challenges related to rate-limiting 
steps of crystal growth and radiation sensitivity. This method can also be used for Lipidic 
Cubic Phases (LCP) grown microcrystals with a specialized LCP injector (197). As 
discussed in Chapter 5, LCP is another recent technique developed for membrane protein 
crystallization. It uses native-like three-dimensional lipid bilayer system for so called in 
meso crystallization instead of detergent environment (136). LCP has gained considerable 
popularity particularly for GPCRs (198-201). A third approach which combines 
conventional crystallization with native-like environment is Lipopeptide Detergents 
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(LPDs) (202). LPDs are lipid-mimicking detergents consisting of an amphipathic α-helix 
supported by alkyl chains at both ends of the α-helix (203). 
In recent years, cryo-EM became extremely powerful in membrane protein 
structure determination. The data resolution improved a lot over the recent years from 
medium to high resolution (204). Disadvantages of membrane protein crystallization such 
as need for high amount of pure protein and poor diffraction quality can be overcome 
with cryo-EM. There is an increasing number of cryo-EM structures, this technique has 
been used to solve more than 100 protein structures so far (205). 
7.2. Perspectives on structural and biophysical studies of intramembrane 
peptidases 
Intramembrane proteolysis is unusual in that hydrolysis of peptide bonds occurs 
within a hydrophobic lipid bilayer environment, presumably by utilizing bulk water. 
Although these cleavage events are involved in essential roles in various biological 
processes, little is known about the biochemical/biophysical/structural properties or 
details of the catalytic mechanisms of intramembrane proteases (IPs). With the 
availability of the first SPP structure (42), some key insights have been gleaned regarding 
the overall architecture, but most questions surrounding function remain unanswered 
(Chapter 1). 
Structure-function studies systematically probe structure usually by site-directed-
mutagenesis, to compare function with the wild-type version of the target protein. Such 
differences could be related to enzyme kinetics, substrate binding affinity or kinetics, 
substrate specificity, and interactions with other proteins. Due to the presence of 
detergents and/or lipids, biochemical investigations of IPs have been largely limited to 
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discontinuous assays where catalytic parameters and substrate specificity are mostly 
absent (68). Application of modern biophysical techniques such as Förster resonance 
energy transfer (FRET) assay (68) and surface plasmon resonance (SPR) (206) would 
give additional details, but have not been implemented for the study of IPs.  
 
7.3. A preliminary structure-function study of MCMSPP to probe its substrate 
gating  
7.3.1. Introduction 
7.3.1.1. Substrate gating for IPs 
A major unanswered question about IPs is which structural elements are 
important for substrate recognition and processing (Chapter 1). For presenilin, the 
catalytic subunit of γ-secretase responsible for the generation of amyloid β-peptides of 
different lengths and pathogenicity in Alzheimer’s disease (33), studies probing substrate 
gating have demonstrated that the α-helical region of its hydrophilic loop 1 and its C-
terminal transmembrane helices are important for the cleavage: a conformational change 
occurs around these regions upon substrate binding (207-209). Conformational changes 
were also observed in TM2, TM6 (210) and TM9 (211) upon binding of substrate or 
transition state analog inhibitor. A lateral gate could allow for substrate access (212, 213) 
but roles of responsible residues and detailed structural mechanism are still unknown.  
Presenilin and Signal Peptide Peptidase (SPP) are two members of intramembrane 
aspartyl peptidase family and they share common structures (Chapter 2) (214). There is a 
conserved Pro-Ala-Leu (PAL) motif both in presenilin and SPP in the aforementioned C-
terminal region, the functional importance of which derives from several studies. First, 
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according to one study investigating the effect of transition-state analogs on the 
conserved catalytic GxGD and PAL motifs, water accessibility of all residues around 
those motifs decreased significantly in the presence of inhibitor (215, 216). Second, the 
presenilin PAL motif was shown to be in close proximity of the catalytic center via a 
cross-linking experiment (217). Third, while it was initially proposed that PAL motif was 
important for both stabilization of γ-secretase multiprotein complex and catalytic activity 
of presenilin (218), later studies indicate it is only important for the activity and substrate 
gating, not complex formation (219). To the best of our knowledge, there is only one 
study which investigates the importance of PAL motif in SPP activity, which shows that 
mutation of these residues inhibits the activity of SPP and abolishes its binding to a 
transition state analog, similar to presenilin (220). 
7.3.1.2. Chapter overview and publications 
In this chapter, I present preliminary data for a structure-function study of 
MCMSPP substrate gating, which, compared to studies of presenilin, is underrepresented 
in the literature. Studies probing the PAL motif role in substrate gating of presenilin were 
conducted using discontinuous assays where enzyme and substrate binding kinetics were 
not investigated. By studying MCMSPP enzyme kinetics and substrate binding kinetics 
with different mutants, we can differentiate between catalytic impairment due to an 
incomplete active site versus impaired substrate binding to the enzyme. Notably, 
MCMSPP harbors the motif “AGL”, not “PAL”, which is conserved among archaeal 
SPPs (Figure 7.1A, B). We hypothesize that similar to presenilin, the substrate enters the 
active site via the interface between catalytic motif (“YD”)-harboring TM6 and TM9; to 
do so, it first encounters residues in and surrounding the PAL motif to reach active site 
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(Figure 7.1C). This might be accompanied by a conformational change, as also proposed 
for presenilin (section 7.3.1.1). Expansion and completion of this study will be carried 
out by Swe-Htet Naing (a current PhD candidate in Lieberman Lab) and manuscript will 
be subsequently written and published. 
 
Figure 7.1. Proposed substrate gating mechanism for MCMSPP. (A) Multiple sequence 
alignment of human presenilin, human SPP (HsSPP) and MCMSPP. Conserved PAL 
motif and a residue before and after PAL motif are boxed in red. Yellow highlights show 
Familial Alzheimer’s Disease (FAD) mutation residues of human presenilin. (B)  
Multiple sequence alignment of archeal SPPs. Conserved AGL motif is boxed in red. (C) 
Structure of catalytic region of MCMSPP (PDB ID: 4Y6K). Catalytic aspartates, residues 
selected for this structure-function study and corresponding TMs were labeled. Proposed 





7.3.2.1. Generation of MCMSPP variants 
Residues expected to affect substrate gating were determined by comparing 
published structures of MCMSPP and presenilin (42, 213). Selected amino acids were 
mutated to either Familial Alzhemier’s Disease (FAD) mutations extracted from 
Alzheimer Disease & Frontotemporal Dementia Mutation Database (221) or other 
residues by chemical intuition (Table 7.1). Nucleotides were mutated by SDM (Agilent 
QuickChange II) using full-length WT MCMSPP cloned in the pet22b(+) plasmid as the 
template (Chapter 2). Correct sequences were confirmed by DNA sequencing (MWG 
Operon). Primers for all mutants are listed in Table 7.1.  
Table 7.1. Primers for MCMSPP mutants. 
12 Mutation Forward (F) and Reverse (R) Primers (5’-3’) 
E177A FAD mutation F: CACATGATCACGCTGGCCGCGGGCGTCCTCGAGACG 
R: CGTCTCGAGGACGCCCGCGGCCAGCGTGATCATGTG 
P185S FAD mutation F: GTCCTCGAGACGAAGGCGTCTATAATGGTCGTGGTTCCG 
R: CGGAACCACGACCATTATAGACGCCTTCGTCTCGAGGAC 












G274C FAD mutation F: GGGCAACCCCCAGGCGTGCCTCCCCCCCTTAAACG 
R:  CGTTTAAGGGGGGGAGGCACGCCTGGGGGTTGCCC 
G274T FAD mutation F: GGGCAACCCCCAGGCGACCCTCCCCCCCTTAAACG 
R: CGTTTAAGGGGGGGAGGGTCGCCTGGGGGTTGCCC 
L275F FAD mutation F: GGGCAACCCCCAGGCGGGTTTTCCCCCCTTAAACGGCG 
R: CGCCGTTTAAGGGGGGAAAACCCGCCTGGGGGTTGCCC 
P276S FAD mutation F: CCCCCAGGCGGGTCTCTCTCCCTTAAACGGCGGGGC 
R: GCCCCGCCGTTTAAGGGAGAGAGACCCGCCTGGGGG 
P276Q FAD mutation F: CCCCCAGGCGGGTCTCCAGCCCTTAAACGGCGGGGC 
R: GCCCCGCCGTTTAAGGGCTGGAGACCCGCCTGGGGG 
 
7.3.2.2. Cell growth, membrane isolation and purification 
WT MCMSPP and MCMSPP mutants were expressed, their membranes were 
isolated and proteins were purified as in Chapters 2.2.2, 2.2.3 and 2.2.4 respectively. In 
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order to eliminate more impurities (e.g. AcrB), a 5% wash step of imidazole (44 mM) 
after injection and prior to elution from the Ni2+-affinity column was used for all 
purifications, as explained in Chapter 2.2.4.  
I grew cell paste and isolated membranes for all mutants listed in Table 7.1. 
Because we decided to focus on mutants around “PAL” motif, I did at least one 
purification and further characterization for all mutants except E177A, P185S and P185L. 
I had very low protein yield for some of the mutants (G274T, A273P/G274A), so I 
solubilized more membrane (~1g).  
7.3.2.3. Protein stability analysis by circular dichroism (CD) melt 
Each purified sample was concentrated using a 50K MWCO Amicon filter to 5 
µM. Protein concentration was measured by absorbance at 280 nm using a calculated 
extinction coefficient. CD spectra and thermal melts were acquired on a Jasco J-810 
spectropolarimeter equipped with Neslab RTE 111 circulating water bath and a Jasco 
PTC-4245/15 temperature control system. CD spectra were taken at room temperature for 
both gel filtration buffer (blank) and protein sample in gel filtration buffer. CD thermal 
melt was performed utilizing a 1 °C/min increase in temperature from 5 to 89°C. Both 
CD spectra and thermal melt (temperature points for every 2°C) were acquired with 15 
averaged scans from 300 to 200 nm at a 200 nm/min scan rate, using a 0.1-cm cuvette. 
CD spectra for each mutant were plotted from 300 nm to 200 nm. For each 
mutant, the temperature versus the normalized observed ellipticity (degrees) was plotted 
at the minimum wavelength (222 nm for α-helical proteins). Because membrane proteins 
are very stable in protein-detergent-complex, we could not reach the plateau at higher end 
of temperature to obtain a good sigmoidal fit. Therefore, melting temperatures were not 
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reported. Both CD spectra and melting curves were plotted using GraphPad Prism 5 
software. 
7.3.2.4. Activity assays for enzyme kinetics analysis 
Enzyme assays for all purified mutants were conducted as described in Chapter 
5.3.4 (68). Data were fit using the Michaelis−Menten analysis within GraphPad Prism 5. 
Initial velocities were calculated by the blank-subtracted fluorescence reading over the 
first 20 min plotted against corresponding substrate concentrations. The 
Michaelis−Menten equation is V = Vmax[S]/(Km + [S]) where V is the initial velocity, 
Vmax is the maximum velocity at infinite substrate concentration, [S] is substrate 
concentration, and Km is the substrate concentration required to reach half the maximal 
velocity.  
Three independent samples of purified enzyme were tested for G274T and two 
independent samples of purified enzyme were tested for WT, L275F, Q272A. Only one 
independent sample of purified enzyme was tested for the rest of the mutants 
(A273P/G274A, G274C, P276S, P276Q). 
7.3.2.5. Surface plasmon resonance (SPR) assay for analysis of substrate 
binding kinetics and affinity 
Kinetic substrate binding assays were performed with a BIAcore T200 (GE 
Healthcare) instrument using Series S Sensor Chip NTA (GE Healthcare). The instrument 
was located in Organic Cleanroom at Georgia Tech. Each C-terminal hexahistidine-
tagged WT or mutant MCMSPP was immobilized onto the NTA chip via Ni+2/NTA 
chelation to a level of ~1500 Response Unit (RU) as bait for substrate peptides. Running 
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buffer supplemented with DDM (10mM HEPES, pH 7.4, 150mM NaCl, 0.1% DDM) was 
also used for Ni2+ solution (0.5mM NiCl2), regeneration solution (350mM EDTA), wash 
solution (3mM EDTA) and protein/peptide dilutions. Ni2+ solution was used to charge the 
NTA chip, regeneration solution was used to regenerate NTA chip between each run 
cycles (see “Instruction 22-0607-37 AG” document on GE Healthcare website for further 
details). 
The kinetics wizard within the BIAcore software was used to build the 
experimental program. The program started with one regeneration cycle (with 
regeneration buffer) and 2-3 start-up cycles (with running buffer). 50 µg/ml protein 
sample (ligand) was captured with 120 sec contact time at a flow rate of 10 μl/min. The 
naked Ren390 peptide (analyte, IHPFHLVIHT, lacking fluorophore and quencher; 
molecular weight of 1369.7 g/mol) was injected from 2 to 40 μM (0, 2, 5, 10, 20, 30, 40 
μM) at a flow rate of 10 μl/min with 90 sec of association time and 180 sec of 
dissociation time. The 2 μM concentration was eliminated from the analysis and/or 
experiment because it was very close to the baseline and it did not significantly improve 
the data analysis. The 20 μM sample was injected twice to check the stability of analyte 
injection (RU responses for those two 20 μM injections should overlay well to continue 
with the data analysis). Regeneration was performed after each run with a single 180 sec 
contact time at a flow rate of 30 μl/min and a stabilization period of 60 sec. All 
experiments were performed at 25 °C. 
Before data fitting, spikes at the start and end of injections were removed (see 
“Biacore Assay Handbook” for further details). The association rate constant (kon), 
dissociation rate constant (koff) and equilibrium dissociation constant (KD; KD = koff/kon) 
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were calculated assuming a Langmuir 1:1 binding model and local Rmax with the 
BIAevaluation software. Chi2 (Chi2 (RU2) / Rmax) and U-value was used to assess the 
quality of the fit. For reliable data, Chi2 (accuracy of fitting) should be lower than 0.5 and 
U-value (statistical significance of parameters) should be lower than 25. BIAcore 
evaluation software and GraphPad Prism 5 were used for graphical representation of raw 
and fitted data. 
7.3.2.6. In-gel cleavage assay for mass spectrometry (MS) analysis of 
cleavage site 
Freshly prepared enzyme (10-16 μM) was mixed with 4 μM fusion protein MRS 
substrate (MBP-IHPFHLVIHT-SUMO-His6) (68) in 10 mM sodium phosphate, pH 7.2, 
150 mM NaCl (PBS), 0.05% DDM (w/v). The reaction was continued for 48 hours at 37 
°C. The reaction was stopped by the addition of ice-cold acetone (6.5 × sample volume) 
and the mixture was incubated at -20 °C for at least 2 hours. Samples were centrifuged at 
8000 x g at 4 °C for 5 min followed by decanting the acetone and air-drying at RT for 30 
min. Reducing laemmli sample buffer was added to the precipitated materials, which 
were then boiled in a 95 °C water bath for 15 min, and loaded onto a 12% (w/v) 
polyacrylamide gel for SDS-PAGE analysis and coomassie staining. For analysis of 
cleavage site, LC-MS/MS analysis will be performed for each cleaved band as explained 
previously. (68).  
7.3.3. Results 
7.3.3.1. Purification and protein yield 
MCMSPP (WT and 7 mutants) were purified at least once (Table 7.2). Same 
membrane amount (~0.4g) was used for most of the mutant purifications until low protein 
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yield was the issue with two of the mutants, G274T and A273P/G274A (Table 7.2). 
Membrane amount was doubled for some purifications to get higher protein yields 
(Figure 7.2). MCMSPP variants eluted from HiPrep 16/60 Sephacryl S-300 column 
(S300) at ~65-70 ml and their peaks appeared Gaussian, except G274C and G274T where 
there was an obvious shoulder around 60 ml (Figure 7.2). According to SDS-PAGE, the 
shoulder contained mostly the variant of interest plus some higher molecular weight 
contaminants (Figure 7.3) 
Table 7.2. Number of purifications and protein yield for WT and 7 mutants. 
MCMSPP variant Number of 
purifications 
Protein yield (mg/g of membrane) 
WT 2 1.05 
L275F 2 2.55 
Q272A 2 1.17 
G274T 3 0.50 
G274C 1 0.74 
A273P/G274A 1 0.67 
P276S 1 1.38 







Figure 7.2. Overlayed S300 chromatograms for WT and 7 mutants. Different amounts of 
membrane were used as stated in the legend. Y-axis is absorbance reading at 280 nm in 
mAU from AKTA FPLC instrument and x-axis is the elution volume in ml. 
 
 





According to SDS-PAGE analysis, WT and 7 mutants were pure enough for 
downstream experiments (Figure 7.4). Notably, G274C and A273P/G274A showed a 
second band between 45 and 66.2 kDa molecular marker bands. Because SPP always 
runs right below 31 kDa, we surmised this might be a dimer. Mass spectrometry analysis 
(Systems Mass Spectrometry Core at EBB) identified both bands as corresponding 
G274C or A273P/G274A (data not shown), indicating the higher band is a dimer. No 
reducing agent (e.g. β-mercaptoethanol) was present in laemmli sample buffer used for 
SDS-PAGE because WT MCMSPP does not have any cysteines for possible disulfide 
bond formation. Thus, while the presence of dimer for G274C could be due to lack of 
reducing agent, the A273P/G274A dimer is apparently SDS-resistant. 
 
Figure 7.4. SDS-PAGE analysis of final protein samples (after S300 GF) used for further 
experiments. 
 
7.3.3.2. CD spectra and thermal melt 
After each purification, CD spectra and melt were run to make sure proteins were 
folded and stable enough for downstream experiments. According to their CD spectra 
conducted at 5µM, all mutants had similar α-helix content as WT except G274T and 
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A273P/G274A which showed less (Figure 7.5A). The only difference between G274T, 
A273P/G274A and the rest of mutants were their lower protein yield (Table 7.2). 
Because of their lower yield, more concentration steps were required to achieve the same 
protein concentration, which might affect the final concentration of detergent in the 
sample (Chapter 2). To see whether protein yield/detergent amount was the issue behind 
this CD spectra, I performed another purification and CD spectra for G274T using higher 
starting membrane quantities (Figure 7.5B, G274T_1 used 0.4 g membrane, G274T_2 
used 1 g membrane). The α-helix content of G274T from second purification was similar 
to that of WT. This might mean that too much detergent affects the structure of the 
protein in protein-detergent complex.  
 
 
Figure 7.5. CD spectra of (A) WT and 7 mutants (B) G274T with two batches of 
purification. G274T_1 used 0.4 g membrane with more filtration steps for final sample 
and G274T_2 used 1 g membrane with similar number of filtration steps to that of WT. 
 
CD thermal melts were conducted for WT and 7 mutants from 5 to 89 °C and 
changes in α-helix content were monitored at 222 nm (Figure 7.6). The CD signal was 
normalized because some of mutants had lower apparent CD signal (see above). The data 
do not conform to a sigmoidal fit characteristic of a two-state unfolding protein, which 
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could be due to the high stability of protein-detergent complexes (Chapter 2), but melts 
overlay with one another and WT, suggestive of similar stability.  
 
Figure 7.6. Normalized CD thermal melts of WT and 7 mutants at 222 nm. 
 
7.3.3.3. Enzymatic assays and Michaelis-Menten kinetics 
Activity assays of WT and all 7 mutants were performed in triplicates (analytical 
replicates) immediately after purification (Figure 7.7). Assays of WT, L275F, Q272A 
and G274T were repeated with second batches of purified protein because they were 
selected as a high priority for further testing according to their preliminary data (see 
Discussion). 
All mutations altered the catalytic activity of MCMSPP toward the Ren390FRET 
substrate. They were all slower than WT except A273P/G274A, which had slightly 
higher kcat but notably higher Km (Table 7.3). When specificities/efficiencies (kcat/Km) are 
compared, all mutants were less efficient than WT.  
The first (low yielding) purification of G274T mysteriously yielded a 3-fold 
higher kcat (data not shown). For this sample, samples were extensively concentrated 
(60x) to get the desired concentration of protein. I repeated its purification two more 
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times with more membrane to make it comparable to rest of the mutants (30x filtration). 
For both purifications, its kinetics were slower than WT (Table 7.3, Figure 7.7) and 
parameters were consistent between those two purifications. The reason for the aberrant 
behavior of the first purification is unknown; it might be due to the altered sample 
handling, results were subsequently omitted from this study. For the final purification 
attempt of G274T, I further tried to replicate the first purification condition by setting 
aside some protein after S300 gel filtration and applying 60x concentration as in the first 
sample. Kinetics were indeed faster than the remaining G274T but still slower than WT 
(data not shown). Although it is not the exact replication of first purification, we infer 
that kinetics are sensitive to concentration steps and likely related to the detergent 
concentration. In sum, in order to fairly compare kinetics data, mutants should be purified 
and concentrated as closely as possible to one another.  
Michelis-Menten kinetics























Figure 7.7. Michaelis-Menten analysis of WT and 7 mutants. Some traces represent 








Table 7.3. Michaelis-Menten parameters of WT and 7 mutants. 
MCMSPP 
variants 
Vmax (nM/min) kcat (min-1) x10-3 Km (μM) kcat/Km x10-3 
WT 4.06 ± 0.14 8.12 ± 0.28 7.84 ± 0.74 1.04 ± 0.10 
WT at 25 °C 0.98 ± 0.14 1.96 ± 0.28 26.59 ± 7.11 0.07 ± 0.02 
L275F 1.54 ± 0.05 3.08 ± 0.10 3.85 ± 0.48 0.80 ± 0.10 
Q272A 1.60 ± 0.05 3.21 ± 0.11 6.18 ± 0.61 0.52 ± 0.05 
G274T 2.20 ± 0.18 4.41 ± 0.35 7.59 ± 1.65 0.58 ± 0.13 
G274C 2.10 ± 0.08 4.21 ± 0.16 7.38 ± 0.77 0.57 ± 0.06 
A273P/G274A 5.22 ± 0.21 10.44 ± 0.43 18.67 ± 1.54 0.56 ± 0.05 
P276S 1.08 ± 0.04 2.17 ± 0.09 8.09 ± 0.88 0.27 ± 0.03 
P276Q 0.39 ± 0.02 0.78 ± 0.04 4.27 ± 0.87 0.18 ± 0.04 
 
We tested the activity of WT at 25 °C because all SPR experiments were done at 
the same temperature (section 7.3.2.5) and we wanted to ensure that cleavage was not 
occurring during the association time span of the SPR experiment (90 s). As expected, it 
was 4-fold slower and much less efficient than at 37 °C (Table 7.3, Figure 7.8), 
justifying our use of WT MCMSPP in SPR experiments. 
 
Figure 7.8. Michaelis-Menten analysis of WT at 37 °C and 25 °C. 
 
7.3.3.4. SPR analysis 
Because Michaelis-Menten analysis only gives information on reaction kinetics, 
an SPR assay was developed to determine binding kinetics and affinity. A Ni2+-NTA chip 
was used to immobilize MCMSPP through its C-terminus His6 tag and the substrate 
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corresponding to the peptide sequence of Ren390FRET (without fluorophore/quencher) 
was tested for binding. All of the assays were run at 25 °C and association time was 
optimized to 90 seconds. Based on our estimation from reaction kinetics at 25 °C (Figure 
7.8), during only 90 seconds of association time, cleavage would be insignificant and it 
would not affect the binding kinetics of the peptide to our protein. 
Many parameters were optimized to obtain binding parameters with acceptable 
statistics. Using WT MCMSPP, parameters tested included: (i) DDM concentration in 
running buffer (0.05% and 0.1% were tested, 0.1% gave better results), (ii) presence of 
DDM in Ni2+, regeneration and wash buffers (0.1% DDM is required in all buffers), (iii) 
regeneration buffer content (350 mM EDTA was better than 500 mM imidazole), (iv) 
concentration of ligand MCMSPP (25, 50, 100 µg/ml were tried, 50 µg/ml gave the best 
result with immobilization signal of 1000-1500 RU), (v) concentration range of analyte 
peptide substrate (120-0 µM and 40-0 µM were tried, 40-0 µM gave better data fit), (vii) 
association, dissociation times and flow rates (optimal values stated in methods). 
Subsequently, all mutants were run with the same program and variables. 
Figure 7.9 shows the representative SPR sensorgrams of WT and tested mutants; 
G274T and A273P/G274A could not be tested with SPR due to insufficient yield of 
purified enzyme. Binding of substrate to tested mutants was measured with only one 
batch of protein in duplicates; WT MCMSPP was tested with two independent batches of 
protein with the same binding results (Table 7.4). As judged by Chi2 values from data 
fitting, only binding values for WT, L275F and Q272A are acceptable. For G274C, 
P276Q and P276S, reliable fit values are probably restricted by the detection limit of the 
instrument for kon (“Quality control” tab in Biacore evaluation software, also see 
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“Biacore T200” document for further details). Binding kinetics rates and KD values for 
substrate binding to L275F were similar to WT while Q272A showed significantly higher 
dissociation rate and lower binding affinity (Table 7.4, Figure 7.10). However, both of 
them exhibited slower enzyme kinetics (Figure 7.7). 
 
Figure 7.9. Representative SPR sensorgrams of WT and tested mutants. Raw data (black) 
and fitted data (colored) were overlayed. Response unit (RU) is on y-axis and time in 




Table 7.4. SPR binding kinetics and affinity parameters calculated from data fitting. 
Variant Number of 
SPR assays 
kon (1/Ms) koff (1/s) x10-5 KD (µM) 
 
Chi2 U-value 
WT 2 duplicates 2113.8 ± 6.3 1683.8 ± 1.7 7.99 ± 0.02 0.25 0.49 
L275F 1 duplicate 1664.0 ± 4.2 1751.0 ± 1.5 10.53 ± 0.03 0.13 0.65 
Q272A 1 duplicate 1357.5 ± 12.4 2549.0 ± 7.4 18.81 ± 0.18 0.57 1.65 
G274C* 1 duplicate 1097.0 ± 18.4 2875.0 ± 22.4 26.30 ± 0.50 0.91 2.78 
P276Q* 1 duplicate 1440.0 ± 30.0 2981.0 ± 21.0 20.79 ± 0.46 1.65 4.08 
P276S* Single 972.8 ± 36.0 3853.0 ± 39.0 39.61 ± 1.52 2.01 6.90 
* Parameters should be considered with caution due to their high Chi2 values (>0.5) 
 
 
Figure 7.10. SPR sensorgrams of (A) WT with raw and fitted data (B) WT and L275F 
overlayed (C) WT and Q272A overlayed. (B) and (C) were plotted with corresponding 
raw data. 
 
7.3.3.5. Cleavage site 
In-gel cleavage assay was performed for the most promising mutants (L275F, 
Q272A and G274T) to compare the cleavage site preferences. This high resolution 
160 
 
proteomics mass spectrometry experiment is ongoing and conducted in collaboration with 
the Torres Lab (School of Biology).  
7.3.4. Discussion and future directions 
This study aims to differentiate residues in MCMSPP that are involved in 
substrate gating from those directly involved in catalysis. Mutations generated within and 
adjacent to the conserved so-called PAL motif (Figure 7.1, “AGL” in archaeal SPP) were 
motivated in part by the presence of Alzheimer-associated FAD mutations in this region 
within presenilin. Included here are preliminary results for seven of the mutants (Q272A, 
A273P/G274A, G274C, G274T, L275F, P276S, and P276Q). Additional mutants were 
prepared (E177A, P185S, and P185L) for further study: (a) E177A because it is a 
conserved charged residue on loop between TM6-TM7 and a FAD mutation (b) P185 
because it is in a predicted β-sheet (Chapter 5) and has FAD mutations (P185S, P185L 
are both documented at this position). Indeed, the function of this conserved predicted β-
sheet on TM6-TM7 loop remains obscure as electron density for this feature is absent in 
the published inactive MCMSPP structure (42). 
To our knowledge, this is the first SPR analysis of substrate binding to any IP. 
SPR gave reliable data for WT MCMSPP: KD values obtained by SPR (7.99 ± 0.02 µM) 
were in line with our published Km (7.84 ± 0.74 µM) from the  enzyme activity assay and 
fluorescence polarization binding experiments using the fluorescent substrate (6.5 ± 2.2 
µM) (68). 
Because this study was started at the late stages of thesis work, only preliminary 
data is presented, of which L275F, Q272A have emerged as the most intriguing. The 
L275F variant is less efficient and 2-fold slower than WT but surprisingly, its binding 
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kinetics and affinity remain unchanged. These results demonstrate that L275 is 
specifically important for the fidelity of enzyme catalysis, not for substrate gating. This 
effect can be rationalized by the location of L275 between the two catalytic aspartates 
(Figure 7.1C) (42). The bulkier FAD mutation L275F retains hydrophobicity but the 
larger side chain could shift aspartates to a position too far for efficient catalysis. Q272A 
is 2-fold slower and less efficient than WT, but the SPR result reveals significantly lower 
kon (slower association) and higher koff (faster dissociation) (Table 7.4). Q272, located 
just N-terminal to the PAL motif on TM9 near the membrane interface, may form a 
hydrogen bonding interaction with K170 on TM6 (Figure 7.1C) to properly orient the 
two helices for proper substrate binding, which is disrupted in Q272A.  
More mutants will be tested by Swe-Htet Naing to investigate the importance of 
conserved “GXGD” and “YD” motifs which locate two catalytic aspartates. We 
anticipate that application of the suite of biochemical, biophysical, and bioanalytical 
methods to the study the structural elements that confer enzymatic function of MCMSPP 
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